<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/organoids">
		<title>Organoids</title>
		<description>Latest open access articles published in Organoids at https://www.mdpi.com/journal/organoids</description>
		<link>https://www.mdpi.com/journal/organoids</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/organoids"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
		<image rdf:resource="https://pub.mdpi-res.com/img/design/mdpi-pub-logo.png?13cf3b5bd783e021?1775632654"/>
				<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/5/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/33" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/32" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/31" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/30" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/29" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/28" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/27" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/26" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/25" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/4/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/3/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/2/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/4/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/4/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/4/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/4/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/4/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/3/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/3/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/3/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/3/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/3/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/2/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/2/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/2/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/3/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/4/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/3/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/3/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/3/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/2/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/2/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/2/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/2/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/2/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/2/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2674-1172/1/1/1" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/2674-1172/5/2/11">

	<title>Organoids, Vol. 5, Pages 11: Glucose Levels Impact the Morphology and Cell Type Composition of Human Cerebral Organoids</title>
	<link>https://www.mdpi.com/2674-1172/5/2/11</link>
	<description>Human cerebral organoids, derived from pluripotent stem cells, are powerful models for studying human brain development. The understanding of how morphogens can be used to guide patterning and differentiation has matured rapidly; however, the influence of basal media components on organoid development remains unclear. Standard organoid media frequently contain non-physiological concentrations of nutrients, including glucose, a central regulator of cellular metabolism and signaling. Here, we examine how glucose availability shapes cerebral organoid growth, morphology, and cell type composition by comparing conventional hyperglycemic media to media with glucose levels more closely resembling normoglycemic conditions. We find that organoids derived from multiple human pluripotent stem cell lines can grow in low glucose, but they exhibit altered growth rates, structural features, and lineage distributions. In H9 embryonic stem cell-derived organoids, inhibition of the mammalian target of rapamycin pathway under low glucose restores neurodevelopmental cell types otherwise diminished in these conditions. These findings highlight glucose as a key determinant of organoid lineage specification and cellular signaling. Importantly, however, glucose modulation does not reduce variability across organoids or cell lines, underscoring the need to better understand and control sources of heterogeneity to improve organoid models.</description>
	<pubDate>2026-04-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 11: Glucose Levels Impact the Morphology and Cell Type Composition of Human Cerebral Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/2/11">doi: 10.3390/organoids5020011</a></p>
	<p>Authors:
		Gautami R. Kelkar
		Balaji M. Rao
		Albert J. Keung
		</p>
	<p>Human cerebral organoids, derived from pluripotent stem cells, are powerful models for studying human brain development. The understanding of how morphogens can be used to guide patterning and differentiation has matured rapidly; however, the influence of basal media components on organoid development remains unclear. Standard organoid media frequently contain non-physiological concentrations of nutrients, including glucose, a central regulator of cellular metabolism and signaling. Here, we examine how glucose availability shapes cerebral organoid growth, morphology, and cell type composition by comparing conventional hyperglycemic media to media with glucose levels more closely resembling normoglycemic conditions. We find that organoids derived from multiple human pluripotent stem cell lines can grow in low glucose, but they exhibit altered growth rates, structural features, and lineage distributions. In H9 embryonic stem cell-derived organoids, inhibition of the mammalian target of rapamycin pathway under low glucose restores neurodevelopmental cell types otherwise diminished in these conditions. These findings highlight glucose as a key determinant of organoid lineage specification and cellular signaling. Importantly, however, glucose modulation does not reduce variability across organoids or cell lines, underscoring the need to better understand and control sources of heterogeneity to improve organoid models.</p>
	]]></content:encoded>

	<dc:title>Glucose Levels Impact the Morphology and Cell Type Composition of Human Cerebral Organoids</dc:title>
			<dc:creator>Gautami R. Kelkar</dc:creator>
			<dc:creator>Balaji M. Rao</dc:creator>
			<dc:creator>Albert J. Keung</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5020011</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-04-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-04-05</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/organoids5020011</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/2/10">

	<title>Organoids, Vol. 5, Pages 10: Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance</title>
	<link>https://www.mdpi.com/2674-1172/5/2/10</link>
	<description>A major limitation in studying gastroesophageal adenocarcinoma (GEA) has been the lack of reliable models that represent the disease&amp;amp;rsquo;s complexity. We present lessons learned from a comprehensive large-scale biobanking effort combining traditional sample collection with several in vitro models, including 3-dimensional patient-derived organoids (PDOs), 2-dimensional cancer-associated fibroblasts (CAFs), tumor-infiltrating lymphocytes (TILs), and/or in vivo xenografts. This initiative started in 2018, integrating multiple advanced ex vivo models such as PDOs, patient-derived xenografts (PDXs), and organoids (PDXOs). This unique resource now includes tumor avatars from over 380 consented patients, making it the world&amp;amp;rsquo;s largest living GEA biobank. We achieved a &amp;amp;gt;90% success rate in creating per-patient models, including 227 tumor-derived and 203 neighboring normal PDOs. These organoids accurately mirror key features of the original tumors, such as their histology (e.g., microsatellite instability), mutations, and drug response across treatment points. Notably, PDOs can predict individual patient responses to chemotherapy within five weeks, underscoring their clinical relevance. Furthermore, high-throughput drug screening on PDO subsets with known genetic landscapes generates personalized chemosensitivity profiles for 22 drugs. Through a process of continued refinement of culture techniques and tumor sampling approach, our large-scale comprehensive collection of GEA avatars represents a unique and valuable preclinical experimental resource for precision oncology.</description>
	<pubDate>2026-03-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 10: Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/2/10">doi: 10.3390/organoids5020010</a></p>
	<p>Authors:
		Mingyang Kong
		Sanjima Pal
		Shuyuan Wang
		Julie Bérubé
		Ruoyu Ma
		Yifei Yan
		Wotan Zeng
		France Bourdeau
		Betty Giannias
		Hong Zhao
		Nathan Osman
		Yehonatan Nevo
		Kulsum Tai
		Hellen Kuasne
		James Tankel
		Gertruda Evaristo
		Pierre O. Fiset
		Xin Su
		Swneke Bailey
		Morag Park
		Nicholas Bertos
		Veena Sangwan
		Lorenzo Ferri
		</p>
	<p>A major limitation in studying gastroesophageal adenocarcinoma (GEA) has been the lack of reliable models that represent the disease&amp;amp;rsquo;s complexity. We present lessons learned from a comprehensive large-scale biobanking effort combining traditional sample collection with several in vitro models, including 3-dimensional patient-derived organoids (PDOs), 2-dimensional cancer-associated fibroblasts (CAFs), tumor-infiltrating lymphocytes (TILs), and/or in vivo xenografts. This initiative started in 2018, integrating multiple advanced ex vivo models such as PDOs, patient-derived xenografts (PDXs), and organoids (PDXOs). This unique resource now includes tumor avatars from over 380 consented patients, making it the world&amp;amp;rsquo;s largest living GEA biobank. We achieved a &amp;amp;gt;90% success rate in creating per-patient models, including 227 tumor-derived and 203 neighboring normal PDOs. These organoids accurately mirror key features of the original tumors, such as their histology (e.g., microsatellite instability), mutations, and drug response across treatment points. Notably, PDOs can predict individual patient responses to chemotherapy within five weeks, underscoring their clinical relevance. Furthermore, high-throughput drug screening on PDO subsets with known genetic landscapes generates personalized chemosensitivity profiles for 22 drugs. Through a process of continued refinement of culture techniques and tumor sampling approach, our large-scale comprehensive collection of GEA avatars represents a unique and valuable preclinical experimental resource for precision oncology.</p>
	]]></content:encoded>

	<dc:title>Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance</dc:title>
			<dc:creator>Mingyang Kong</dc:creator>
			<dc:creator>Sanjima Pal</dc:creator>
			<dc:creator>Shuyuan Wang</dc:creator>
			<dc:creator>Julie Bérubé</dc:creator>
			<dc:creator>Ruoyu Ma</dc:creator>
			<dc:creator>Yifei Yan</dc:creator>
			<dc:creator>Wotan Zeng</dc:creator>
			<dc:creator>France Bourdeau</dc:creator>
			<dc:creator>Betty Giannias</dc:creator>
			<dc:creator>Hong Zhao</dc:creator>
			<dc:creator>Nathan Osman</dc:creator>
			<dc:creator>Yehonatan Nevo</dc:creator>
			<dc:creator>Kulsum Tai</dc:creator>
			<dc:creator>Hellen Kuasne</dc:creator>
			<dc:creator>James Tankel</dc:creator>
			<dc:creator>Gertruda Evaristo</dc:creator>
			<dc:creator>Pierre O. Fiset</dc:creator>
			<dc:creator>Xin Su</dc:creator>
			<dc:creator>Swneke Bailey</dc:creator>
			<dc:creator>Morag Park</dc:creator>
			<dc:creator>Nicholas Bertos</dc:creator>
			<dc:creator>Veena Sangwan</dc:creator>
			<dc:creator>Lorenzo Ferri</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5020010</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-03-30</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-03-30</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/organoids5020010</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/9">

	<title>Organoids, Vol. 5, Pages 9: Organoid Models: Revolutionizing Disease Modeling and Personalized Therapeutics</title>
	<link>https://www.mdpi.com/2674-1172/5/1/9</link>
	<description>As a three-dimensional in vitro model, organoid technology represents a revolutionary breakthrough in precision medicine. By harnessing the self-organizing capabilities of stem cells within biomimetic extracellular matrices, it enables the generation of miniature tissues that recapitulate key structural and functional characteristics of their source organs. Conventional two-dimensional cell cultures lack tissue architecture and microenvironmental cues, whereas animal models are hindered by interspecies differences and inadequate representation of human pathological heterogeneity. By effectively addressing these limitations, organoids have emerged as powerful platforms that are highly representative of human physiology and disease processes in oncology, genetic disorders, and infectious diseases. They demonstrate significant potential for use in drug screening, toxicity assessment, and the development of personalized treatment strategies. Although challenges such as limited vascularization, lack of standardized culture protocols, and ethical considerations remain, the integration of multidisciplinary approaches such as AI-assisted analysis, organ-on-a-chip systems, and 3D bioprinting, together with increasing policy support and industrial advancement, is accelerating the clinical translation of organoid technology. In this review, the construction strategies for and applications of organoid models are systematically summarized, and their value and limitations in disease modeling, precision medicine, and preclinical research are highlighted. Finally, future development pathways driven by multidisciplinary collaboration and standardization are outlined.</description>
	<pubDate>2026-03-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 9: Organoid Models: Revolutionizing Disease Modeling and Personalized Therapeutics</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/9">doi: 10.3390/organoids5010009</a></p>
	<p>Authors:
		Zhifeng Xue
		Runze Yang
		Yaling Liu
		Han Luo
		</p>
	<p>As a three-dimensional in vitro model, organoid technology represents a revolutionary breakthrough in precision medicine. By harnessing the self-organizing capabilities of stem cells within biomimetic extracellular matrices, it enables the generation of miniature tissues that recapitulate key structural and functional characteristics of their source organs. Conventional two-dimensional cell cultures lack tissue architecture and microenvironmental cues, whereas animal models are hindered by interspecies differences and inadequate representation of human pathological heterogeneity. By effectively addressing these limitations, organoids have emerged as powerful platforms that are highly representative of human physiology and disease processes in oncology, genetic disorders, and infectious diseases. They demonstrate significant potential for use in drug screening, toxicity assessment, and the development of personalized treatment strategies. Although challenges such as limited vascularization, lack of standardized culture protocols, and ethical considerations remain, the integration of multidisciplinary approaches such as AI-assisted analysis, organ-on-a-chip systems, and 3D bioprinting, together with increasing policy support and industrial advancement, is accelerating the clinical translation of organoid technology. In this review, the construction strategies for and applications of organoid models are systematically summarized, and their value and limitations in disease modeling, precision medicine, and preclinical research are highlighted. Finally, future development pathways driven by multidisciplinary collaboration and standardization are outlined.</p>
	]]></content:encoded>

	<dc:title>Organoid Models: Revolutionizing Disease Modeling and Personalized Therapeutics</dc:title>
			<dc:creator>Zhifeng Xue</dc:creator>
			<dc:creator>Runze Yang</dc:creator>
			<dc:creator>Yaling Liu</dc:creator>
			<dc:creator>Han Luo</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010009</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-03-13</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-03-13</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/organoids5010009</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/8">

	<title>Organoids, Vol. 5, Pages 8: Understanding Alzheimer&amp;rsquo;s Disease Through Neurodevelopment: Insights from Human Cerebral Organoids</title>
	<link>https://www.mdpi.com/2674-1172/5/1/8</link>
	<description>Alzheimer&amp;amp;rsquo;s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, for which there is currently no cure. The causes of AD are still not well understood, although 5% of cases are known to have a genetic origin, associated with pathogenic genetic variants of the APP and PSEN1/2 genes. There is growing evidence that both APP and PSEN1/2 are also essential for proper human brain development and neural/neuronal function. This implies that abnormalities in early brain development could increase neuronal vulnerability to AD later in life. Human cerebral organoids (hCOs), generated from induced pluripotent stem cells (iPSCs) from AD patients, provide an exceptional model for better understanding the cellular and molecular mechanisms involved in human brain development, as well as early neurological alterations in the evolution of AD. This review compiles the main studies in which hCOs are used as a model for studying AD and for the discovery of new biomarkers. We also discuss the advantages and applications of these hCOs for studying the early stages of AD from a neurodevelopmental perspective. Finally, we mention the main current challenges in the use of hCOs for future research into AD.</description>
	<pubDate>2026-03-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 8: Understanding Alzheimer&amp;rsquo;s Disease Through Neurodevelopment: Insights from Human Cerebral Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/8">doi: 10.3390/organoids5010008</a></p>
	<p>Authors:
		Patricia Mateos-Martínez
		Deanira Patrone
		Milagros González-Flores
		Cristina Soriano-Amador
		Rosa González-Sastre
		Sabela Martín-Benito
		Andreea Rosca
		Raquel Coronel
		Victoria López-Alonso
		Isabel Liste
		</p>
	<p>Alzheimer&amp;amp;rsquo;s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, for which there is currently no cure. The causes of AD are still not well understood, although 5% of cases are known to have a genetic origin, associated with pathogenic genetic variants of the APP and PSEN1/2 genes. There is growing evidence that both APP and PSEN1/2 are also essential for proper human brain development and neural/neuronal function. This implies that abnormalities in early brain development could increase neuronal vulnerability to AD later in life. Human cerebral organoids (hCOs), generated from induced pluripotent stem cells (iPSCs) from AD patients, provide an exceptional model for better understanding the cellular and molecular mechanisms involved in human brain development, as well as early neurological alterations in the evolution of AD. This review compiles the main studies in which hCOs are used as a model for studying AD and for the discovery of new biomarkers. We also discuss the advantages and applications of these hCOs for studying the early stages of AD from a neurodevelopmental perspective. Finally, we mention the main current challenges in the use of hCOs for future research into AD.</p>
	]]></content:encoded>

	<dc:title>Understanding Alzheimer&amp;amp;rsquo;s Disease Through Neurodevelopment: Insights from Human Cerebral Organoids</dc:title>
			<dc:creator>Patricia Mateos-Martínez</dc:creator>
			<dc:creator>Deanira Patrone</dc:creator>
			<dc:creator>Milagros González-Flores</dc:creator>
			<dc:creator>Cristina Soriano-Amador</dc:creator>
			<dc:creator>Rosa González-Sastre</dc:creator>
			<dc:creator>Sabela Martín-Benito</dc:creator>
			<dc:creator>Andreea Rosca</dc:creator>
			<dc:creator>Raquel Coronel</dc:creator>
			<dc:creator>Victoria López-Alonso</dc:creator>
			<dc:creator>Isabel Liste</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010008</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-03-10</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-03-10</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/organoids5010008</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/7">

	<title>Organoids, Vol. 5, Pages 7: A Spheroid-Based In Vitro Model to Generate the Zonal Organisation of the Tendon-to-Bone Enthesis</title>
	<link>https://www.mdpi.com/2674-1172/5/1/7</link>
	<description>The tendon-to-bone enthesis is a multiphasic structure with four structurally continuous and compositionally distinct regions: tendon, uncalcified fibrocartilage, calcified fibrocartilage and bone. Our study aimed to develop 3D scaffold-free in vitro spheroids and macro-tissues of the enthesis for applications as experimental tools to understand the development and repair of enthesis injury. This study hypothesises that integrating tendon and bone cell spheroids with bone marrow mesenchymal stem cell spheroids will facilitate the production of a fibrocartilaginous interface. 3D Spheroids: The biphasic (tendon&amp;amp;ndash;bone) and triphasic co-culture (tendon&amp;amp;ndash;stem cell&amp;amp;ndash;bone) of spheroids in growth media and chondrogenic media were investigated to establish fusion kinetics, and the cellular and ECM components produced via histology and immunohistochemistry. Complete fusion between spheroids occurred within 6-to-8 days in biphasic co-culture, and 15-to-20 days in triphasic co-culture. Compared to biphasic, the triphasic co-culture in chondrogenic media showed a continuous interface connecting the tendon and bone regions. The presence of collagen I, sulphated proteoglycans and collagen type II in the interface region of triphasic co-culture indicates fibrochondrogenic differentiation. 3D macro-tissues: The modular tissue engineering strategy was used in this study to produce enthesis macro-tissues using spheroids as building blocks. Spheroids were bio-assembled in the triphasic manner (12 tendon spheroids, 12 stem cell spheroids and 8 bone spheroids) in the custom-designed and 3D-printed temporary supports (Formlabs Clear Resin&amp;amp;reg;) using a customised spheroid bio-assembly system. The fusion of spheroids occurred by day 8 after bio-assembly, and they were removed from temporary supports and cultured in scaffold-free conditions. Although the bio-assembly methodology was successful in producing fused scaffold-free macro-tissues, the histological analysis revealed the presence of an extensive necrotic core due to the large-sized constructs. To conclude, the findings support the hypothesis that a triphasic co-culture has the potential to produce a structurally continuous fibrocartilaginous interface but requires further optimisation to produce macro-tissues with anatomical morphologies and reduced necrotic cores.</description>
	<pubDate>2026-02-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 7: A Spheroid-Based In Vitro Model to Generate the Zonal Organisation of the Tendon-to-Bone Enthesis</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/7">doi: 10.3390/organoids5010007</a></p>
	<p>Authors:
		Vinothini Prabhakaran
		Jennifer Z. Paxton
		</p>
	<p>The tendon-to-bone enthesis is a multiphasic structure with four structurally continuous and compositionally distinct regions: tendon, uncalcified fibrocartilage, calcified fibrocartilage and bone. Our study aimed to develop 3D scaffold-free in vitro spheroids and macro-tissues of the enthesis for applications as experimental tools to understand the development and repair of enthesis injury. This study hypothesises that integrating tendon and bone cell spheroids with bone marrow mesenchymal stem cell spheroids will facilitate the production of a fibrocartilaginous interface. 3D Spheroids: The biphasic (tendon&amp;amp;ndash;bone) and triphasic co-culture (tendon&amp;amp;ndash;stem cell&amp;amp;ndash;bone) of spheroids in growth media and chondrogenic media were investigated to establish fusion kinetics, and the cellular and ECM components produced via histology and immunohistochemistry. Complete fusion between spheroids occurred within 6-to-8 days in biphasic co-culture, and 15-to-20 days in triphasic co-culture. Compared to biphasic, the triphasic co-culture in chondrogenic media showed a continuous interface connecting the tendon and bone regions. The presence of collagen I, sulphated proteoglycans and collagen type II in the interface region of triphasic co-culture indicates fibrochondrogenic differentiation. 3D macro-tissues: The modular tissue engineering strategy was used in this study to produce enthesis macro-tissues using spheroids as building blocks. Spheroids were bio-assembled in the triphasic manner (12 tendon spheroids, 12 stem cell spheroids and 8 bone spheroids) in the custom-designed and 3D-printed temporary supports (Formlabs Clear Resin&amp;amp;reg;) using a customised spheroid bio-assembly system. The fusion of spheroids occurred by day 8 after bio-assembly, and they were removed from temporary supports and cultured in scaffold-free conditions. Although the bio-assembly methodology was successful in producing fused scaffold-free macro-tissues, the histological analysis revealed the presence of an extensive necrotic core due to the large-sized constructs. To conclude, the findings support the hypothesis that a triphasic co-culture has the potential to produce a structurally continuous fibrocartilaginous interface but requires further optimisation to produce macro-tissues with anatomical morphologies and reduced necrotic cores.</p>
	]]></content:encoded>

	<dc:title>A Spheroid-Based In Vitro Model to Generate the Zonal Organisation of the Tendon-to-Bone Enthesis</dc:title>
			<dc:creator>Vinothini Prabhakaran</dc:creator>
			<dc:creator>Jennifer Z. Paxton</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010007</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-02-10</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-02-10</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/organoids5010007</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/6">

	<title>Organoids, Vol. 5, Pages 6: Xenograft-Derived Human Breast Cancer Organoids Can Form Chimeras with Host Mouse Mammary Epithelial Cells Which Promote Tumor Cell Proliferation</title>
	<link>https://www.mdpi.com/2674-1172/5/1/6</link>
	<description>Breast cancer progression and treatment responsiveness are significantly influenced by the tumor microenvironment. Therefore, transplantation into the mammary fat pad is widely employed to establish a mouse xenograft model of breast cancer. This study reports chimeric organoids derived from breast cancer xenografts composed of human and mouse cells. During passaging of an organoid line derived from breast cancer xenografts, characteristic cell clusters composed of smaller cells were observed. Immunostaining with a mouse-specific antibody revealed that the smaller cells were mouse cells composed of luminal- and basal-like cells. Chimeric organoids were observed in four of the six xenograft-derived organoid lines. Organoids composed solely of human cells rapidly diminished after passaging, with chimeric and mouse-cell-only organoids becoming predominant. When human breast cancer cells were co-cultured with mouse mammary epithelial cells, chimeras were frequently observed. The PCNA positivity rate in breast cancer cells within chimeras was higher than that in breast cancer cells within organoids composed solely of human cells. These findings indicate that xenograft-derived breast cancer organoids frequently contain mouse cells and that mouse mammary epithelial cells promote the proliferation of human breast cancer cells.</description>
	<pubDate>2026-02-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 6: Xenograft-Derived Human Breast Cancer Organoids Can Form Chimeras with Host Mouse Mammary Epithelial Cells Which Promote Tumor Cell Proliferation</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/6">doi: 10.3390/organoids5010006</a></p>
	<p>Authors:
		Hiroyuki Uematsu
		Chieko Saito
		Jumpei Kondo
		Kunishige Onuma
		Roberto Coppo
		Hiroko Endo
		Takahiro Nakayama
		Katsuhide Yoshidome
		Taisei Nomura
		Arihiro Kohara
		Masahiro Inoue
		</p>
	<p>Breast cancer progression and treatment responsiveness are significantly influenced by the tumor microenvironment. Therefore, transplantation into the mammary fat pad is widely employed to establish a mouse xenograft model of breast cancer. This study reports chimeric organoids derived from breast cancer xenografts composed of human and mouse cells. During passaging of an organoid line derived from breast cancer xenografts, characteristic cell clusters composed of smaller cells were observed. Immunostaining with a mouse-specific antibody revealed that the smaller cells were mouse cells composed of luminal- and basal-like cells. Chimeric organoids were observed in four of the six xenograft-derived organoid lines. Organoids composed solely of human cells rapidly diminished after passaging, with chimeric and mouse-cell-only organoids becoming predominant. When human breast cancer cells were co-cultured with mouse mammary epithelial cells, chimeras were frequently observed. The PCNA positivity rate in breast cancer cells within chimeras was higher than that in breast cancer cells within organoids composed solely of human cells. These findings indicate that xenograft-derived breast cancer organoids frequently contain mouse cells and that mouse mammary epithelial cells promote the proliferation of human breast cancer cells.</p>
	]]></content:encoded>

	<dc:title>Xenograft-Derived Human Breast Cancer Organoids Can Form Chimeras with Host Mouse Mammary Epithelial Cells Which Promote Tumor Cell Proliferation</dc:title>
			<dc:creator>Hiroyuki Uematsu</dc:creator>
			<dc:creator>Chieko Saito</dc:creator>
			<dc:creator>Jumpei Kondo</dc:creator>
			<dc:creator>Kunishige Onuma</dc:creator>
			<dc:creator>Roberto Coppo</dc:creator>
			<dc:creator>Hiroko Endo</dc:creator>
			<dc:creator>Takahiro Nakayama</dc:creator>
			<dc:creator>Katsuhide Yoshidome</dc:creator>
			<dc:creator>Taisei Nomura</dc:creator>
			<dc:creator>Arihiro Kohara</dc:creator>
			<dc:creator>Masahiro Inoue</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010006</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-02-06</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-02-06</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/organoids5010006</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/5">

	<title>Organoids, Vol. 5, Pages 5: High-Throughput Analysis of 3D Cell Culture Oxygen Consumption Using Sensor Arrays: A Novel Platform for Hypoxia/Normoxia Research</title>
	<link>https://www.mdpi.com/2674-1172/5/1/5</link>
	<description>Precise control and measurement of the cellular microenvironment, particularly oxygen concentration, are crucial for developing physiologically relevant in vitro models. However, current methods often lack the spatial resolution and throughput needed to investigate complex, oxygen-dependent biological mechanisms in 3D cell cultures. Here, we present an advanced platform based on microcavity arrays featuring integrated, ratiometric oxygen sensors, so-called SensoSpheres. A unique bevel design at the cavity entrance enables the non-invasive, real-time measurement of pericellular oxygen concentration and oxygen gradients. We established protocols for generating spheroids from various cell lines (e.g., HepG2, HeLa) and characterized their metabolic responses under precisely controlled hypoxic, normoxic, and hyperoxic conditions. Using a dose&amp;amp;ndash;response assay, we demonstrate the platform&amp;amp;rsquo;s sensitivity in capturing distinct metabolic shifts in response to acetaminophen and cisplatin. Furthermore, we introduce the Oxygen Consumption Recovery Rate (OCRR) as a novel parameter to quantify cellular resilience after exposure to toxic compounds such as cisplatin and acetaminophen. This high-throughput-compatible platform represents a significant methodological advancement, enabling detailed studies of oxygen-dependent cellular processes, drug toxicity, and metabolic adaptation. Its potential for integration into microfluidic systems paves the way for more sophisticated organ-on-chip models, ultimately improving the predictive power of preclinical research.</description>
	<pubDate>2026-02-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 5: High-Throughput Analysis of 3D Cell Culture Oxygen Consumption Using Sensor Arrays: A Novel Platform for Hypoxia/Normoxia Research</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/5">doi: 10.3390/organoids5010005</a></p>
	<p>Authors:
		Christoph Grün
		Cordula Nies
		Magdalena Klesen
		Enja Schwarz
		Jonah ter Haseborg
		Cornelius Dettmer
		Christian Beyer
		Larissa Funk
		Eric Gottwald
		</p>
	<p>Precise control and measurement of the cellular microenvironment, particularly oxygen concentration, are crucial for developing physiologically relevant in vitro models. However, current methods often lack the spatial resolution and throughput needed to investigate complex, oxygen-dependent biological mechanisms in 3D cell cultures. Here, we present an advanced platform based on microcavity arrays featuring integrated, ratiometric oxygen sensors, so-called SensoSpheres. A unique bevel design at the cavity entrance enables the non-invasive, real-time measurement of pericellular oxygen concentration and oxygen gradients. We established protocols for generating spheroids from various cell lines (e.g., HepG2, HeLa) and characterized their metabolic responses under precisely controlled hypoxic, normoxic, and hyperoxic conditions. Using a dose&amp;amp;ndash;response assay, we demonstrate the platform&amp;amp;rsquo;s sensitivity in capturing distinct metabolic shifts in response to acetaminophen and cisplatin. Furthermore, we introduce the Oxygen Consumption Recovery Rate (OCRR) as a novel parameter to quantify cellular resilience after exposure to toxic compounds such as cisplatin and acetaminophen. This high-throughput-compatible platform represents a significant methodological advancement, enabling detailed studies of oxygen-dependent cellular processes, drug toxicity, and metabolic adaptation. Its potential for integration into microfluidic systems paves the way for more sophisticated organ-on-chip models, ultimately improving the predictive power of preclinical research.</p>
	]]></content:encoded>

	<dc:title>High-Throughput Analysis of 3D Cell Culture Oxygen Consumption Using Sensor Arrays: A Novel Platform for Hypoxia/Normoxia Research</dc:title>
			<dc:creator>Christoph Grün</dc:creator>
			<dc:creator>Cordula Nies</dc:creator>
			<dc:creator>Magdalena Klesen</dc:creator>
			<dc:creator>Enja Schwarz</dc:creator>
			<dc:creator>Jonah ter Haseborg</dc:creator>
			<dc:creator>Cornelius Dettmer</dc:creator>
			<dc:creator>Christian Beyer</dc:creator>
			<dc:creator>Larissa Funk</dc:creator>
			<dc:creator>Eric Gottwald</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010005</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-02-06</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-02-06</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/organoids5010005</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/4">

	<title>Organoids, Vol. 5, Pages 4: A Fully Annotated Hepatoblastoma Tumoroid Biobank Details Treatment-Induced Evolution and Clonal Dynamics in Paediatric Cancer Patients</title>
	<link>https://www.mdpi.com/2674-1172/5/1/4</link>
	<description>Hepatoblastoma (HB) is a paediatric liver malignancy arising from hepatic precursor cells, with &amp;amp;gt;90% of cases harbouring a mutation in exon 3 of CTNNB1. We present a fully genetically characterised HB tumour organoid (tumoroid) biobank, which allows for in vitro studies of disease progression and clonal dynamics in vitro. We established a biobank of 14 tumoroid lines from 9 different patients. Tumours and tumoroids were characterised by whole genome sequencing (WGS) and histology, revealing strong concordance in cell morphology and &amp;amp;beta;-catenin staining. In tumour&amp;amp;mdash;tumoroid pairs, identical pathogenic CTNNB1 variants were found, alongside shared copy number alterations (CNAs) and mutations. Variant allele frequency (VAF) was consistently higher in tumoroids, indicating increased tumour purity in vitro. In addition to CTNNB1, we frequently observed ARID1A alterations (single-nucleotide variants [SNVs] or CNAs in 56% of patients), and MYC gains as described previously. In paired pre- and post-treatment samples, we observed a clear increase in mutational load, attributed to a chemotherapy signature. Notably, from one patient, we analysed 4 tumour samples (3 post-treatment) with 4 matching tumoroid lines, all carrying a novel BCL6 mutation and loss of ARID1A. Mutational profiles varied across samples from different locations, suggesting intratumoral heterogeneity and clonal selection during tumoroid derivation. Taken together, this biobank allows detailed analysis of HB tumour biology, including treatment-induced progression and clonal dynamics across temporally and spatially distinct samples.</description>
	<pubDate>2026-01-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 4: A Fully Annotated Hepatoblastoma Tumoroid Biobank Details Treatment-Induced Evolution and Clonal Dynamics in Paediatric Cancer Patients</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/4">doi: 10.3390/organoids5010004</a></p>
	<p>Authors:
		Gijs J. F. van Son
		Femke C. A. S. Ringnalda
		Markus J. van Roosmalen
		Thomas A. Kluiver
		Quinty Hansen
		Evelien Duiker
		Marius C. van den Heuvel
		Vincent E. de Meijer
		Ruben H. de Kleine
		Ronald R. de Krijger
		József Zsiros
		Weng Chuan Peng
		Ruben van Boxtel
		Marc van de Wetering
		Karin Sanders
		Hans Clevers
		</p>
	<p>Hepatoblastoma (HB) is a paediatric liver malignancy arising from hepatic precursor cells, with &amp;amp;gt;90% of cases harbouring a mutation in exon 3 of CTNNB1. We present a fully genetically characterised HB tumour organoid (tumoroid) biobank, which allows for in vitro studies of disease progression and clonal dynamics in vitro. We established a biobank of 14 tumoroid lines from 9 different patients. Tumours and tumoroids were characterised by whole genome sequencing (WGS) and histology, revealing strong concordance in cell morphology and &amp;amp;beta;-catenin staining. In tumour&amp;amp;mdash;tumoroid pairs, identical pathogenic CTNNB1 variants were found, alongside shared copy number alterations (CNAs) and mutations. Variant allele frequency (VAF) was consistently higher in tumoroids, indicating increased tumour purity in vitro. In addition to CTNNB1, we frequently observed ARID1A alterations (single-nucleotide variants [SNVs] or CNAs in 56% of patients), and MYC gains as described previously. In paired pre- and post-treatment samples, we observed a clear increase in mutational load, attributed to a chemotherapy signature. Notably, from one patient, we analysed 4 tumour samples (3 post-treatment) with 4 matching tumoroid lines, all carrying a novel BCL6 mutation and loss of ARID1A. Mutational profiles varied across samples from different locations, suggesting intratumoral heterogeneity and clonal selection during tumoroid derivation. Taken together, this biobank allows detailed analysis of HB tumour biology, including treatment-induced progression and clonal dynamics across temporally and spatially distinct samples.</p>
	]]></content:encoded>

	<dc:title>A Fully Annotated Hepatoblastoma Tumoroid Biobank Details Treatment-Induced Evolution and Clonal Dynamics in Paediatric Cancer Patients</dc:title>
			<dc:creator>Gijs J. F. van Son</dc:creator>
			<dc:creator>Femke C. A. S. Ringnalda</dc:creator>
			<dc:creator>Markus J. van Roosmalen</dc:creator>
			<dc:creator>Thomas A. Kluiver</dc:creator>
			<dc:creator>Quinty Hansen</dc:creator>
			<dc:creator>Evelien Duiker</dc:creator>
			<dc:creator>Marius C. van den Heuvel</dc:creator>
			<dc:creator>Vincent E. de Meijer</dc:creator>
			<dc:creator>Ruben H. de Kleine</dc:creator>
			<dc:creator>Ronald R. de Krijger</dc:creator>
			<dc:creator>József Zsiros</dc:creator>
			<dc:creator>Weng Chuan Peng</dc:creator>
			<dc:creator>Ruben van Boxtel</dc:creator>
			<dc:creator>Marc van de Wetering</dc:creator>
			<dc:creator>Karin Sanders</dc:creator>
			<dc:creator>Hans Clevers</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010004</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-01-18</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-01-18</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/organoids5010004</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/3">

	<title>Organoids, Vol. 5, Pages 3: Synergistic Overexpression of Sox9, TGF&amp;beta;1, and Col II Induces Functional Chondrogenesis in hUC-MSCs Using a 3D Culture Approach</title>
	<link>https://www.mdpi.com/2674-1172/5/1/3</link>
	<description>Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) possess the potential for chondrogenic differentiation, offering a promising alternative source for cartilage regeneration. To address the limited availability and expansion capacity of autologous chondrocytes, we investigated the effect of co-overexpression of Sox9, TGF&amp;amp;beta;1, and type II collagen (Col II) on the chondrogenic differentiation of hUC-MSCs using both 2D and 3D pellet culture systems. Following transfection, the cells exhibited a chondrocyte-like morphology and a marked downregulation of the stemness marker Stro-1. After 21 days in a 3D pellet culture system, the cells formed cartilage-like tissue characterized by the strong expression of chondrocyte-specific genes (Sox9, TGF&amp;amp;beta;1, Col II, Aggrecan) along with the significant secretion of sulfated glycosaminoglycans (sGaGs). These effects were attributed to enhanced cell&amp;amp;ndash;cell contact and extracellular matrix interactions promoted by the 3D environment. Our findings suggest that genetically modified hUC-MSCs cultured in a 3D pellet system represent a robust in vitro model for cartilage regeneration, with potential applications in transplantation and drug toxicity screening.</description>
	<pubDate>2026-01-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 3: Synergistic Overexpression of Sox9, TGF&amp;beta;1, and Col II Induces Functional Chondrogenesis in hUC-MSCs Using a 3D Culture Approach</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/3">doi: 10.3390/organoids5010003</a></p>
	<p>Authors:
		Shumaila Khalid
		Sobia Ekram
		Faiza Ramzan
		Asmat Salim
		Irfan Khan
		</p>
	<p>Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) possess the potential for chondrogenic differentiation, offering a promising alternative source for cartilage regeneration. To address the limited availability and expansion capacity of autologous chondrocytes, we investigated the effect of co-overexpression of Sox9, TGF&amp;amp;beta;1, and type II collagen (Col II) on the chondrogenic differentiation of hUC-MSCs using both 2D and 3D pellet culture systems. Following transfection, the cells exhibited a chondrocyte-like morphology and a marked downregulation of the stemness marker Stro-1. After 21 days in a 3D pellet culture system, the cells formed cartilage-like tissue characterized by the strong expression of chondrocyte-specific genes (Sox9, TGF&amp;amp;beta;1, Col II, Aggrecan) along with the significant secretion of sulfated glycosaminoglycans (sGaGs). These effects were attributed to enhanced cell&amp;amp;ndash;cell contact and extracellular matrix interactions promoted by the 3D environment. Our findings suggest that genetically modified hUC-MSCs cultured in a 3D pellet system represent a robust in vitro model for cartilage regeneration, with potential applications in transplantation and drug toxicity screening.</p>
	]]></content:encoded>

	<dc:title>Synergistic Overexpression of Sox9, TGF&amp;amp;beta;1, and Col II Induces Functional Chondrogenesis in hUC-MSCs Using a 3D Culture Approach</dc:title>
			<dc:creator>Shumaila Khalid</dc:creator>
			<dc:creator>Sobia Ekram</dc:creator>
			<dc:creator>Faiza Ramzan</dc:creator>
			<dc:creator>Asmat Salim</dc:creator>
			<dc:creator>Irfan Khan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010003</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-01-14</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-01-14</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/organoids5010003</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/2">

	<title>Organoids, Vol. 5, Pages 2: Decellularized Extracellular Matrix for Organoids Development and 3D Bioprinting</title>
	<link>https://www.mdpi.com/2674-1172/5/1/2</link>
	<description>Organoids are three-dimensional multicellular structures that mimic key aspects of native tissues consisting ideal tools to study organ development and pathophysiology when incorporated in customized bioscaffolds. In vivo, the extracellular matrix (ECM) maintains tissue integrity and regulates cell adhesion, migration, differentiation, and survival through biochemical and mechanical signals. Tissue-derived decellularized extracellular matrix (dECM) can preserve organ-specific biochemical signals and cell-adhesive motifs, creating a bioactive environment that supports physiologically relevant organoid growth. 3D bioprinting technology marks a transformative phase in organoid research by enhancing the structural and functional complexity of organoid models and expanding their application in pharmacology and regenerative medicine. These systems enhance tissue modeling and drug testing while adhering to the principles of animal replacement, reduction, and refining (3Rs) in research. Remaining challenges include donor variability, limited mechanical stability, and the lack of standardized decellularization protocols that can be addressed by adopting quality and safety metrics. The combination of dECM-based biomaterials and 3D bioprinting holds great potential for the development of human-relevant, customizable, and ethically sound in vitro models for regenerative medicine and personalized therapies. In this review, we discuss the latest (2021&amp;amp;ndash;2025) developments in applying extracellular matrix bioprinting techniques to organoid technology, presenting examples for the most commonly referenced organoid types.</description>
	<pubDate>2026-01-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 2: Decellularized Extracellular Matrix for Organoids Development and 3D Bioprinting</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/2">doi: 10.3390/organoids5010002</a></p>
	<p>Authors:
		Elena Gkantzou
		Alexandro Rodríguez-Rojas
		Aleksandra Chmielewska
		Barbara Pratscher
		Surina Surina
		Patricia Freund
		Iwan A. Burgener
		</p>
	<p>Organoids are three-dimensional multicellular structures that mimic key aspects of native tissues consisting ideal tools to study organ development and pathophysiology when incorporated in customized bioscaffolds. In vivo, the extracellular matrix (ECM) maintains tissue integrity and regulates cell adhesion, migration, differentiation, and survival through biochemical and mechanical signals. Tissue-derived decellularized extracellular matrix (dECM) can preserve organ-specific biochemical signals and cell-adhesive motifs, creating a bioactive environment that supports physiologically relevant organoid growth. 3D bioprinting technology marks a transformative phase in organoid research by enhancing the structural and functional complexity of organoid models and expanding their application in pharmacology and regenerative medicine. These systems enhance tissue modeling and drug testing while adhering to the principles of animal replacement, reduction, and refining (3Rs) in research. Remaining challenges include donor variability, limited mechanical stability, and the lack of standardized decellularization protocols that can be addressed by adopting quality and safety metrics. The combination of dECM-based biomaterials and 3D bioprinting holds great potential for the development of human-relevant, customizable, and ethically sound in vitro models for regenerative medicine and personalized therapies. In this review, we discuss the latest (2021&amp;amp;ndash;2025) developments in applying extracellular matrix bioprinting techniques to organoid technology, presenting examples for the most commonly referenced organoid types.</p>
	]]></content:encoded>

	<dc:title>Decellularized Extracellular Matrix for Organoids Development and 3D Bioprinting</dc:title>
			<dc:creator>Elena Gkantzou</dc:creator>
			<dc:creator>Alexandro Rodríguez-Rojas</dc:creator>
			<dc:creator>Aleksandra Chmielewska</dc:creator>
			<dc:creator>Barbara Pratscher</dc:creator>
			<dc:creator>Surina Surina</dc:creator>
			<dc:creator>Patricia Freund</dc:creator>
			<dc:creator>Iwan A. Burgener</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010002</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-01-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-01-08</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/organoids5010002</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/5/1/1">

	<title>Organoids, Vol. 5, Pages 1: Permeability of the Blood&amp;ndash;Brain Barrier (BBB) to Nanoparticles, Bacteria and Phages Studied in BBB Organoids Under Normoxic and Hypoxic Conditions In Vitro</title>
	<link>https://www.mdpi.com/2674-1172/5/1/1</link>
	<description>Organoids consisting of primary human cells, i.e., astrocytes, pericytes, and endothelial cells, form a functional blood&amp;amp;ndash;brain barrier (BBB) in vitro. The ability of FITC-dextran (70 kDa), calcium phosphate nanoparticles (100 nm), Escherichia coli bacteria (2 &amp;amp;micro;m), and MS2 coliphages (27 nm, a model for viruses) to penetrate the BBB under normoxic and hypoxic conditions (2.5% oxygen) for up to 12 days was assessed by fluorescence microscopy and confocal laser scanning microscopy. All agents were fluorescently labeled to trace them inside the organoids. Under normoxia, FITC-dextran, calcium phosphate nanoparticles, E. coli bacteria and MS2 coliphages did not penetrate the BBB. However, oxygen deficiency (hypoxia) triggered the penetration of the BBB by FITC-dextran and E. coli cells. This was underscored by a strong hypoxic center inside the organoids that developed in the presence of E. coli bacteria.</description>
	<pubDate>2026-01-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 5, Pages 1: Permeability of the Blood&amp;ndash;Brain Barrier (BBB) to Nanoparticles, Bacteria and Phages Studied in BBB Organoids Under Normoxic and Hypoxic Conditions In Vitro</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/5/1/1">doi: 10.3390/organoids5010001</a></p>
	<p>Authors:
		Kathrin Kostka-Wirtz
		Nataniel Białas
		Ivanna Kostina
		Matthias Epple
		</p>
	<p>Organoids consisting of primary human cells, i.e., astrocytes, pericytes, and endothelial cells, form a functional blood&amp;amp;ndash;brain barrier (BBB) in vitro. The ability of FITC-dextran (70 kDa), calcium phosphate nanoparticles (100 nm), Escherichia coli bacteria (2 &amp;amp;micro;m), and MS2 coliphages (27 nm, a model for viruses) to penetrate the BBB under normoxic and hypoxic conditions (2.5% oxygen) for up to 12 days was assessed by fluorescence microscopy and confocal laser scanning microscopy. All agents were fluorescently labeled to trace them inside the organoids. Under normoxia, FITC-dextran, calcium phosphate nanoparticles, E. coli bacteria and MS2 coliphages did not penetrate the BBB. However, oxygen deficiency (hypoxia) triggered the penetration of the BBB by FITC-dextran and E. coli cells. This was underscored by a strong hypoxic center inside the organoids that developed in the presence of E. coli bacteria.</p>
	]]></content:encoded>

	<dc:title>Permeability of the Blood&amp;amp;ndash;Brain Barrier (BBB) to Nanoparticles, Bacteria and Phages Studied in BBB Organoids Under Normoxic and Hypoxic Conditions In Vitro</dc:title>
			<dc:creator>Kathrin Kostka-Wirtz</dc:creator>
			<dc:creator>Nataniel Białas</dc:creator>
			<dc:creator>Ivanna Kostina</dc:creator>
			<dc:creator>Matthias Epple</dc:creator>
		<dc:identifier>doi: 10.3390/organoids5010001</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2026-01-02</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2026-01-02</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/organoids5010001</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/5/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/33">

	<title>Organoids, Vol. 4, Pages 33: Organoids: Promoting Innovation in Organoid Technology for Basic Research and Therapeutic Applications</title>
	<link>https://www.mdpi.com/2674-1172/4/4/33</link>
	<description>Over the past decade, organoids representing a wide range of tissues have been developed, with increasing efforts to enhance their complexity, maturity, and resemblance to the corresponding native organs [...]</description>
	<pubDate>2025-12-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 33: Organoids: Promoting Innovation in Organoid Technology for Basic Research and Therapeutic Applications</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/33">doi: 10.3390/organoids4040033</a></p>
	<p>Authors:
		Süleyman Ergün
		Philipp Wörsdörfer
		</p>
	<p>Over the past decade, organoids representing a wide range of tissues have been developed, with increasing efforts to enhance their complexity, maturity, and resemblance to the corresponding native organs [...]</p>
	]]></content:encoded>

	<dc:title>Organoids: Promoting Innovation in Organoid Technology for Basic Research and Therapeutic Applications</dc:title>
			<dc:creator>Süleyman Ergün</dc:creator>
			<dc:creator>Philipp Wörsdörfer</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040033</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-12-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-12-08</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>33</prism:startingPage>
		<prism:doi>10.3390/organoids4040033</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/33</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/32">

	<title>Organoids, Vol. 4, Pages 32: Evaluation of a Gene Expression-Based Machine Learning Classifier to Discriminate Normal from Cancer Gastric Organoids</title>
	<link>https://www.mdpi.com/2674-1172/4/4/32</link>
	<description>Three-dimensional cell model systems such as tumour organoids allow for in vitro modelling of self-organized tissue with functional and histologic similarity to in vivo tissue. However, there is a need for standard protocols and techniques to confirm the presence of cancer within organoids derived from tumour tissue. The aim of this study was to assess the utility of a Nanostring gene expression-based machine learning classifier to determine the presence of cancer or normal organoids in cultures developed from both benign and cancerous stomach biopsies. A prospective cohort of normal and cancer stomach biopsies were collected from 2019 to 2022. Tissue specimens were processed for formalin-fixed paraffin-embedding (FFPE) and a subset of specimens were established in organoid cultures. Specimens were labelled as normal or cancer according to analysis of the FFPE tissue by two pathologists. The gene expression in FFPE and organoid tissue was measured using a 107 gene Nanostring codeset and normalized using the Removal of Unwanted Variation III algorithm. Our machine learning model was developed using five-fold nested cross-validation to classify normal or cancer gastric tissue from publicly available Asian Cancer Research Group (ACRG) gene expression data. The models were externally validated using the Cancer Genome Atlas (TCGA), as well as our own FFPE and organoid gene expression data. A total of 60 samples were collected, including 38 cancer FFPE specimens, 5 normal FFPE specimens, 12 cancer organoids, and 5 normal organoids. The optimal model design used a Least Absolute Shrinkage and Selection Operator model for feature selection and an ElasticNet model for classification, yielding area under the curve (AUC) values of 0.99 [95% CI: 0.99&amp;amp;ndash;1], 0.90 [95% CI: 0.87&amp;amp;ndash;0.93], and 0.79 [95% CI: 0.74&amp;amp;ndash;0.84] for ACRG (internal test), FFPE, and organoid (external test) data, respectively. The performance of our final model on external data achieved AUC values of 0.99 [95% CI: 0.98&amp;amp;ndash;1], 0.94 [95% CI: 0.86&amp;amp;ndash;1], and 0.85 [95% CI: 0.63&amp;amp;ndash;1] for TCGA, FFPE, and organoid specimens, respectively. Using a public database to create a machine learning model in combination with a Nanostring gene expression assay allows us to allocate organoids and their paired whole tissue samples. This platform yielded reasonable accuracy for FFPE and organoid specimens, with the former being more accurate. This study re-affirms that although organoids are a high-fidelity model, there are still limitations in validating the recapitulation of cancer in vitro.</description>
	<pubDate>2025-12-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 32: Evaluation of a Gene Expression-Based Machine Learning Classifier to Discriminate Normal from Cancer Gastric Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/32">doi: 10.3390/organoids4040032</a></p>
	<p>Authors:
		Daniel Skubleny
		Hasnaien Ahmed
		Sebastiao N. Martins-Filho
		David Ross McLean
		Daniel E. Schiller
		Gina R. Rayat
		</p>
	<p>Three-dimensional cell model systems such as tumour organoids allow for in vitro modelling of self-organized tissue with functional and histologic similarity to in vivo tissue. However, there is a need for standard protocols and techniques to confirm the presence of cancer within organoids derived from tumour tissue. The aim of this study was to assess the utility of a Nanostring gene expression-based machine learning classifier to determine the presence of cancer or normal organoids in cultures developed from both benign and cancerous stomach biopsies. A prospective cohort of normal and cancer stomach biopsies were collected from 2019 to 2022. Tissue specimens were processed for formalin-fixed paraffin-embedding (FFPE) and a subset of specimens were established in organoid cultures. Specimens were labelled as normal or cancer according to analysis of the FFPE tissue by two pathologists. The gene expression in FFPE and organoid tissue was measured using a 107 gene Nanostring codeset and normalized using the Removal of Unwanted Variation III algorithm. Our machine learning model was developed using five-fold nested cross-validation to classify normal or cancer gastric tissue from publicly available Asian Cancer Research Group (ACRG) gene expression data. The models were externally validated using the Cancer Genome Atlas (TCGA), as well as our own FFPE and organoid gene expression data. A total of 60 samples were collected, including 38 cancer FFPE specimens, 5 normal FFPE specimens, 12 cancer organoids, and 5 normal organoids. The optimal model design used a Least Absolute Shrinkage and Selection Operator model for feature selection and an ElasticNet model for classification, yielding area under the curve (AUC) values of 0.99 [95% CI: 0.99&amp;amp;ndash;1], 0.90 [95% CI: 0.87&amp;amp;ndash;0.93], and 0.79 [95% CI: 0.74&amp;amp;ndash;0.84] for ACRG (internal test), FFPE, and organoid (external test) data, respectively. The performance of our final model on external data achieved AUC values of 0.99 [95% CI: 0.98&amp;amp;ndash;1], 0.94 [95% CI: 0.86&amp;amp;ndash;1], and 0.85 [95% CI: 0.63&amp;amp;ndash;1] for TCGA, FFPE, and organoid specimens, respectively. Using a public database to create a machine learning model in combination with a Nanostring gene expression assay allows us to allocate organoids and their paired whole tissue samples. This platform yielded reasonable accuracy for FFPE and organoid specimens, with the former being more accurate. This study re-affirms that although organoids are a high-fidelity model, there are still limitations in validating the recapitulation of cancer in vitro.</p>
	]]></content:encoded>

	<dc:title>Evaluation of a Gene Expression-Based Machine Learning Classifier to Discriminate Normal from Cancer Gastric Organoids</dc:title>
			<dc:creator>Daniel Skubleny</dc:creator>
			<dc:creator>Hasnaien Ahmed</dc:creator>
			<dc:creator>Sebastiao N. Martins-Filho</dc:creator>
			<dc:creator>David Ross McLean</dc:creator>
			<dc:creator>Daniel E. Schiller</dc:creator>
			<dc:creator>Gina R. Rayat</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040032</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-12-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-12-05</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>32</prism:startingPage>
		<prism:doi>10.3390/organoids4040032</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/32</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/31">

	<title>Organoids, Vol. 4, Pages 31: Organoids as a Tool for Assessing Drinking Water Safety and Guidelines Relevance</title>
	<link>https://www.mdpi.com/2674-1172/4/4/31</link>
	<description>Ensuring access to safe drinking water is a fundamental public health priority, yet the growing diversity of contaminants demands more human-relevant toxicity assessment frameworks. Conventional models based on immortalized cell lines or sentinel species, while informative, lack the tissue complexity and inter-individual variability required to capture realistic human responses. Organoids, three-dimensional epithelial structures derived from adult or pluripotent stem cells, retain the genomic, histological, and functional characteristics of their original tissue, enabling assessment of contaminant-induced toxicity, short-term peak exposures, and inter-donor variability within a single system. This study examined whether current international drinking water guidelines remain protective or if recent organoid-based findings reveal toxicity at differing concentrations. Comparative synthesis indicates that per- and polyfluoroalkyl substances (PFAS) often display organoid toxicity at concentrations above current thresholds, suggesting conservative guidelines, whereas most metals are properly regulated. However, some metals exhibit toxicity at concentrations that include levels below guideline values, highlighting the need for further investigation. Emerging contaminants, including pesticides, nanoparticles, microplastics, and endocrine disruptors, induce adverse effects at environmentally relevant concentrations, despite limited or absent regulatory limits. Integrating organoid-based toxicology with high-frequency monitoring and dynamic exposure modeling could refine water quality guidelines and support adaptive regulatory frameworks that better reflect real-world exposure patterns and human diversity.</description>
	<pubDate>2025-12-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 31: Organoids as a Tool for Assessing Drinking Water Safety and Guidelines Relevance</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/31">doi: 10.3390/organoids4040031</a></p>
	<p>Authors:
		Roberto Coppo
		Edoardo Bertone
		</p>
	<p>Ensuring access to safe drinking water is a fundamental public health priority, yet the growing diversity of contaminants demands more human-relevant toxicity assessment frameworks. Conventional models based on immortalized cell lines or sentinel species, while informative, lack the tissue complexity and inter-individual variability required to capture realistic human responses. Organoids, three-dimensional epithelial structures derived from adult or pluripotent stem cells, retain the genomic, histological, and functional characteristics of their original tissue, enabling assessment of contaminant-induced toxicity, short-term peak exposures, and inter-donor variability within a single system. This study examined whether current international drinking water guidelines remain protective or if recent organoid-based findings reveal toxicity at differing concentrations. Comparative synthesis indicates that per- and polyfluoroalkyl substances (PFAS) often display organoid toxicity at concentrations above current thresholds, suggesting conservative guidelines, whereas most metals are properly regulated. However, some metals exhibit toxicity at concentrations that include levels below guideline values, highlighting the need for further investigation. Emerging contaminants, including pesticides, nanoparticles, microplastics, and endocrine disruptors, induce adverse effects at environmentally relevant concentrations, despite limited or absent regulatory limits. Integrating organoid-based toxicology with high-frequency monitoring and dynamic exposure modeling could refine water quality guidelines and support adaptive regulatory frameworks that better reflect real-world exposure patterns and human diversity.</p>
	]]></content:encoded>

	<dc:title>Organoids as a Tool for Assessing Drinking Water Safety and Guidelines Relevance</dc:title>
			<dc:creator>Roberto Coppo</dc:creator>
			<dc:creator>Edoardo Bertone</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040031</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-12-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-12-04</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>31</prism:startingPage>
		<prism:doi>10.3390/organoids4040031</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/31</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/30">

	<title>Organoids, Vol. 4, Pages 30: AI-Enhanced Patient-Derived Cancer Organoids: Integrating Machine Learning for Precision Oncology</title>
	<link>https://www.mdpi.com/2674-1172/4/4/30</link>
	<description>Cancer remains a leading cause of mortality worldwide. Patient-derived organoids (PDOs) are three-dimensional (3D) cultures that recapitulate tumor histology, genetics, and cellular heterogeneity, providing physiologically relevant preclinical models. Integrating PDOs with artificial intelligence (AI) and machine learning (ML) enables scalable analysis of high-dimensional datasets, including imaging, transcriptomics, proteomics, and pharmacological readouts. These approaches support prediction of drug sensitivity, biomarker discovery, and patient stratification. Recent advances&amp;amp;mdash;such as deep learning (DL), transfer learning, federated learning, and self-supervised learning&amp;amp;mdash;enhance phenotypic profiling, cross-institutional model training, and translational prediction. In this review, we summarize the current state of AI-driven PDO research, highlighting methodological approaches, preclinical and clinical applications, challenges, and emerging trends. We also propose strategies for standardization, validation, and multi-modal integration to accelerate patient-specific therapeutic strategies.</description>
	<pubDate>2025-12-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 30: AI-Enhanced Patient-Derived Cancer Organoids: Integrating Machine Learning for Precision Oncology</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/30">doi: 10.3390/organoids4040030</a></p>
	<p>Authors:
		Elisa Heinzelmann
		Francesco Piraino
		</p>
	<p>Cancer remains a leading cause of mortality worldwide. Patient-derived organoids (PDOs) are three-dimensional (3D) cultures that recapitulate tumor histology, genetics, and cellular heterogeneity, providing physiologically relevant preclinical models. Integrating PDOs with artificial intelligence (AI) and machine learning (ML) enables scalable analysis of high-dimensional datasets, including imaging, transcriptomics, proteomics, and pharmacological readouts. These approaches support prediction of drug sensitivity, biomarker discovery, and patient stratification. Recent advances&amp;amp;mdash;such as deep learning (DL), transfer learning, federated learning, and self-supervised learning&amp;amp;mdash;enhance phenotypic profiling, cross-institutional model training, and translational prediction. In this review, we summarize the current state of AI-driven PDO research, highlighting methodological approaches, preclinical and clinical applications, challenges, and emerging trends. We also propose strategies for standardization, validation, and multi-modal integration to accelerate patient-specific therapeutic strategies.</p>
	]]></content:encoded>

	<dc:title>AI-Enhanced Patient-Derived Cancer Organoids: Integrating Machine Learning for Precision Oncology</dc:title>
			<dc:creator>Elisa Heinzelmann</dc:creator>
			<dc:creator>Francesco Piraino</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040030</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-12-03</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-12-03</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>30</prism:startingPage>
		<prism:doi>10.3390/organoids4040030</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/30</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/29">

	<title>Organoids, Vol. 4, Pages 29: Organoid Intelligence: Can We Separate Intelligent Behavior from an Intelligent Being?</title>
	<link>https://www.mdpi.com/2674-1172/4/4/29</link>
	<description>As brain organoids and organoid-based computational models grow in complexity, they increasingly exhibit electrophysiological patterns consistent with plasticity and information processing. This article explores a central question at the intersection of neuroscience, synthetic biology, and philosophy of mind: Can intelligent behavior be meaningfully separated from an intelligent being? In other words, can adaptive, goal-directed behavior exist independently of subjective awareness&amp;amp;mdash;a question that challenges conventional definitions of cognition and consciousness. Drawing from neuroscience, artificial intelligence, and philosophy, I propose a tiered framework based on neural complexity and environmental responsiveness. This includes a simple level analysis and a context-sensitive benchmark for evaluating intelligence in organoid systems without presupposing sentience. Ethical and ontological implications are also addressed, particularly the risk of anthropomorphizing synthetic cognition and the importance of developing context-aware definitions of intelligence. By distinguishing functional sophistication from subjective experience, the framework aims to guide responsible scientific inquiry while clarifying the boundaries of synthetic cognition.</description>
	<pubDate>2025-11-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 29: Organoid Intelligence: Can We Separate Intelligent Behavior from an Intelligent Being?</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/29">doi: 10.3390/organoids4040029</a></p>
	<p>Authors:
		Daniel Montoya
		</p>
	<p>As brain organoids and organoid-based computational models grow in complexity, they increasingly exhibit electrophysiological patterns consistent with plasticity and information processing. This article explores a central question at the intersection of neuroscience, synthetic biology, and philosophy of mind: Can intelligent behavior be meaningfully separated from an intelligent being? In other words, can adaptive, goal-directed behavior exist independently of subjective awareness&amp;amp;mdash;a question that challenges conventional definitions of cognition and consciousness. Drawing from neuroscience, artificial intelligence, and philosophy, I propose a tiered framework based on neural complexity and environmental responsiveness. This includes a simple level analysis and a context-sensitive benchmark for evaluating intelligence in organoid systems without presupposing sentience. Ethical and ontological implications are also addressed, particularly the risk of anthropomorphizing synthetic cognition and the importance of developing context-aware definitions of intelligence. By distinguishing functional sophistication from subjective experience, the framework aims to guide responsible scientific inquiry while clarifying the boundaries of synthetic cognition.</p>
	]]></content:encoded>

	<dc:title>Organoid Intelligence: Can We Separate Intelligent Behavior from an Intelligent Being?</dc:title>
			<dc:creator>Daniel Montoya</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040029</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-11-18</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-11-18</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Commentary</prism:section>
	<prism:startingPage>29</prism:startingPage>
		<prism:doi>10.3390/organoids4040029</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/29</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/28">

	<title>Organoids, Vol. 4, Pages 28: Combining Proteomics and Organoid Research to Unravel the Multifunctional Complexity of Kidney Physiology Enhances the Need for Controlled Organoid Maturation</title>
	<link>https://www.mdpi.com/2674-1172/4/4/28</link>
	<description>This review aims to highlight how the study of kidney organoids combined with proteomic analysis can deepen our understanding of renal physiology and disease. Proteomics quantifies proteins in a sample, allowing us to determine which proteins are present, how abundant they are, and how they are modified. These data may reveal the pathways that are active in the kidney organoids and how they change in disease, helping to pinpoint candidate biomarkers. Kidney organoids are three-dimensional structures derived from induced pluripotent stem cells (iPS) that recapitulate many architectural and functional features of the adult organ. Because they can be generated in large numbers under defined conditions, organoids provide a promising platform for testing how genetic mutations, environmental stresses, or drugs affect kidney development and pathology. When proteomic profiles are obtained from mature organoids, researchers can directly link protein-level changes to phenotypic outcomes observed in the model. This integration makes it possible to map disease-related networks at the molecular level and to assess the impact of therapeutic interventions in a system that more closely resembles human kidney tissue than traditional cell lines. A current limitation is that many kidney organoids do not reach the full maturation seen in vivo; they often lack complete segmental differentiation and the functional robustness of adult nephrons. Improving the maturation state of organoids will be essential for accurately modeling chronic kidney diseases and for translating findings into clinically relevant therapies.</description>
	<pubDate>2025-11-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 28: Combining Proteomics and Organoid Research to Unravel the Multifunctional Complexity of Kidney Physiology Enhances the Need for Controlled Organoid Maturation</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/28">doi: 10.3390/organoids4040028</a></p>
	<p>Authors:
		Kathrin Groeneveld
		Ralf Mrowka
		</p>
	<p>This review aims to highlight how the study of kidney organoids combined with proteomic analysis can deepen our understanding of renal physiology and disease. Proteomics quantifies proteins in a sample, allowing us to determine which proteins are present, how abundant they are, and how they are modified. These data may reveal the pathways that are active in the kidney organoids and how they change in disease, helping to pinpoint candidate biomarkers. Kidney organoids are three-dimensional structures derived from induced pluripotent stem cells (iPS) that recapitulate many architectural and functional features of the adult organ. Because they can be generated in large numbers under defined conditions, organoids provide a promising platform for testing how genetic mutations, environmental stresses, or drugs affect kidney development and pathology. When proteomic profiles are obtained from mature organoids, researchers can directly link protein-level changes to phenotypic outcomes observed in the model. This integration makes it possible to map disease-related networks at the molecular level and to assess the impact of therapeutic interventions in a system that more closely resembles human kidney tissue than traditional cell lines. A current limitation is that many kidney organoids do not reach the full maturation seen in vivo; they often lack complete segmental differentiation and the functional robustness of adult nephrons. Improving the maturation state of organoids will be essential for accurately modeling chronic kidney diseases and for translating findings into clinically relevant therapies.</p>
	]]></content:encoded>

	<dc:title>Combining Proteomics and Organoid Research to Unravel the Multifunctional Complexity of Kidney Physiology Enhances the Need for Controlled Organoid Maturation</dc:title>
			<dc:creator>Kathrin Groeneveld</dc:creator>
			<dc:creator>Ralf Mrowka</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040028</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-11-14</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-11-14</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>28</prism:startingPage>
		<prism:doi>10.3390/organoids4040028</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/28</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/27">

	<title>Organoids, Vol. 4, Pages 27: Improved Differentiation of Human Retinal Organoids Producing Mature Photoreceptors with Budding Calyceal Process-like Structure and Usher Protein Expression</title>
	<link>https://www.mdpi.com/2674-1172/4/4/27</link>
	<description>Human retinal organoids derived from pluripotent stem cells represent a robust in vitro model for investigating retinal development and disease mechanisms of retinal disorders. However, achieving structural maturation that faithfully recapitulates the intricate architecture of photoreceptors within a feasible and cost-efficient culture timeframe remains a significant challenge. Here, we present an optimized differentiation protocol that enables the generation of retinal organoids exhibiting advanced photoreceptor maturation within 140 days. Photoreceptors in the retinal organoids displayed compartmentalized architecture, including distinct inner and outer segments and connecting cilia. Notably, we observed the emergence of budding calyceal process-like structures&amp;amp;mdash;a feature not previously emphasized in photoreceptors derived from pluripotent stem cells. These results suggest that our protocol may promote advanced photoreceptor maturation within a relatively shortened culture period. Thus, this method could serve as a useful model for investigating retinal development and related pathologies, building upon previous protocols.</description>
	<pubDate>2025-11-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 27: Improved Differentiation of Human Retinal Organoids Producing Mature Photoreceptors with Budding Calyceal Process-like Structure and Usher Protein Expression</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/27">doi: 10.3390/organoids4040027</a></p>
	<p>Authors:
		Tokiyoshi Matsushita
		Takahiro Matsuyama
		Takayuki Kawasaki
		Fumiaki Uchiumi
		</p>
	<p>Human retinal organoids derived from pluripotent stem cells represent a robust in vitro model for investigating retinal development and disease mechanisms of retinal disorders. However, achieving structural maturation that faithfully recapitulates the intricate architecture of photoreceptors within a feasible and cost-efficient culture timeframe remains a significant challenge. Here, we present an optimized differentiation protocol that enables the generation of retinal organoids exhibiting advanced photoreceptor maturation within 140 days. Photoreceptors in the retinal organoids displayed compartmentalized architecture, including distinct inner and outer segments and connecting cilia. Notably, we observed the emergence of budding calyceal process-like structures&amp;amp;mdash;a feature not previously emphasized in photoreceptors derived from pluripotent stem cells. These results suggest that our protocol may promote advanced photoreceptor maturation within a relatively shortened culture period. Thus, this method could serve as a useful model for investigating retinal development and related pathologies, building upon previous protocols.</p>
	]]></content:encoded>

	<dc:title>Improved Differentiation of Human Retinal Organoids Producing Mature Photoreceptors with Budding Calyceal Process-like Structure and Usher Protein Expression</dc:title>
			<dc:creator>Tokiyoshi Matsushita</dc:creator>
			<dc:creator>Takahiro Matsuyama</dc:creator>
			<dc:creator>Takayuki Kawasaki</dc:creator>
			<dc:creator>Fumiaki Uchiumi</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040027</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-11-06</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-11-06</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>27</prism:startingPage>
		<prism:doi>10.3390/organoids4040027</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/27</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/26">

	<title>Organoids, Vol. 4, Pages 26: Integrating 3D Bioprinting with Organoid Technology-Based Breast Cancer Models for Drug Evaluation</title>
	<link>https://www.mdpi.com/2674-1172/4/4/26</link>
	<description>Breast cancer remains one of the leading causes of cancer morbidity and mortality among women worldwide. Conventional two-dimensional (2D) cell culture models and animal studies often fail to accurately recapitulate the complex tumor microenvironment and heterogeneous nature of breast cancer. Recent advancements in tissue engineering have enabled the development of more physiologically relevant models using three-dimensional (3D) bioprinting and organoid technology. This study focuses on integrating 3D bioprinting with patient-derived organoid models to replicate breast cancer tissue architecture, cellular heterogeneity, and tumor-stroma interactions. Utilizing biomimetic bioinks and customized bioprinting protocols, we successfully fabricated breast cancer tissue constructs embedded with stromal and immune components. These engineered models demonstrated high fidelity in mimicking in vivo tumor pathophysiology, including angiogenesis, epithelial&amp;amp;ndash;mesenchymal transition, and extracellular matrix remodeling. Furthermore, the platform allowed for high-throughput drug screening and evaluation of therapeutic responses, revealing differential sensitivities to chemotherapeutics and targeted therapies. Our findings highlight the potential of bioprinted organoid models as powerful tools for personalized medicine, enabling more predictive and reliable cancer research and drug development.</description>
	<pubDate>2025-11-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 26: Integrating 3D Bioprinting with Organoid Technology-Based Breast Cancer Models for Drug Evaluation</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/26">doi: 10.3390/organoids4040026</a></p>
	<p>Authors:
		Arvind Kumar Shukla
		Sandhya Shukla
		Raj Kumar Mongre
		Adarsha Mahendra Upadhyay
		Govindhan Thiruppathi
		Chandra Dhar Shukla
		Shuktika Mishra
		Sayan Deb Dutta
		</p>
	<p>Breast cancer remains one of the leading causes of cancer morbidity and mortality among women worldwide. Conventional two-dimensional (2D) cell culture models and animal studies often fail to accurately recapitulate the complex tumor microenvironment and heterogeneous nature of breast cancer. Recent advancements in tissue engineering have enabled the development of more physiologically relevant models using three-dimensional (3D) bioprinting and organoid technology. This study focuses on integrating 3D bioprinting with patient-derived organoid models to replicate breast cancer tissue architecture, cellular heterogeneity, and tumor-stroma interactions. Utilizing biomimetic bioinks and customized bioprinting protocols, we successfully fabricated breast cancer tissue constructs embedded with stromal and immune components. These engineered models demonstrated high fidelity in mimicking in vivo tumor pathophysiology, including angiogenesis, epithelial&amp;amp;ndash;mesenchymal transition, and extracellular matrix remodeling. Furthermore, the platform allowed for high-throughput drug screening and evaluation of therapeutic responses, revealing differential sensitivities to chemotherapeutics and targeted therapies. Our findings highlight the potential of bioprinted organoid models as powerful tools for personalized medicine, enabling more predictive and reliable cancer research and drug development.</p>
	]]></content:encoded>

	<dc:title>Integrating 3D Bioprinting with Organoid Technology-Based Breast Cancer Models for Drug Evaluation</dc:title>
			<dc:creator>Arvind Kumar Shukla</dc:creator>
			<dc:creator>Sandhya Shukla</dc:creator>
			<dc:creator>Raj Kumar Mongre</dc:creator>
			<dc:creator>Adarsha Mahendra Upadhyay</dc:creator>
			<dc:creator>Govindhan Thiruppathi</dc:creator>
			<dc:creator>Chandra Dhar Shukla</dc:creator>
			<dc:creator>Shuktika Mishra</dc:creator>
			<dc:creator>Sayan Deb Dutta</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040026</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-11-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-11-05</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>26</prism:startingPage>
		<prism:doi>10.3390/organoids4040026</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/26</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/24">

	<title>Organoids, Vol. 4, Pages 24: Development of a Trophoblast Organoid Resource in a Translational Primate Model</title>
	<link>https://www.mdpi.com/2674-1172/4/4/24</link>
	<description>First-trimester placental development comprises many critical yet understudied cellular events that determine pregnancy outcomes. Improper placentation leads to a host of health issues that not only impact the fetal period but also influence later-life offspring health. Thus, an experimental paradigm for studying early placental development is necessary and has spurred the development of new in vitro models. Organoid model systems are three-dimensional structures comprising multiple differentiated cell types that originate from a progenitor population. Trophoblasts are the progenitor cells that serve as the proliferative base for the differentiation and maintenance of the placenta. Due to research constraints, experimental studies on the causal mechanisms underlying pathological pregnancies cannot readily be performed in human subjects. The nonhuman primate (NHP) offers a solution to this problem as it circumvents the limitations of human pregnancy sampling. Importantly, NHPs share many developmental features of human pregnancy, including placenta type and a similar fetal growth trajectory, making longitudinal pregnancy studies feasible and relevant. Since perturbations made in vivo can be validated in vitro, an NHP model of early pregnancy would facilitate mechanistic studies of pregnancy disorders. Herein, we describe the methodology for the establishment of a first-trimester NHP placenta trophoblast organoid model system.</description>
	<pubDate>2025-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 24: Development of a Trophoblast Organoid Resource in a Translational Primate Model</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/24">doi: 10.3390/organoids4040024</a></p>
	<p>Authors:
		Brady M. Wessel
		Jenna N. Castro
		Henry F. Harrison
		Brian P. Scottoline
		Margaret C. Wilcox
		Maureen K. Baldwin
		Victoria H. J. Roberts
		</p>
	<p>First-trimester placental development comprises many critical yet understudied cellular events that determine pregnancy outcomes. Improper placentation leads to a host of health issues that not only impact the fetal period but also influence later-life offspring health. Thus, an experimental paradigm for studying early placental development is necessary and has spurred the development of new in vitro models. Organoid model systems are three-dimensional structures comprising multiple differentiated cell types that originate from a progenitor population. Trophoblasts are the progenitor cells that serve as the proliferative base for the differentiation and maintenance of the placenta. Due to research constraints, experimental studies on the causal mechanisms underlying pathological pregnancies cannot readily be performed in human subjects. The nonhuman primate (NHP) offers a solution to this problem as it circumvents the limitations of human pregnancy sampling. Importantly, NHPs share many developmental features of human pregnancy, including placenta type and a similar fetal growth trajectory, making longitudinal pregnancy studies feasible and relevant. Since perturbations made in vivo can be validated in vitro, an NHP model of early pregnancy would facilitate mechanistic studies of pregnancy disorders. Herein, we describe the methodology for the establishment of a first-trimester NHP placenta trophoblast organoid model system.</p>
	]]></content:encoded>

	<dc:title>Development of a Trophoblast Organoid Resource in a Translational Primate Model</dc:title>
			<dc:creator>Brady M. Wessel</dc:creator>
			<dc:creator>Jenna N. Castro</dc:creator>
			<dc:creator>Henry F. Harrison</dc:creator>
			<dc:creator>Brian P. Scottoline</dc:creator>
			<dc:creator>Margaret C. Wilcox</dc:creator>
			<dc:creator>Maureen K. Baldwin</dc:creator>
			<dc:creator>Victoria H. J. Roberts</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040024</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-10-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-10-08</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>24</prism:startingPage>
		<prism:doi>10.3390/organoids4040024</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/25">

	<title>Organoids, Vol. 4, Pages 25: Dysregulated Intestinal Nutrient Absorption in Obesity Is Associated with Altered Chromatin Accessibility</title>
	<link>https://www.mdpi.com/2674-1172/4/4/25</link>
	<description>Obesity is an epidemic with myriad health effects, but little is understood regarding individual obese phenotypes and how they may respond to therapy. Epigenetic changes associated with obesity have been detected in blood, liver, pancreas, and adipose tissues. Previous work using human organoids found that dietary glucose hyperabsorption is a steadfast trait in cultures derived from some obese subjects, but detailed transcriptional or epigenomic features of the intestinal epithelia associated with this persistent phenotype are unknown. This study evaluated differentially expressed genes and relative chromatin accessibility in intestinal organoids established from donors classified as non-obese, obese, or obese hyperabsorptive by body mass index and glucose transport assays. Transcriptomic analysis indicated that obese hyperabsorptive subject organoids have significantly upregulated dietary nutrient absorption transcripts and downregulated type I interferon targets. Chromatin accessibility and transcription factor footprinting predicted that enhanced HNF4G binding may promote the obese hyperabsorption phenotype. Quantitative RT-PCR assessment in organoids representing a larger subject cohort suggested that intestinal epithelial expression of CUBN, GIP, SLC5A11, and SLC2A5 were highly correlated with hyperabsorption. Thus, the obese hyperabsorption phenotype was characterized by transcriptional changes that support increased nutrient uptake by intestinal epithelia, potentially driven by differentially accessible chromatin. Recognizing unique intestinal phenotypes in obesity provides a new perspective in considering therapeutic targets and options with which to manage the disease.</description>
	<pubDate>2025-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 25: Dysregulated Intestinal Nutrient Absorption in Obesity Is Associated with Altered Chromatin Accessibility</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/25">doi: 10.3390/organoids4040025</a></p>
	<p>Authors:
		Dilhana S. Badurdeen
		Zhen Li
		Jeong-Heon Lee
		Tao Ma
		Aditya Vijay Bhagwate
		Rachel Latanich
		Arjit Dogiparthi
		Tamas Ordog
		Olga Kovbasnjuk
		Vivek Kumbhari
		Jennifer Foulke-Abel
		</p>
	<p>Obesity is an epidemic with myriad health effects, but little is understood regarding individual obese phenotypes and how they may respond to therapy. Epigenetic changes associated with obesity have been detected in blood, liver, pancreas, and adipose tissues. Previous work using human organoids found that dietary glucose hyperabsorption is a steadfast trait in cultures derived from some obese subjects, but detailed transcriptional or epigenomic features of the intestinal epithelia associated with this persistent phenotype are unknown. This study evaluated differentially expressed genes and relative chromatin accessibility in intestinal organoids established from donors classified as non-obese, obese, or obese hyperabsorptive by body mass index and glucose transport assays. Transcriptomic analysis indicated that obese hyperabsorptive subject organoids have significantly upregulated dietary nutrient absorption transcripts and downregulated type I interferon targets. Chromatin accessibility and transcription factor footprinting predicted that enhanced HNF4G binding may promote the obese hyperabsorption phenotype. Quantitative RT-PCR assessment in organoids representing a larger subject cohort suggested that intestinal epithelial expression of CUBN, GIP, SLC5A11, and SLC2A5 were highly correlated with hyperabsorption. Thus, the obese hyperabsorption phenotype was characterized by transcriptional changes that support increased nutrient uptake by intestinal epithelia, potentially driven by differentially accessible chromatin. Recognizing unique intestinal phenotypes in obesity provides a new perspective in considering therapeutic targets and options with which to manage the disease.</p>
	]]></content:encoded>

	<dc:title>Dysregulated Intestinal Nutrient Absorption in Obesity Is Associated with Altered Chromatin Accessibility</dc:title>
			<dc:creator>Dilhana S. Badurdeen</dc:creator>
			<dc:creator>Zhen Li</dc:creator>
			<dc:creator>Jeong-Heon Lee</dc:creator>
			<dc:creator>Tao Ma</dc:creator>
			<dc:creator>Aditya Vijay Bhagwate</dc:creator>
			<dc:creator>Rachel Latanich</dc:creator>
			<dc:creator>Arjit Dogiparthi</dc:creator>
			<dc:creator>Tamas Ordog</dc:creator>
			<dc:creator>Olga Kovbasnjuk</dc:creator>
			<dc:creator>Vivek Kumbhari</dc:creator>
			<dc:creator>Jennifer Foulke-Abel</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040025</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-10-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-10-08</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>25</prism:startingPage>
		<prism:doi>10.3390/organoids4040025</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/25</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/23">

	<title>Organoids, Vol. 4, Pages 23: Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions</title>
	<link>https://www.mdpi.com/2674-1172/4/4/23</link>
	<description>Organoid technology has emerged as a revolutionary tool in cancer research, offering physiologically accurate, three-dimensional models that preserve the histoarchitecture, genetic stability, and phenotypic complexity of primary tumors. These self-organizing structures, derived from adult stem cells, induced pluripotent stem cells, or patient tumor biopsies, recapitulate critical aspects of tumor heterogeneity, clonal evolution, and microenvironmental interactions. Organoids serve as powerful systems for modeling tumor progression, assessing drug sensitivity and resistance, and guiding precision oncology strategies. Recent innovations have extended organoid capabilities beyond static culture systems. Integration with microfluidic organoid-on-chip platforms, high-throughput CRISPR-based functional genomics, and AI-driven phenotypic analytics has enhanced mechanistic insight and translational relevance. Co-culture systems incorporating immune, stromal, and endothelial components now permit dynamic modeling of tumor&amp;amp;ndash;host interactions, immunotherapeutic responses, and metastatic behavior. Comparative analyses with conventional platforms, 2D monolayers, spheroids, and patient-derived xenografts emphasize the superior fidelity and clinical potential of organoids. Despite these advances, several challenges remain, such as protocol variability, incomplete recapitulation of systemic physiology, and limitations in scalability, standardization, and regulatory alignment. Addressing these gaps with unified workflows, synthetic matrices, vascularized and innervated co-cultures, and GMP-compliant manufacturing will be crucial for clinical integration. Proactive engagement with regulatory frameworks and ethical guidelines will be pivotal to ensuring safe, responsible, and equitable clinical translation. With the convergence of bioengineering, multi-omics, and computational modeling, organoids are poised to become indispensable tools in next-generation oncology, driving mechanistic discovery, predictive diagnostics, and personalized therapy optimization.</description>
	<pubDate>2025-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 23: Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/23">doi: 10.3390/organoids4040023</a></p>
	<p>Authors:
		Ayush Madan
		Ramandeep Saini
		Nainci Dhiman
		Shu-Hui Juan
		Mantosh Kumar Satapathy
		</p>
	<p>Organoid technology has emerged as a revolutionary tool in cancer research, offering physiologically accurate, three-dimensional models that preserve the histoarchitecture, genetic stability, and phenotypic complexity of primary tumors. These self-organizing structures, derived from adult stem cells, induced pluripotent stem cells, or patient tumor biopsies, recapitulate critical aspects of tumor heterogeneity, clonal evolution, and microenvironmental interactions. Organoids serve as powerful systems for modeling tumor progression, assessing drug sensitivity and resistance, and guiding precision oncology strategies. Recent innovations have extended organoid capabilities beyond static culture systems. Integration with microfluidic organoid-on-chip platforms, high-throughput CRISPR-based functional genomics, and AI-driven phenotypic analytics has enhanced mechanistic insight and translational relevance. Co-culture systems incorporating immune, stromal, and endothelial components now permit dynamic modeling of tumor&amp;amp;ndash;host interactions, immunotherapeutic responses, and metastatic behavior. Comparative analyses with conventional platforms, 2D monolayers, spheroids, and patient-derived xenografts emphasize the superior fidelity and clinical potential of organoids. Despite these advances, several challenges remain, such as protocol variability, incomplete recapitulation of systemic physiology, and limitations in scalability, standardization, and regulatory alignment. Addressing these gaps with unified workflows, synthetic matrices, vascularized and innervated co-cultures, and GMP-compliant manufacturing will be crucial for clinical integration. Proactive engagement with regulatory frameworks and ethical guidelines will be pivotal to ensuring safe, responsible, and equitable clinical translation. With the convergence of bioengineering, multi-omics, and computational modeling, organoids are poised to become indispensable tools in next-generation oncology, driving mechanistic discovery, predictive diagnostics, and personalized therapy optimization.</p>
	]]></content:encoded>

	<dc:title>Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions</dc:title>
			<dc:creator>Ayush Madan</dc:creator>
			<dc:creator>Ramandeep Saini</dc:creator>
			<dc:creator>Nainci Dhiman</dc:creator>
			<dc:creator>Shu-Hui Juan</dc:creator>
			<dc:creator>Mantosh Kumar Satapathy</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040023</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-10-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-10-08</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>23</prism:startingPage>
		<prism:doi>10.3390/organoids4040023</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/4/22">

	<title>Organoids, Vol. 4, Pages 22: The Cell of Origin Defines the Transcriptional Program of APC-Transformed Organoids</title>
	<link>https://www.mdpi.com/2674-1172/4/4/22</link>
	<description>In many cancers, tumorigenesis is determined in part by the cell type in the tissue that transforms, which has been called the cell of origin. In intestinal cancer, previous observations suggested that transformation can occur from both stem cells and more differentiated cells; in the latter case, this is provided that NF-kB is activated and apoptosis is blocked. However, whether these distinct transformation trajectories yield similar types of cancer remains unresolved. In this study the effect of APC loss within different cellular backgrounds was analyzed. Transformation of either stem-like cells or secretory-like cells, as defined by CD24 or c-KIT expression, by deleting the APC function in organoids in vitro, led to WNT-independent growth of organoids in both cellular populations. Importantly, transformed cultures derived from secretory-like cells had significantly distinct gene expression profiles as compared to the more stem cell-derived (CD44high cells) APC mutant cultures and in fact preserved a level of gene expression that relates back to their original cell lineage. Our data highlights the influence of different cellular backgrounds on the initiation of intestinal cancer and suggests that the cell of origin could be a defining factor in colorectal cancer heterogeneity.</description>
	<pubDate>2025-09-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 22: The Cell of Origin Defines the Transcriptional Program of APC-Transformed Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/4/22">doi: 10.3390/organoids4040022</a></p>
	<p>Authors:
		Aleksandar B. Kirov
		Veerle Lammers
		Arezo Torang
		Jan Koster
		Jan Paul Medema
		</p>
	<p>In many cancers, tumorigenesis is determined in part by the cell type in the tissue that transforms, which has been called the cell of origin. In intestinal cancer, previous observations suggested that transformation can occur from both stem cells and more differentiated cells; in the latter case, this is provided that NF-kB is activated and apoptosis is blocked. However, whether these distinct transformation trajectories yield similar types of cancer remains unresolved. In this study the effect of APC loss within different cellular backgrounds was analyzed. Transformation of either stem-like cells or secretory-like cells, as defined by CD24 or c-KIT expression, by deleting the APC function in organoids in vitro, led to WNT-independent growth of organoids in both cellular populations. Importantly, transformed cultures derived from secretory-like cells had significantly distinct gene expression profiles as compared to the more stem cell-derived (CD44high cells) APC mutant cultures and in fact preserved a level of gene expression that relates back to their original cell lineage. Our data highlights the influence of different cellular backgrounds on the initiation of intestinal cancer and suggests that the cell of origin could be a defining factor in colorectal cancer heterogeneity.</p>
	]]></content:encoded>

	<dc:title>The Cell of Origin Defines the Transcriptional Program of APC-Transformed Organoids</dc:title>
			<dc:creator>Aleksandar B. Kirov</dc:creator>
			<dc:creator>Veerle Lammers</dc:creator>
			<dc:creator>Arezo Torang</dc:creator>
			<dc:creator>Jan Koster</dc:creator>
			<dc:creator>Jan Paul Medema</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4040022</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-09-30</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-09-30</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>22</prism:startingPage>
		<prism:doi>10.3390/organoids4040022</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/4/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/21">

	<title>Organoids, Vol. 4, Pages 21: Air&amp;ndash;Liquid-Interface-Differentiated Human Nose Epithelium: The Benchmark Culture Model for SARS-CoV-2 Infection</title>
	<link>https://www.mdpi.com/2674-1172/4/3/21</link>
	<description>COVID-19 has triggered the rapid adoption of human organoid-based tissue culture models to overcome the limitations of the commonly used Vero cell line that did not fully recapitulate SARS-CoV-2 infection of human tissues. As the primary site of SARS-CoV-2 infection, the human nasal epithelium (HNE) cultivated in vitro and differentiated at air&amp;amp;ndash;liquid interface (ALI) is an ideal model to study infection processes and for testing anti-viral antibodies and drugs. However, the need for primary basal cells to establish the ALI-HNE limits the scalability of this model system. To try and bypass this bottleneck, we devised an ALI-differentiated form of the human adenocarcinoma cell line Calu-3, reported to model most aspects of authentic SARS-CoV-2 infection, including viral entry. The ALI-Calu-3 were tested for infection by a panel of SARS-CoV-2 variants, including ancestral (VIC01) and early pandemic lineages (VIC2089, Beta, Delta), and Omicron subvariants (BA2.75, BA4, BA5, XBB1.5). All tested lineages infected the ALI-HNE. In stark contrast, infection of the ALI-Calu-3 by Omicron subvariants BA4 and XBB1.5 was reduced. These data support the use of ALI-Calu-3 as a complementary, intermediary model for most but not all SARS-CoV-2 lineages, and places the ALI-HNE as the benchmark culture model for SARS-CoV-2 infection.</description>
	<pubDate>2025-09-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 21: Air&amp;ndash;Liquid-Interface-Differentiated Human Nose Epithelium: The Benchmark Culture Model for SARS-CoV-2 Infection</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/21">doi: 10.3390/organoids4030021</a></p>
	<p>Authors:
		Sarah L. Harbach
		Bang M. Tran
		Abderrahman Hachani
		Samantha Leigh Grimley
		Damian F. J. Purcell
		Georgia Deliyannis
		Joseph Torresi
		Julie L. McAuley
		Elizabeth Vincan
		</p>
	<p>COVID-19 has triggered the rapid adoption of human organoid-based tissue culture models to overcome the limitations of the commonly used Vero cell line that did not fully recapitulate SARS-CoV-2 infection of human tissues. As the primary site of SARS-CoV-2 infection, the human nasal epithelium (HNE) cultivated in vitro and differentiated at air&amp;amp;ndash;liquid interface (ALI) is an ideal model to study infection processes and for testing anti-viral antibodies and drugs. However, the need for primary basal cells to establish the ALI-HNE limits the scalability of this model system. To try and bypass this bottleneck, we devised an ALI-differentiated form of the human adenocarcinoma cell line Calu-3, reported to model most aspects of authentic SARS-CoV-2 infection, including viral entry. The ALI-Calu-3 were tested for infection by a panel of SARS-CoV-2 variants, including ancestral (VIC01) and early pandemic lineages (VIC2089, Beta, Delta), and Omicron subvariants (BA2.75, BA4, BA5, XBB1.5). All tested lineages infected the ALI-HNE. In stark contrast, infection of the ALI-Calu-3 by Omicron subvariants BA4 and XBB1.5 was reduced. These data support the use of ALI-Calu-3 as a complementary, intermediary model for most but not all SARS-CoV-2 lineages, and places the ALI-HNE as the benchmark culture model for SARS-CoV-2 infection.</p>
	]]></content:encoded>

	<dc:title>Air&amp;amp;ndash;Liquid-Interface-Differentiated Human Nose Epithelium: The Benchmark Culture Model for SARS-CoV-2 Infection</dc:title>
			<dc:creator>Sarah L. Harbach</dc:creator>
			<dc:creator>Bang M. Tran</dc:creator>
			<dc:creator>Abderrahman Hachani</dc:creator>
			<dc:creator>Samantha Leigh Grimley</dc:creator>
			<dc:creator>Damian F. J. Purcell</dc:creator>
			<dc:creator>Georgia Deliyannis</dc:creator>
			<dc:creator>Joseph Torresi</dc:creator>
			<dc:creator>Julie L. McAuley</dc:creator>
			<dc:creator>Elizabeth Vincan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030021</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-09-18</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-09-18</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>21</prism:startingPage>
		<prism:doi>10.3390/organoids4030021</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/20">

	<title>Organoids, Vol. 4, Pages 20: Breaking and Remaking: Using Organoids to Model Gastric Tissue Damage and Repair</title>
	<link>https://www.mdpi.com/2674-1172/4/3/20</link>
	<description>The stomach epithelium is a highly dynamic tissue that undergoes continuous self-renewal and responds robustly to injury through tightly regulated repair processes. Organoids have emerged as powerful tools for modelling gastrointestinal biology. This review focuses on the capacity of gastric organoids to model epithelial homeostasis, injury and repair in the stomach. We examine how organoid systems recapitulate key features of in vivo gastric architecture and stem cell dynamics, enabling detailed interrogation of lineage specification, proliferative hierarchies and regional identity. Gastric organoids have proven particularly useful for studying how environmental factors, such as Helicobacter pylori infection or inflammatory cytokines, disrupt epithelial equilibrium and drive metaplastic transformation. Furthermore, we discuss the emerging use of injury-mimicking conditions, co-cultures and bioengineered platforms to model regeneration and inflammatory responses in vitro. While organoids offer unparalleled accessibility and experimental manipulation, they remain limited by the absence of critical niche components such as immune, stromal and neural elements. Nevertheless, advances in multi-cellular and spatially resolved organoid models are closing this gap, making them increasingly relevant for disease modelling and regenerative medicine. Overall, gastric organoids represent a transformative approach to dissecting the cellular and molecular underpinnings of stomach homeostasis and repair.</description>
	<pubDate>2025-09-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 20: Breaking and Remaking: Using Organoids to Model Gastric Tissue Damage and Repair</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/20">doi: 10.3390/organoids4030020</a></p>
	<p>Authors:
		Nikki Liddelow
		Jie Yu Tan
		Dustin J. Flanagan
		</p>
	<p>The stomach epithelium is a highly dynamic tissue that undergoes continuous self-renewal and responds robustly to injury through tightly regulated repair processes. Organoids have emerged as powerful tools for modelling gastrointestinal biology. This review focuses on the capacity of gastric organoids to model epithelial homeostasis, injury and repair in the stomach. We examine how organoid systems recapitulate key features of in vivo gastric architecture and stem cell dynamics, enabling detailed interrogation of lineage specification, proliferative hierarchies and regional identity. Gastric organoids have proven particularly useful for studying how environmental factors, such as Helicobacter pylori infection or inflammatory cytokines, disrupt epithelial equilibrium and drive metaplastic transformation. Furthermore, we discuss the emerging use of injury-mimicking conditions, co-cultures and bioengineered platforms to model regeneration and inflammatory responses in vitro. While organoids offer unparalleled accessibility and experimental manipulation, they remain limited by the absence of critical niche components such as immune, stromal and neural elements. Nevertheless, advances in multi-cellular and spatially resolved organoid models are closing this gap, making them increasingly relevant for disease modelling and regenerative medicine. Overall, gastric organoids represent a transformative approach to dissecting the cellular and molecular underpinnings of stomach homeostasis and repair.</p>
	]]></content:encoded>

	<dc:title>Breaking and Remaking: Using Organoids to Model Gastric Tissue Damage and Repair</dc:title>
			<dc:creator>Nikki Liddelow</dc:creator>
			<dc:creator>Jie Yu Tan</dc:creator>
			<dc:creator>Dustin J. Flanagan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030020</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-09-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-09-05</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>20</prism:startingPage>
		<prism:doi>10.3390/organoids4030020</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/19">

	<title>Organoids, Vol. 4, Pages 19: Paraffin Embedding and Histological Analyses of Sw71-Spheroids as Human Blastocyst-like Surrogates</title>
	<link>https://www.mdpi.com/2674-1172/4/3/19</link>
	<description>Implantation studies are extremely important to solve reproductive problems since about 60% of abortions occur around this period. The 3D in vitro models emerge as closest to the in vivo structures and processes. Here, we constructed trophoblast Sw71-spheroids as implanting human blastocyst&amp;amp;ndash;like surrogates (BLS). The model is well-characterized, standardized, validated tool to study extravillous trophoblast (EVT) invasion/migration during implantation. A limitation is that it is a short-living 3D-culture that must be generated de novo. This study aimed to create and embed Sw71-spheroids in paraffin for permanent histological preparations. The main challenges were the micro-size and the preservation of the intact structure. The standardly generated compact and stable Sw71-spheroids were intact, with blastocyst-like morphology. Histological analysis showed preserved cell morphology, shape, and intact periphery of the embedded Sw71-spheroids. These were usable for immunohistochemistry(IHC) and expressed common EVT markers: EpCAM, HLA-C and and HLA-G. Our protocol for spheroid paraffin embedding is suitable for simultaneous histological analyses of several Sw71-spheroids. It might be further optimized to embed migrating/invading Sw71-BLS as snapshots of trophoblast implantation steps in permanent histological preparations for in depth IHC studies.</description>
	<pubDate>2025-08-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 19: Paraffin Embedding and Histological Analyses of Sw71-Spheroids as Human Blastocyst-like Surrogates</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/19">doi: 10.3390/organoids4030019</a></p>
	<p>Authors:
		Marina Alexandrova
		Mariela Ivanova
		Martina Metodieva
		Antonia Terzieva
		Tanya Dimova
		</p>
	<p>Implantation studies are extremely important to solve reproductive problems since about 60% of abortions occur around this period. The 3D in vitro models emerge as closest to the in vivo structures and processes. Here, we constructed trophoblast Sw71-spheroids as implanting human blastocyst&amp;amp;ndash;like surrogates (BLS). The model is well-characterized, standardized, validated tool to study extravillous trophoblast (EVT) invasion/migration during implantation. A limitation is that it is a short-living 3D-culture that must be generated de novo. This study aimed to create and embed Sw71-spheroids in paraffin for permanent histological preparations. The main challenges were the micro-size and the preservation of the intact structure. The standardly generated compact and stable Sw71-spheroids were intact, with blastocyst-like morphology. Histological analysis showed preserved cell morphology, shape, and intact periphery of the embedded Sw71-spheroids. These were usable for immunohistochemistry(IHC) and expressed common EVT markers: EpCAM, HLA-C and and HLA-G. Our protocol for spheroid paraffin embedding is suitable for simultaneous histological analyses of several Sw71-spheroids. It might be further optimized to embed migrating/invading Sw71-BLS as snapshots of trophoblast implantation steps in permanent histological preparations for in depth IHC studies.</p>
	]]></content:encoded>

	<dc:title>Paraffin Embedding and Histological Analyses of Sw71-Spheroids as Human Blastocyst-like Surrogates</dc:title>
			<dc:creator>Marina Alexandrova</dc:creator>
			<dc:creator>Mariela Ivanova</dc:creator>
			<dc:creator>Martina Metodieva</dc:creator>
			<dc:creator>Antonia Terzieva</dc:creator>
			<dc:creator>Tanya Dimova</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030019</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-08-11</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-08-11</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>19</prism:startingPage>
		<prism:doi>10.3390/organoids4030019</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/18">

	<title>Organoids, Vol. 4, Pages 18: Applications of Organoids and Spheroids in Anaplastic and Papillary Thyroid Cancer Research: A Comprehensive Review</title>
	<link>https://www.mdpi.com/2674-1172/4/3/18</link>
	<description>Organoid and spheroid technologies have rapidly become pivotal in thyroid cancer research, offering models that are more physiologically relevant than traditional two-dimensional culture. In the study of papillary and anaplastic thyroid carcinomas, two subtypes that differ both histologically and clinically, three-dimensional (3D) models offer unparalleled insights into tumor biology, therapeutic vulnerabilities, and resistance mechanisms. These models maintain essential tumor characteristics such as cellular diversity, spatial structure, and interactions with the microenvironment, making them extremely valuable for disease modeling and drug testing. This review emphasizes recent progress in the development and use of thyroid cancer organoids and spheroids, focusing on their role in replicating disease features, evaluating targeted therapies, and investigating epithelial&amp;amp;ndash;mesenchymal transition (EMT), cancer stem cell behavior, and treatment resistance. Patient-derived organoids have shown potential in capturing individualized drug responses, supporting precision oncology strategies for both differentiated and aggressive subtypes. Additionally, new platforms, such as thyroid organoid-on-a-chip systems, provide dynamic, high-fidelity models for functional studies and assessments of endocrine disruption. Despite ongoing challenges, such as standardization, limited inclusion of immune and stromal components, and culture reproducibility, advancements in microfluidics, biomaterials, and machine learning have enhanced the clinical and translational potential of these systems. Organoids and spheroids are expected to become essential in the future of thyroid cancer research, particularly in bridging the gap between laboratory discoveries and patient-focused therapies.</description>
	<pubDate>2025-08-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 18: Applications of Organoids and Spheroids in Anaplastic and Papillary Thyroid Cancer Research: A Comprehensive Review</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/18">doi: 10.3390/organoids4030018</a></p>
	<p>Authors:
		Deepak Gulwani
		Neha Singh
		Manisha Gupta
		Ridhima Goel
		Thoudam Debraj Singh
		</p>
	<p>Organoid and spheroid technologies have rapidly become pivotal in thyroid cancer research, offering models that are more physiologically relevant than traditional two-dimensional culture. In the study of papillary and anaplastic thyroid carcinomas, two subtypes that differ both histologically and clinically, three-dimensional (3D) models offer unparalleled insights into tumor biology, therapeutic vulnerabilities, and resistance mechanisms. These models maintain essential tumor characteristics such as cellular diversity, spatial structure, and interactions with the microenvironment, making them extremely valuable for disease modeling and drug testing. This review emphasizes recent progress in the development and use of thyroid cancer organoids and spheroids, focusing on their role in replicating disease features, evaluating targeted therapies, and investigating epithelial&amp;amp;ndash;mesenchymal transition (EMT), cancer stem cell behavior, and treatment resistance. Patient-derived organoids have shown potential in capturing individualized drug responses, supporting precision oncology strategies for both differentiated and aggressive subtypes. Additionally, new platforms, such as thyroid organoid-on-a-chip systems, provide dynamic, high-fidelity models for functional studies and assessments of endocrine disruption. Despite ongoing challenges, such as standardization, limited inclusion of immune and stromal components, and culture reproducibility, advancements in microfluidics, biomaterials, and machine learning have enhanced the clinical and translational potential of these systems. Organoids and spheroids are expected to become essential in the future of thyroid cancer research, particularly in bridging the gap between laboratory discoveries and patient-focused therapies.</p>
	]]></content:encoded>

	<dc:title>Applications of Organoids and Spheroids in Anaplastic and Papillary Thyroid Cancer Research: A Comprehensive Review</dc:title>
			<dc:creator>Deepak Gulwani</dc:creator>
			<dc:creator>Neha Singh</dc:creator>
			<dc:creator>Manisha Gupta</dc:creator>
			<dc:creator>Ridhima Goel</dc:creator>
			<dc:creator>Thoudam Debraj Singh</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030018</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-08-01</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-08-01</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:doi>10.3390/organoids4030018</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/17">

	<title>Organoids, Vol. 4, Pages 17: Mimicking Senescence Factors to Characterize the Mechanisms Responsible for Hair Regression and Hair Loss: An In Vitro Study</title>
	<link>https://www.mdpi.com/2674-1172/4/3/17</link>
	<description>Background/Objectives: VitroScreenORA&amp;amp;reg; (by VitroScreen srl) Dermo Papilla spheroids, based on two micro-physiological systems (non-vascularized DP and vascularized VASC-DP), were used to study the molecular mechanisms behind hair cycle regression. Methods: Dermal papilla cells (HFDPC) were cultured to develop both models. Hair cycle regression was induced by exposing DP spheroids to TGF-&amp;amp;beta;1 for 72 h and/or FGF-18 for an additional 24 h. Catagen phase entrance was evaluated by modulating specific genes (FGF7, CCND1, and WNT5B). The VASC-DP model was obtained by sequentially co-culturing HFDPC and primary dermal microvascular endothelial cells (HMDEC), mimicking the surrounding capillary loop. The vascular system&amp;amp;rsquo;s impact was assessed at 5 and 10 days using IF on CD31 (micro-vessels) and Fibronectin (FN). Nanostring nCounter&amp;amp;reg; technology was applied to investigate the transcriptional signature based on the WNT pathway. Extended culture time up to 11 days simulated natural hair cycle regression, monitored by versican and FN expression (IF). Minoxidil, Doxorubicin, and Retinol-based products were used to modify physiological aging over time. Results: Data shows that the vascular system improves tissue physiology by modulating the associated genes. Extended culture time confirms progressive DP structure degeneration that is partially recoverable with Retinol-based treatments. Conclusions: Both models provide a reliable platform to investigate the hair cycle, paving the way for new testing systems for personalized therapies.</description>
	<pubDate>2025-07-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 17: Mimicking Senescence Factors to Characterize the Mechanisms Responsible for Hair Regression and Hair Loss: An In Vitro Study</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/17">doi: 10.3390/organoids4030017</a></p>
	<p>Authors:
		Giacomo Masi
		Camilla Guiducci
		Francesca Rescigno
		</p>
	<p>Background/Objectives: VitroScreenORA&amp;amp;reg; (by VitroScreen srl) Dermo Papilla spheroids, based on two micro-physiological systems (non-vascularized DP and vascularized VASC-DP), were used to study the molecular mechanisms behind hair cycle regression. Methods: Dermal papilla cells (HFDPC) were cultured to develop both models. Hair cycle regression was induced by exposing DP spheroids to TGF-&amp;amp;beta;1 for 72 h and/or FGF-18 for an additional 24 h. Catagen phase entrance was evaluated by modulating specific genes (FGF7, CCND1, and WNT5B). The VASC-DP model was obtained by sequentially co-culturing HFDPC and primary dermal microvascular endothelial cells (HMDEC), mimicking the surrounding capillary loop. The vascular system&amp;amp;rsquo;s impact was assessed at 5 and 10 days using IF on CD31 (micro-vessels) and Fibronectin (FN). Nanostring nCounter&amp;amp;reg; technology was applied to investigate the transcriptional signature based on the WNT pathway. Extended culture time up to 11 days simulated natural hair cycle regression, monitored by versican and FN expression (IF). Minoxidil, Doxorubicin, and Retinol-based products were used to modify physiological aging over time. Results: Data shows that the vascular system improves tissue physiology by modulating the associated genes. Extended culture time confirms progressive DP structure degeneration that is partially recoverable with Retinol-based treatments. Conclusions: Both models provide a reliable platform to investigate the hair cycle, paving the way for new testing systems for personalized therapies.</p>
	]]></content:encoded>

	<dc:title>Mimicking Senescence Factors to Characterize the Mechanisms Responsible for Hair Regression and Hair Loss: An In Vitro Study</dc:title>
			<dc:creator>Giacomo Masi</dc:creator>
			<dc:creator>Camilla Guiducci</dc:creator>
			<dc:creator>Francesca Rescigno</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030017</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-07-11</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-07-11</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>17</prism:startingPage>
		<prism:doi>10.3390/organoids4030017</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/16">

	<title>Organoids, Vol. 4, Pages 16: A Concise Review of Organoid Tissue Engineering: Regenerative Applications and Precision Medicine</title>
	<link>https://www.mdpi.com/2674-1172/4/3/16</link>
	<description>Organoids are three-dimensional tissue culture models derived from stem cells, and they have become one of the most valuable tools in biomedical research. These self-organizing miniature organs mimic the structure&amp;amp;minus;function properties of their in vivo counterparts and offer an exceptional prospective for disease modeling, drug discovery, and regenerative medicine. By replicating the complexity of human tissue, organoids enable the study of disease pathophysiology, tissue development, and cellular interactions in a highly controlled and manipulable environment. Recent developments in organoid technology have enabled the production of functional organoids of various tissues. These systems have proven to be highly promising tools for personalized medicine. In addition, organoids have also raised hopes for the development of functional transplantable organs, transforming the study of regenerative medicine. This review provides an overview of the current state of organoid technology and its application and prospects and focuses on the transformative impact of organoid technology on biomedical research and its contribution to human health.</description>
	<pubDate>2025-07-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 16: A Concise Review of Organoid Tissue Engineering: Regenerative Applications and Precision Medicine</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/16">doi: 10.3390/organoids4030016</a></p>
	<p>Authors:
		Karnika Yogeswari Makesh
		Abilash Navaneethan
		Mrithika Ajay
		Ganesh Munuswamy-Ramanujam
		Arulvasu Chinnasamy
		Dhanavathy Gnanasampanthapandian
		Kanagaraj Palaniyandi
		</p>
	<p>Organoids are three-dimensional tissue culture models derived from stem cells, and they have become one of the most valuable tools in biomedical research. These self-organizing miniature organs mimic the structure&amp;amp;minus;function properties of their in vivo counterparts and offer an exceptional prospective for disease modeling, drug discovery, and regenerative medicine. By replicating the complexity of human tissue, organoids enable the study of disease pathophysiology, tissue development, and cellular interactions in a highly controlled and manipulable environment. Recent developments in organoid technology have enabled the production of functional organoids of various tissues. These systems have proven to be highly promising tools for personalized medicine. In addition, organoids have also raised hopes for the development of functional transplantable organs, transforming the study of regenerative medicine. This review provides an overview of the current state of organoid technology and its application and prospects and focuses on the transformative impact of organoid technology on biomedical research and its contribution to human health.</p>
	]]></content:encoded>

	<dc:title>A Concise Review of Organoid Tissue Engineering: Regenerative Applications and Precision Medicine</dc:title>
			<dc:creator>Karnika Yogeswari Makesh</dc:creator>
			<dc:creator>Abilash Navaneethan</dc:creator>
			<dc:creator>Mrithika Ajay</dc:creator>
			<dc:creator>Ganesh Munuswamy-Ramanujam</dc:creator>
			<dc:creator>Arulvasu Chinnasamy</dc:creator>
			<dc:creator>Dhanavathy Gnanasampanthapandian</dc:creator>
			<dc:creator>Kanagaraj Palaniyandi</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030016</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-07-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-07-04</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/organoids4030016</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/3/15">

	<title>Organoids, Vol. 4, Pages 15: Pyrvinium Pamoate and BCL-XL Inhibitors Act Synergistically to Kill Patient-Derived Colorectal Adenoma Organoids</title>
	<link>https://www.mdpi.com/2674-1172/4/3/15</link>
	<description>Current systemic therapies for advanced colorectal cancer (CRC) have limited efficacy, so more effective strategies for the treatment and prevention of CRC are needed. The majority of colorectal cancers are initiated by mutations in Wnt signalling pathway genes, including mutations in the APC gene, which result in a truncated APC protein and lead to excess signalling from &amp;amp;beta;-catenin and the formation of pre-cancerous adenomas. The aim of this study was to determine if targeting the Wnt pathway in combination with pro-apoptotic mimetics altered the proliferative capacity or viability of human colorectal adenoma cells. Patient-derived colorectal adenoma organoid cultures were established from colon adenoma tissue collected by colonoscopy and recapitulated the histopathology of primary colorectal adenoma tissue. The growth of colorectal adenoma organoids is inhibited by the Wnt-signalling antagonist pyrvinium pamoate (PP) and a pro-apoptotic inhibitor of BCL-XL but not BCL-2 (venetoclax) or MCL-1 inhibitors. At low concentrations, the PP and the BCL-XL inhibitor combination demonstrated potent synergy and induced apoptosis in APC-defective patient-derived adenoma organoids, even in the presence of oncogenic KRAS or BRAF mutations, providing a new strategy for colon cancer prevention.</description>
	<pubDate>2025-07-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 15: Pyrvinium Pamoate and BCL-XL Inhibitors Act Synergistically to Kill Patient-Derived Colorectal Adenoma Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/3/15">doi: 10.3390/organoids4030015</a></p>
	<p>Authors:
		Maree C. Faux
		Chenkai Ma
		Serena R. Kane
		Andre Samson
		Yumiko Hirokawa
		Ilka Priebe
		Leah Cosgrove
		Rajvinder Singh
		Michael Christie
		Gregor Brown
		Kim Y. C. Fung
		Antony W. Burgess
		</p>
	<p>Current systemic therapies for advanced colorectal cancer (CRC) have limited efficacy, so more effective strategies for the treatment and prevention of CRC are needed. The majority of colorectal cancers are initiated by mutations in Wnt signalling pathway genes, including mutations in the APC gene, which result in a truncated APC protein and lead to excess signalling from &amp;amp;beta;-catenin and the formation of pre-cancerous adenomas. The aim of this study was to determine if targeting the Wnt pathway in combination with pro-apoptotic mimetics altered the proliferative capacity or viability of human colorectal adenoma cells. Patient-derived colorectal adenoma organoid cultures were established from colon adenoma tissue collected by colonoscopy and recapitulated the histopathology of primary colorectal adenoma tissue. The growth of colorectal adenoma organoids is inhibited by the Wnt-signalling antagonist pyrvinium pamoate (PP) and a pro-apoptotic inhibitor of BCL-XL but not BCL-2 (venetoclax) or MCL-1 inhibitors. At low concentrations, the PP and the BCL-XL inhibitor combination demonstrated potent synergy and induced apoptosis in APC-defective patient-derived adenoma organoids, even in the presence of oncogenic KRAS or BRAF mutations, providing a new strategy for colon cancer prevention.</p>
	]]></content:encoded>

	<dc:title>Pyrvinium Pamoate and BCL-XL Inhibitors Act Synergistically to Kill Patient-Derived Colorectal Adenoma Organoids</dc:title>
			<dc:creator>Maree C. Faux</dc:creator>
			<dc:creator>Chenkai Ma</dc:creator>
			<dc:creator>Serena R. Kane</dc:creator>
			<dc:creator>Andre Samson</dc:creator>
			<dc:creator>Yumiko Hirokawa</dc:creator>
			<dc:creator>Ilka Priebe</dc:creator>
			<dc:creator>Leah Cosgrove</dc:creator>
			<dc:creator>Rajvinder Singh</dc:creator>
			<dc:creator>Michael Christie</dc:creator>
			<dc:creator>Gregor Brown</dc:creator>
			<dc:creator>Kim Y. C. Fung</dc:creator>
			<dc:creator>Antony W. Burgess</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4030015</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-07-02</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-07-02</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/organoids4030015</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/3/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/14">

	<title>Organoids, Vol. 4, Pages 14: Resistance to MAPK Pathway Inhibition in BRAF-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors</title>
	<link>https://www.mdpi.com/2674-1172/4/2/14</link>
	<description>The current treatment for refractory BRAF-V600E mutant metastatic colorectal cancer (mCRC) involves combined inhibition of BRAF and the epidermal growth factor receptor (EGFR). However, tumour responses are often short-lived due to a rebound in mitogen-activated protein kinase (MAPK) activity. In this study, we combined short-term cell viability assays with long-term regrowth assays following drug removal over a period of three weeks. This allowed assessment of regrowth after therapy discontinuation. We tested the effect of combined BRAF inhibition (encorafenib) and EGFR inhibition (afatinib) on BRAF-V600E mutant CRC patient-derived organoids (PDOs). Combined EGFR/BRAF inhibition initially caused a major reduction in PDO growth capacity in BRAF-V600E mutant PDOs. This was followed by rapid regrowth after drug removal, mirroring clinical outcomes. EGFR inhibition in BRAF-V600E mutant PDOs led to activation of the insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R). The IGF1R/IR inhibitor linsitinib prevented the rebound in MAPK activity following removal of afatinib and encorafenib, prevented regrowth of CRC PDOs, and improved the anti-tumour response in an in vivo model. PDO regrowth assays allow the identification of pathways driving tumour recurrence. IR/IGF1R-inhibition prevents regrowth following golden standard MAPK pathway-targeted therapy and provides a strategy to improve the treatment of BRAF-V600E mutant CRC</description>
	<pubDate>2025-06-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 14: Resistance to MAPK Pathway Inhibition in BRAF-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/14">doi: 10.3390/organoids4020014</a></p>
	<p>Authors:
		Layla El Bouazzaoui
		Daniëlle A. E. Raats
		André Verheem
		Inne H. M. Borel Rinkes
		Hugo J. G. Snippert
		Madelon M. Maurice
		Onno Kranenburg
		</p>
	<p>The current treatment for refractory BRAF-V600E mutant metastatic colorectal cancer (mCRC) involves combined inhibition of BRAF and the epidermal growth factor receptor (EGFR). However, tumour responses are often short-lived due to a rebound in mitogen-activated protein kinase (MAPK) activity. In this study, we combined short-term cell viability assays with long-term regrowth assays following drug removal over a period of three weeks. This allowed assessment of regrowth after therapy discontinuation. We tested the effect of combined BRAF inhibition (encorafenib) and EGFR inhibition (afatinib) on BRAF-V600E mutant CRC patient-derived organoids (PDOs). Combined EGFR/BRAF inhibition initially caused a major reduction in PDO growth capacity in BRAF-V600E mutant PDOs. This was followed by rapid regrowth after drug removal, mirroring clinical outcomes. EGFR inhibition in BRAF-V600E mutant PDOs led to activation of the insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R). The IGF1R/IR inhibitor linsitinib prevented the rebound in MAPK activity following removal of afatinib and encorafenib, prevented regrowth of CRC PDOs, and improved the anti-tumour response in an in vivo model. PDO regrowth assays allow the identification of pathways driving tumour recurrence. IR/IGF1R-inhibition prevents regrowth following golden standard MAPK pathway-targeted therapy and provides a strategy to improve the treatment of BRAF-V600E mutant CRC</p>
	]]></content:encoded>

	<dc:title>Resistance to MAPK Pathway Inhibition in BRAF-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors</dc:title>
			<dc:creator>Layla El Bouazzaoui</dc:creator>
			<dc:creator>Daniëlle A. E. Raats</dc:creator>
			<dc:creator>André Verheem</dc:creator>
			<dc:creator>Inne H. M. Borel Rinkes</dc:creator>
			<dc:creator>Hugo J. G. Snippert</dc:creator>
			<dc:creator>Madelon M. Maurice</dc:creator>
			<dc:creator>Onno Kranenburg</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020014</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-06-12</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-06-12</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/organoids4020014</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/13">

	<title>Organoids, Vol. 4, Pages 13: Development of Low-Cost CNC-Milled PMMA Microfluidic Chips as a Prototype for Organ-on-a-Chip and Neurospheroid Applications</title>
	<link>https://www.mdpi.com/2674-1172/4/2/13</link>
	<description>Improved in vitro models are needed to reduce costs and delays in central nervous system (CNS) drug discovery. The FDA Modernization Acts 2.0 and 3.0 require human-centered alternative testing methods to mitigate animal-based experiments and discovery delays, and to ensure human safety. Developing cost-efficient, flexible microfluidic chips is essential to advance organ-on-chip (OoC) technology for drug discovery and disease modeling. While CNC micromilling shows promise for fabricating microfluidic devices, it remains underutilized due to limited accessibility. We present a simple CNC-milled flexible microfluidic chip fabricated from thermoplastic poly (methyl methacrylate) (PMMA). The structure of the microplate included drilled openings for connecting the wells. The chip&amp;amp;rsquo;s biocompatibility was evaluated with isolated primary neuronal cultures from postnatal Wistar rat pups (p1). Primary cells cultured in the device showed high viability, differentiation, and 3D neurosphere formation, similar to conventional well-plate cultures. Neuronal cultures showed neurite growth and functional markers. Although cleanroom-based methods provide higher accuracy, the chip effectively promotes cell viability, differentiation, and alignment, offering an ideal platform for tissue modeling and OoC applications. It allows cell biologists to quickly create prototypes at lower cost and in less time than required for soft lithography and is a viable alternative to the current manufacturing methods.</description>
	<pubDate>2025-06-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 13: Development of Low-Cost CNC-Milled PMMA Microfluidic Chips as a Prototype for Organ-on-a-Chip and Neurospheroid Applications</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/13">doi: 10.3390/organoids4020013</a></p>
	<p>Authors:
		Sushmita Mishra
		Ginia Mondal
		Murali Kumarasamy
		</p>
	<p>Improved in vitro models are needed to reduce costs and delays in central nervous system (CNS) drug discovery. The FDA Modernization Acts 2.0 and 3.0 require human-centered alternative testing methods to mitigate animal-based experiments and discovery delays, and to ensure human safety. Developing cost-efficient, flexible microfluidic chips is essential to advance organ-on-chip (OoC) technology for drug discovery and disease modeling. While CNC micromilling shows promise for fabricating microfluidic devices, it remains underutilized due to limited accessibility. We present a simple CNC-milled flexible microfluidic chip fabricated from thermoplastic poly (methyl methacrylate) (PMMA). The structure of the microplate included drilled openings for connecting the wells. The chip&amp;amp;rsquo;s biocompatibility was evaluated with isolated primary neuronal cultures from postnatal Wistar rat pups (p1). Primary cells cultured in the device showed high viability, differentiation, and 3D neurosphere formation, similar to conventional well-plate cultures. Neuronal cultures showed neurite growth and functional markers. Although cleanroom-based methods provide higher accuracy, the chip effectively promotes cell viability, differentiation, and alignment, offering an ideal platform for tissue modeling and OoC applications. It allows cell biologists to quickly create prototypes at lower cost and in less time than required for soft lithography and is a viable alternative to the current manufacturing methods.</p>
	]]></content:encoded>

	<dc:title>Development of Low-Cost CNC-Milled PMMA Microfluidic Chips as a Prototype for Organ-on-a-Chip and Neurospheroid Applications</dc:title>
			<dc:creator>Sushmita Mishra</dc:creator>
			<dc:creator>Ginia Mondal</dc:creator>
			<dc:creator>Murali Kumarasamy</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020013</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-06-11</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-06-11</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/organoids4020013</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/12">

	<title>Organoids, Vol. 4, Pages 12: Non-Animal Technologies to Study and Target the Tumour Vasculature and Angiogenesis</title>
	<link>https://www.mdpi.com/2674-1172/4/2/12</link>
	<description>Tumour-associated angiogenesis plays a key role at all stages of cancer development and progression by providing a nutrient supply, promoting the creation of protective niches for therapy-resistant cancer stem cells, and supporting the metastatic cascade. Therapeutic strategies aimed at vascular targeting, including vessel disruption and/or normalisation, have yielded promising but inconsistent results, pointing to the need to set up reliable models dissecting the steps of the angiogenic process, as well as the ways to interfere with them, to improve patients&amp;amp;rsquo; outcomes while limiting side effects. Murine models have successfully contributed to both translational and pre-clinical cancer research, but they are time-consuming, expensive, and cannot recapitulate the genetic heterogeneity of cancer inside its native microenvironment. Non-animal technologies (NATs) are rapidly emerging as invaluable human-centric tools to reproduce the complex and dynamic tumour ecosystem, particularly the tumour-associated vasculature. In the present review, we summarise the currently available NATs able to mimic the vascular structure and functions with progressively increasing complexity, starting from two-dimensional static cultures to the more sophisticated tri-dimensional dynamic ones, patient-derived cultures, the perfused engineered microvasculature, and in silico models. We emphasise the added value of a &amp;amp;ldquo;one health&amp;amp;rdquo; approach to cancer research, including studies on spontaneously occurring tumours in companion animals devoid of the ethical concerns associated with traditional animal studies. The limitations of the present tools regarding broader use in pre-clinical oncology, and their translational potential in terms of new target identification, drug development, and personalised therapy, are also discussed.</description>
	<pubDate>2025-06-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 12: Non-Animal Technologies to Study and Target the Tumour Vasculature and Angiogenesis</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/12">doi: 10.3390/organoids4020012</a></p>
	<p>Authors:
		Elisabetta Ferrero
		Jonas Hue
		Marina Ferrarini
		Lorenzo Veschini
		</p>
	<p>Tumour-associated angiogenesis plays a key role at all stages of cancer development and progression by providing a nutrient supply, promoting the creation of protective niches for therapy-resistant cancer stem cells, and supporting the metastatic cascade. Therapeutic strategies aimed at vascular targeting, including vessel disruption and/or normalisation, have yielded promising but inconsistent results, pointing to the need to set up reliable models dissecting the steps of the angiogenic process, as well as the ways to interfere with them, to improve patients&amp;amp;rsquo; outcomes while limiting side effects. Murine models have successfully contributed to both translational and pre-clinical cancer research, but they are time-consuming, expensive, and cannot recapitulate the genetic heterogeneity of cancer inside its native microenvironment. Non-animal technologies (NATs) are rapidly emerging as invaluable human-centric tools to reproduce the complex and dynamic tumour ecosystem, particularly the tumour-associated vasculature. In the present review, we summarise the currently available NATs able to mimic the vascular structure and functions with progressively increasing complexity, starting from two-dimensional static cultures to the more sophisticated tri-dimensional dynamic ones, patient-derived cultures, the perfused engineered microvasculature, and in silico models. We emphasise the added value of a &amp;amp;ldquo;one health&amp;amp;rdquo; approach to cancer research, including studies on spontaneously occurring tumours in companion animals devoid of the ethical concerns associated with traditional animal studies. The limitations of the present tools regarding broader use in pre-clinical oncology, and their translational potential in terms of new target identification, drug development, and personalised therapy, are also discussed.</p>
	]]></content:encoded>

	<dc:title>Non-Animal Technologies to Study and Target the Tumour Vasculature and Angiogenesis</dc:title>
			<dc:creator>Elisabetta Ferrero</dc:creator>
			<dc:creator>Jonas Hue</dc:creator>
			<dc:creator>Marina Ferrarini</dc:creator>
			<dc:creator>Lorenzo Veschini</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020012</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-06-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-06-04</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/organoids4020012</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/11">

	<title>Organoids, Vol. 4, Pages 11: Matrix Stiffness Affects Spheroid Invasion, Collagen Remodeling, and Effective Reach of Stress into ECM</title>
	<link>https://www.mdpi.com/2674-1172/4/2/11</link>
	<description>The extracellular matrix (ECM) provides structural support to cells, thereby forming a functional tissue. In cancer, the growth of the tumor creates internal mechanical stress, which, together with the remodeling activity of tumor cells and fibroblasts, alters the ECM structure, leading to an increased stiffness of the pathological ECM. The enhanced ECM stiffness, in turn, stimulates tumor growth and activates tumor-promoting fibroblasts and tumor cell migration, leading to metastasis and increased therapy resistance. While the relationship between matrix stiffness and migration has been studied before, their connection to internal tumor stress remains unresolved. Here we used 3D ECM-embedded spheroids and hydrogel particle stress sensors to quantify and correlate internal tumor spheroid pressure, ECM stiffness, ECM remodeling, and tumor cell migration. We note that 4T1 breast cancer spheroids and SV80 fibroblast spheroids showed increased invasion&amp;amp;mdash;described by area, complexity, number of branches, and branch area&amp;amp;mdash;in a stiffer, cross-linked ECM. On the other hand, changing ECM stiffness only minimally changed the radial alignment of fibers but highly changed the amount of fibers. For both cell types, the pressure measured in spheroids gradually decreased as the distance into the ECM increased. For 4T1 spheroids, increased ECM stiffness resulted in a further reach of mechanical stress into the ECM, which, together with the invasive phenotype, was reduced by inhibition of ROCK-mediated contractility. By contrast, such correlation between ECM stiffness and stress-reach was not observed for SV80 spheroids. Our findings connect ECM stiffness with tumor invasion, ECM remodeling, and the reach of tumor-induced mechanical stress into the ECM. Such mechanical connections between tumor and ECM are expected to drive early steps in cancer metastasis.</description>
	<pubDate>2025-06-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 11: Matrix Stiffness Affects Spheroid Invasion, Collagen Remodeling, and Effective Reach of Stress into ECM</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/11">doi: 10.3390/organoids4020011</a></p>
	<p>Authors:
		Klara Beslmüller
		Rick Rodrigues de Mercado
		Gijsje H. Koenderink
		Erik H. J. Danen
		Thomas Schmidt
		</p>
	<p>The extracellular matrix (ECM) provides structural support to cells, thereby forming a functional tissue. In cancer, the growth of the tumor creates internal mechanical stress, which, together with the remodeling activity of tumor cells and fibroblasts, alters the ECM structure, leading to an increased stiffness of the pathological ECM. The enhanced ECM stiffness, in turn, stimulates tumor growth and activates tumor-promoting fibroblasts and tumor cell migration, leading to metastasis and increased therapy resistance. While the relationship between matrix stiffness and migration has been studied before, their connection to internal tumor stress remains unresolved. Here we used 3D ECM-embedded spheroids and hydrogel particle stress sensors to quantify and correlate internal tumor spheroid pressure, ECM stiffness, ECM remodeling, and tumor cell migration. We note that 4T1 breast cancer spheroids and SV80 fibroblast spheroids showed increased invasion&amp;amp;mdash;described by area, complexity, number of branches, and branch area&amp;amp;mdash;in a stiffer, cross-linked ECM. On the other hand, changing ECM stiffness only minimally changed the radial alignment of fibers but highly changed the amount of fibers. For both cell types, the pressure measured in spheroids gradually decreased as the distance into the ECM increased. For 4T1 spheroids, increased ECM stiffness resulted in a further reach of mechanical stress into the ECM, which, together with the invasive phenotype, was reduced by inhibition of ROCK-mediated contractility. By contrast, such correlation between ECM stiffness and stress-reach was not observed for SV80 spheroids. Our findings connect ECM stiffness with tumor invasion, ECM remodeling, and the reach of tumor-induced mechanical stress into the ECM. Such mechanical connections between tumor and ECM are expected to drive early steps in cancer metastasis.</p>
	]]></content:encoded>

	<dc:title>Matrix Stiffness Affects Spheroid Invasion, Collagen Remodeling, and Effective Reach of Stress into ECM</dc:title>
			<dc:creator>Klara Beslmüller</dc:creator>
			<dc:creator>Rick Rodrigues de Mercado</dc:creator>
			<dc:creator>Gijsje H. Koenderink</dc:creator>
			<dc:creator>Erik H. J. Danen</dc:creator>
			<dc:creator>Thomas Schmidt</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020011</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-06-03</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-06-03</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/organoids4020011</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/10">

	<title>Organoids, Vol. 4, Pages 10: Three-Dimensional Culture Systems in Neuroblastoma Research</title>
	<link>https://www.mdpi.com/2674-1172/4/2/10</link>
	<description>Basic and translational cancer biology research requires model systems that recapitulate the features of human tumors. While two-dimensional (2D) cell cultures have been foundational and allowed critical advances, they lack the organizational complexity, cellular interactions, and extracellular matrix present in vivo. Mouse models have thus remained the gold standard for studying cancer. In addition to high cost and low throughput, mouse models can also suffer from reduced tumor heterogeneity and species-specific differences. Three-dimensional (3D) culture models have emerged as a key intermediary between 2D cell lines and mouse models, with lower cost and greater flexibility than mouse models and a more accurate representation of the tumor microenvironment than 2D cell lines. In neuroblastoma, an aggressive childhood cancer, 3D models have been applied to study drug responses, cell motility, and tumor&amp;amp;ndash;matrix interactions. Recent advances include the integration of immune cells for immunotherapy studies, mesenchymal stromal cells for tumor&amp;amp;ndash;stroma interactions, and bioprinted systems to manipulate matrix properties. This review examines the use of 3D culture systems in neuroblastoma, highlighting their advantages and limitations while emphasizing their potential to bridge gaps between in vitro, preclinical, and clinical applications. By improving our understanding of neuroblastoma biology, 3D models hold promise for advancing therapeutic strategies and outcomes in this childhood cancer.</description>
	<pubDate>2025-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 10: Three-Dimensional Culture Systems in Neuroblastoma Research</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/10">doi: 10.3390/organoids4020010</a></p>
	<p>Authors:
		Piotr Jung
		Adam J. Wolpaw
		</p>
	<p>Basic and translational cancer biology research requires model systems that recapitulate the features of human tumors. While two-dimensional (2D) cell cultures have been foundational and allowed critical advances, they lack the organizational complexity, cellular interactions, and extracellular matrix present in vivo. Mouse models have thus remained the gold standard for studying cancer. In addition to high cost and low throughput, mouse models can also suffer from reduced tumor heterogeneity and species-specific differences. Three-dimensional (3D) culture models have emerged as a key intermediary between 2D cell lines and mouse models, with lower cost and greater flexibility than mouse models and a more accurate representation of the tumor microenvironment than 2D cell lines. In neuroblastoma, an aggressive childhood cancer, 3D models have been applied to study drug responses, cell motility, and tumor&amp;amp;ndash;matrix interactions. Recent advances include the integration of immune cells for immunotherapy studies, mesenchymal stromal cells for tumor&amp;amp;ndash;stroma interactions, and bioprinted systems to manipulate matrix properties. This review examines the use of 3D culture systems in neuroblastoma, highlighting their advantages and limitations while emphasizing their potential to bridge gaps between in vitro, preclinical, and clinical applications. By improving our understanding of neuroblastoma biology, 3D models hold promise for advancing therapeutic strategies and outcomes in this childhood cancer.</p>
	]]></content:encoded>

	<dc:title>Three-Dimensional Culture Systems in Neuroblastoma Research</dc:title>
			<dc:creator>Piotr Jung</dc:creator>
			<dc:creator>Adam J. Wolpaw</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020010</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-05-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-05-08</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/organoids4020010</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/9">

	<title>Organoids, Vol. 4, Pages 9: Assessing the Utility of Organoid Intelligence: Scientific and Ethical Perspectives</title>
	<link>https://www.mdpi.com/2674-1172/4/2/9</link>
	<description>The development of brain organoids from human-induced pluripotent stem cells (iPSCs) has expanded research into neurodevelopment, disease modeling, and drug testing. More recently, the concept of organoid intelligence (OI) has emerged, proposing that these constructs could evolve to support learning, memory, or even sentience. While this perspective has driven enthusiasm in the field of organoid research and suggested new applications in fields such as neuromorphic computing, it also introduces significant scientific and conceptual concerns. Current brain organoids lack the anatomical complexity, network organization, and sensorimotor integration necessary for intelligence or sentience. Despite this, claims surrounding OI often rely on oversimplified interpretations of neural activity, fueled by neurorealist and reification biases that misattribute neurophysiological properties to biologically limited systems. Beyond scientific limitations, the framing of OI risks imposing ethical and regulatory challenges based on speculative concerns rather than empirical evidence. The assumption that organoids might possess sentience, or could develop it over time, could lead to unnecessary restrictions on legitimate research while misrepresenting their actual capabilities. Additionally, comparing biological systems to silicon-based computing overlooks fundamental differences in scalability, efficiency, and predictability, raising questions about whether organoids can meaningfully contribute to computational advancements. The field must recognize the limitations of these models rather than prematurely defining OI as a distinct research domain. A more cautious, evidence-driven approach is necessary to ensure that brain organoids remain valuable tools for neuroscience without overstating their potential. To maintain scientific credibility and public trust, it is essential to separate speculative narratives from grounded research, thus allowing for continued progress in organoid studies without reinforcing misconceptions about intelligence or sentience.</description>
	<pubDate>2025-05-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 9: Assessing the Utility of Organoid Intelligence: Scientific and Ethical Perspectives</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/9">doi: 10.3390/organoids4020009</a></p>
	<p>Authors:
		Michael W. Nestor
		Richard L. Wilson
		</p>
	<p>The development of brain organoids from human-induced pluripotent stem cells (iPSCs) has expanded research into neurodevelopment, disease modeling, and drug testing. More recently, the concept of organoid intelligence (OI) has emerged, proposing that these constructs could evolve to support learning, memory, or even sentience. While this perspective has driven enthusiasm in the field of organoid research and suggested new applications in fields such as neuromorphic computing, it also introduces significant scientific and conceptual concerns. Current brain organoids lack the anatomical complexity, network organization, and sensorimotor integration necessary for intelligence or sentience. Despite this, claims surrounding OI often rely on oversimplified interpretations of neural activity, fueled by neurorealist and reification biases that misattribute neurophysiological properties to biologically limited systems. Beyond scientific limitations, the framing of OI risks imposing ethical and regulatory challenges based on speculative concerns rather than empirical evidence. The assumption that organoids might possess sentience, or could develop it over time, could lead to unnecessary restrictions on legitimate research while misrepresenting their actual capabilities. Additionally, comparing biological systems to silicon-based computing overlooks fundamental differences in scalability, efficiency, and predictability, raising questions about whether organoids can meaningfully contribute to computational advancements. The field must recognize the limitations of these models rather than prematurely defining OI as a distinct research domain. A more cautious, evidence-driven approach is necessary to ensure that brain organoids remain valuable tools for neuroscience without overstating their potential. To maintain scientific credibility and public trust, it is essential to separate speculative narratives from grounded research, thus allowing for continued progress in organoid studies without reinforcing misconceptions about intelligence or sentience.</p>
	]]></content:encoded>

	<dc:title>Assessing the Utility of Organoid Intelligence: Scientific and Ethical Perspectives</dc:title>
			<dc:creator>Michael W. Nestor</dc:creator>
			<dc:creator>Richard L. Wilson</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020009</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-05-01</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-05-01</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/organoids4020009</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/8">

	<title>Organoids, Vol. 4, Pages 8: In Silico Simulation of Porous Geometry-Guided Diffusion for Drug-Coated Tissue Engineering Scaffold Design</title>
	<link>https://www.mdpi.com/2674-1172/4/2/8</link>
	<description>Recent research works have shown the effect of nutrient concentration on cell activity, such as proliferation and differentiation. In 3D cell culture, the impact of scaffold geometry, including pore size, strut diameter, and pore shape, on the concentration gradient within scaffolds under two different loading conditions&amp;amp;mdash;constant fluid perfusion and non-fluid perfusion&amp;amp;mdash;in a perfusion bioreactor is investigated by developing an in silico model of scaffolds. In this study, both triply periodic minimal surface (TPMS) (with gyroid struts) and non-TPMS (with cubic and spherical pores) scaffolds were investigated. Two types of criteria are applied to the scaffolds: static and perfusion culture conditions. In a static environment, the scaffold in a perfusion bioreactor is loaded with a fluid velocity of 0&amp;amp;nbsp;mm/s, whereas in a dynamic environment, perfusion flow with a velocity of 1 mm/s is applied. The results of in silico simulation indicate that the concentration gradient within the scaffold is significantly influenced by pore size, strut diameter, pore shape, and fluid flow, which in turn affects the diffusion rate during drug delivery.</description>
	<pubDate>2025-04-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 8: In Silico Simulation of Porous Geometry-Guided Diffusion for Drug-Coated Tissue Engineering Scaffold Design</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/8">doi: 10.3390/organoids4020008</a></p>
	<p>Authors:
		Eyad Awad
		Matthew Bedding-Tyrrell
		Alberto Coccarelli
		Feihu Zhao
		</p>
	<p>Recent research works have shown the effect of nutrient concentration on cell activity, such as proliferation and differentiation. In 3D cell culture, the impact of scaffold geometry, including pore size, strut diameter, and pore shape, on the concentration gradient within scaffolds under two different loading conditions&amp;amp;mdash;constant fluid perfusion and non-fluid perfusion&amp;amp;mdash;in a perfusion bioreactor is investigated by developing an in silico model of scaffolds. In this study, both triply periodic minimal surface (TPMS) (with gyroid struts) and non-TPMS (with cubic and spherical pores) scaffolds were investigated. Two types of criteria are applied to the scaffolds: static and perfusion culture conditions. In a static environment, the scaffold in a perfusion bioreactor is loaded with a fluid velocity of 0&amp;amp;nbsp;mm/s, whereas in a dynamic environment, perfusion flow with a velocity of 1 mm/s is applied. The results of in silico simulation indicate that the concentration gradient within the scaffold is significantly influenced by pore size, strut diameter, pore shape, and fluid flow, which in turn affects the diffusion rate during drug delivery.</p>
	]]></content:encoded>

	<dc:title>In Silico Simulation of Porous Geometry-Guided Diffusion for Drug-Coated Tissue Engineering Scaffold Design</dc:title>
			<dc:creator>Eyad Awad</dc:creator>
			<dc:creator>Matthew Bedding-Tyrrell</dc:creator>
			<dc:creator>Alberto Coccarelli</dc:creator>
			<dc:creator>Feihu Zhao</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020008</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-04-27</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-04-27</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/organoids4020008</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/2/7">

	<title>Organoids, Vol. 4, Pages 7: Organoid Models of Lymphoid Tissues</title>
	<link>https://www.mdpi.com/2674-1172/4/2/7</link>
	<description>Lymphoid organs are critical for organizing the development of the immune system, generating immune tolerance, and orchestrating the adaptive immune response to foreign antigens. Defects in their structure and function can lead to immunodeficiency, hypersensitivity, cancer, or autoimmune diseases. To better understand these diseases and assess potential therapies, complex models that recapitulate the anatomy and physiology of these tissues are required. Organoid models possess a number of advantages, including complex 3D microarchitecture, scalability, and personalization, which make them ideal for modelling lymphoid organs and related pathologies. Organoids have been developed for both primary and secondary lymphoid tissues; however, these models possess several limitations, including immature phenotypes and incomplete stromal cell populations. Furthermore, these organoids are often heterogeneous in both structure and function. Several lymphoid organs, such as the spleen, do not yet have robust organoid models, offering opportunities for breakthroughs in the field. Overall, development of lymphoid organoids will pave the way for the rapid development and testing of novel therapies, organ modelling, and personalized medicine. This review summarizes current advances in models for the primary lymphoid organ&amp;amp;mdash;bone marrow and thymus&amp;amp;mdash;as well as the secondary lymphoid organs of the lymph node and spleen.</description>
	<pubDate>2025-04-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 7: Organoid Models of Lymphoid Tissues</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/2/7">doi: 10.3390/organoids4020007</a></p>
	<p>Authors:
		Ania Bogoslowski
		Joice Ren
		Clément Quintard
		Josef M. Penninger
		</p>
	<p>Lymphoid organs are critical for organizing the development of the immune system, generating immune tolerance, and orchestrating the adaptive immune response to foreign antigens. Defects in their structure and function can lead to immunodeficiency, hypersensitivity, cancer, or autoimmune diseases. To better understand these diseases and assess potential therapies, complex models that recapitulate the anatomy and physiology of these tissues are required. Organoid models possess a number of advantages, including complex 3D microarchitecture, scalability, and personalization, which make them ideal for modelling lymphoid organs and related pathologies. Organoids have been developed for both primary and secondary lymphoid tissues; however, these models possess several limitations, including immature phenotypes and incomplete stromal cell populations. Furthermore, these organoids are often heterogeneous in both structure and function. Several lymphoid organs, such as the spleen, do not yet have robust organoid models, offering opportunities for breakthroughs in the field. Overall, development of lymphoid organoids will pave the way for the rapid development and testing of novel therapies, organ modelling, and personalized medicine. This review summarizes current advances in models for the primary lymphoid organ&amp;amp;mdash;bone marrow and thymus&amp;amp;mdash;as well as the secondary lymphoid organs of the lymph node and spleen.</p>
	]]></content:encoded>

	<dc:title>Organoid Models of Lymphoid Tissues</dc:title>
			<dc:creator>Ania Bogoslowski</dc:creator>
			<dc:creator>Joice Ren</dc:creator>
			<dc:creator>Clément Quintard</dc:creator>
			<dc:creator>Josef M. Penninger</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4020007</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-04-07</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-04-07</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/organoids4020007</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/2/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/1/6">

	<title>Organoids, Vol. 4, Pages 6: The Intestinal Stem Cell Niche: Generation and Utilization of Intestinal Organoids</title>
	<link>https://www.mdpi.com/2674-1172/4/1/6</link>
	<description>In cell biology, the stem cell niche is the dynamic microenvironment in which stem cells reside and receive signals that determine their behavior and fate. The stem cell niche has largely been a theoretical construct due to the difficulty in identifying and manipulating individual stem cells and their surroundings. Recent technical advances have made it possible to characterize the niches that maintain and control stem cell activity in several organs, including the small intestine. Although the small intestine has a relatively simple architecture, it has an extraordinary capacity for fast self-renewal. Thus, the organ is a unique model for studying intestinal stem cells (ISCs) and their niche. The intestinal epithelium maintains the intestine, enabling it to perform its absorption, secretion, and barrier functions. ISCs reside at the base of crypts adjacent to Paneth cells. In vivo, ISCs are surrounded by the microenvironment that makes up the niche, which provides a variety of stimuli that determine the fate of the cells. Research on stem cell niches is beginning to deepen our understanding of ISC regulation at the cellular and molecular levels and is expected to provide insights that can be applied to ISC therapy. Intestinal organoids originate from a group of crypt base ISCs. These organoids possess a three-dimensional (3D) cell structure made up of the lumen facing inward. Therefore, 3D intestinal organoids are often digested and seeded in a two-dimensional (2D) manner to form confluent organoid monolayers. Here, we not only review our current understanding of ISC niches with a focus on systems that are well-characterized at the cellular and mechanistic levels, but we also summarize the current applications of intestinal organoids.</description>
	<pubDate>2025-03-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 6: The Intestinal Stem Cell Niche: Generation and Utilization of Intestinal Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/1/6">doi: 10.3390/organoids4010006</a></p>
	<p>Authors:
		Toshio Takahashi
		Yuta Takase
		</p>
	<p>In cell biology, the stem cell niche is the dynamic microenvironment in which stem cells reside and receive signals that determine their behavior and fate. The stem cell niche has largely been a theoretical construct due to the difficulty in identifying and manipulating individual stem cells and their surroundings. Recent technical advances have made it possible to characterize the niches that maintain and control stem cell activity in several organs, including the small intestine. Although the small intestine has a relatively simple architecture, it has an extraordinary capacity for fast self-renewal. Thus, the organ is a unique model for studying intestinal stem cells (ISCs) and their niche. The intestinal epithelium maintains the intestine, enabling it to perform its absorption, secretion, and barrier functions. ISCs reside at the base of crypts adjacent to Paneth cells. In vivo, ISCs are surrounded by the microenvironment that makes up the niche, which provides a variety of stimuli that determine the fate of the cells. Research on stem cell niches is beginning to deepen our understanding of ISC regulation at the cellular and molecular levels and is expected to provide insights that can be applied to ISC therapy. Intestinal organoids originate from a group of crypt base ISCs. These organoids possess a three-dimensional (3D) cell structure made up of the lumen facing inward. Therefore, 3D intestinal organoids are often digested and seeded in a two-dimensional (2D) manner to form confluent organoid monolayers. Here, we not only review our current understanding of ISC niches with a focus on systems that are well-characterized at the cellular and mechanistic levels, but we also summarize the current applications of intestinal organoids.</p>
	]]></content:encoded>

	<dc:title>The Intestinal Stem Cell Niche: Generation and Utilization of Intestinal Organoids</dc:title>
			<dc:creator>Toshio Takahashi</dc:creator>
			<dc:creator>Yuta Takase</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4010006</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-03-20</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-03-20</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/organoids4010006</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/1/5">

	<title>Organoids, Vol. 4, Pages 5: Breast Cancer Tissues and Organoids BioBank: Constitution, Research Activities and Samples Access</title>
	<link>https://www.mdpi.com/2674-1172/4/1/5</link>
	<description>In 2023, at the Center for Biological Resources (CRB) at the Institute of Genetics and Biophysics (IGB, Naples, Italy) of the National Research Council (CNR), the Breast Cancer Tissues and Organoids Biobank (BCTO BioBank) was founded. This is a new generation Biobank, dedicated to the collection, characterization, storage, and distribution of tissues and their 3D &amp;amp;lsquo;organoid&amp;amp;rsquo; patients-derived. Tumor and healthy tissues from breast cancer patients have been collected from surgeons at Monaldi Hospital (Naples, Italy) and used to generate the corresponding tumor and healthy organoids from the same patient. After their establishment in culture, both organoids were characterized for their receptor status on a microfluidic 2-lane OrganoPlate, by immunofluorescence. The resulting data were compared with the expression profile obtained by immunohistochemistry on respective parental tissues. These data allowed us to phenotypically validate the generated organoids and classify them in a dedicated database, where also the clinical data of the corresponding patients were collected. During the six months of activities, we collected and characterized 27 samples. The continuous BCTO BioBank activity is fundamental to generating a high number of samples, for a broader and efficiently elaborated patient stratification at molecular level, biomarker discovery investigations, and for tailored treatment protocols design.</description>
	<pubDate>2025-03-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 5: Breast Cancer Tissues and Organoids BioBank: Constitution, Research Activities and Samples Access</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/1/5">doi: 10.3390/organoids4010005</a></p>
	<p>Authors:
		Lucia Miranda
		Luigi Mandrich
		Simona Massa
		Teresa Nutile
		Clotilde Crovella
		Ilaria De Rosa
		Raffaella Lucci
		Filippo De Rosa
		Pasquale Somma
		Vincenzo Mercadante
		Ciro Abate
		Salvatore Arbucci
		Luigi Panico
		Emilia Caputo
		</p>
	<p>In 2023, at the Center for Biological Resources (CRB) at the Institute of Genetics and Biophysics (IGB, Naples, Italy) of the National Research Council (CNR), the Breast Cancer Tissues and Organoids Biobank (BCTO BioBank) was founded. This is a new generation Biobank, dedicated to the collection, characterization, storage, and distribution of tissues and their 3D &amp;amp;lsquo;organoid&amp;amp;rsquo; patients-derived. Tumor and healthy tissues from breast cancer patients have been collected from surgeons at Monaldi Hospital (Naples, Italy) and used to generate the corresponding tumor and healthy organoids from the same patient. After their establishment in culture, both organoids were characterized for their receptor status on a microfluidic 2-lane OrganoPlate, by immunofluorescence. The resulting data were compared with the expression profile obtained by immunohistochemistry on respective parental tissues. These data allowed us to phenotypically validate the generated organoids and classify them in a dedicated database, where also the clinical data of the corresponding patients were collected. During the six months of activities, we collected and characterized 27 samples. The continuous BCTO BioBank activity is fundamental to generating a high number of samples, for a broader and efficiently elaborated patient stratification at molecular level, biomarker discovery investigations, and for tailored treatment protocols design.</p>
	]]></content:encoded>

	<dc:title>Breast Cancer Tissues and Organoids BioBank: Constitution, Research Activities and Samples Access</dc:title>
			<dc:creator>Lucia Miranda</dc:creator>
			<dc:creator>Luigi Mandrich</dc:creator>
			<dc:creator>Simona Massa</dc:creator>
			<dc:creator>Teresa Nutile</dc:creator>
			<dc:creator>Clotilde Crovella</dc:creator>
			<dc:creator>Ilaria De Rosa</dc:creator>
			<dc:creator>Raffaella Lucci</dc:creator>
			<dc:creator>Filippo De Rosa</dc:creator>
			<dc:creator>Pasquale Somma</dc:creator>
			<dc:creator>Vincenzo Mercadante</dc:creator>
			<dc:creator>Ciro Abate</dc:creator>
			<dc:creator>Salvatore Arbucci</dc:creator>
			<dc:creator>Luigi Panico</dc:creator>
			<dc:creator>Emilia Caputo</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4010005</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-03-03</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-03-03</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/organoids4010005</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/1/4">

	<title>Organoids, Vol. 4, Pages 4: Paneth Cells Are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids</title>
	<link>https://www.mdpi.com/2674-1172/4/1/4</link>
	<description>The healthy gut masks a dynamic balance between pro- and anti-inflammatory activities, largely due to microbial factors in the lumen. IL-10 is vital among the anti-inflammatory mediators, yet confirming constitutive versus stimulated secretion in any cell type is difficult due to the cellular complexity in the gut. Seeking to determine whether intestinal epithelial cells are programmed to constitutively make IL-10, we confirmed that IL-10 mRNA was present in enteroids from C57BL/6 mice and IL-10 protein was co-localized with a Paneth cell marker but not with markers for goblet or tuft cells. Paneth cells positive for IL-10 also possessed apical and basal IL-10RA, while cells negative for IL-10 had only basal IL-10RA, suggesting a possible autocrine role for IL-10. Indeed, Paneth cells in IL-10 gene knockout (IL-10KO) enteroids possessed lower levels of anti-microbial protein mRNAs, which could not be restored by adding IL-10. Enteroids passaged onto Transwell&amp;amp;reg; filters to form monolayers were treated with IL-10 and STAT3 phosphorylation was measured. Apically applied IL-10 resulted in a stronger STAT3 signal than basally applied cytokine. Our results indicate that a subpopulation of Paneth cells constitutively secrete IL-10 apically, which binds apical IL-10RA, impacting the expression of anti-microbial proteins unique to Paneth cells.</description>
	<pubDate>2025-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 4: Paneth Cells Are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/1/4">doi: 10.3390/organoids4010004</a></p>
	<p>Authors:
		Huong Nguyen
		Francesca Di Cara
		Jun Wang
		Andrew W. Stadnyk
		</p>
	<p>The healthy gut masks a dynamic balance between pro- and anti-inflammatory activities, largely due to microbial factors in the lumen. IL-10 is vital among the anti-inflammatory mediators, yet confirming constitutive versus stimulated secretion in any cell type is difficult due to the cellular complexity in the gut. Seeking to determine whether intestinal epithelial cells are programmed to constitutively make IL-10, we confirmed that IL-10 mRNA was present in enteroids from C57BL/6 mice and IL-10 protein was co-localized with a Paneth cell marker but not with markers for goblet or tuft cells. Paneth cells positive for IL-10 also possessed apical and basal IL-10RA, while cells negative for IL-10 had only basal IL-10RA, suggesting a possible autocrine role for IL-10. Indeed, Paneth cells in IL-10 gene knockout (IL-10KO) enteroids possessed lower levels of anti-microbial protein mRNAs, which could not be restored by adding IL-10. Enteroids passaged onto Transwell&amp;amp;reg; filters to form monolayers were treated with IL-10 and STAT3 phosphorylation was measured. Apically applied IL-10 resulted in a stronger STAT3 signal than basally applied cytokine. Our results indicate that a subpopulation of Paneth cells constitutively secrete IL-10 apically, which binds apical IL-10RA, impacting the expression of anti-microbial proteins unique to Paneth cells.</p>
	]]></content:encoded>

	<dc:title>Paneth Cells Are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids</dc:title>
			<dc:creator>Huong Nguyen</dc:creator>
			<dc:creator>Francesca Di Cara</dc:creator>
			<dc:creator>Jun Wang</dc:creator>
			<dc:creator>Andrew W. Stadnyk</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4010004</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-02-12</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-02-12</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/organoids4010004</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/1/3">

	<title>Organoids, Vol. 4, Pages 3: Establishment of Intestinal Organoids from Common Marmosets</title>
	<link>https://www.mdpi.com/2674-1172/4/1/3</link>
	<description>Intestinal organoids are useful for the in vitro investigation of the properties of intestinal epithelial cells and their interaction with the gut microbiome. In this study, we cultured cecal and colonic organoids from common marmosets, which are highlighted as model nonhuman primates but are susceptible to gastrointestinal diseases. The organoids established were capable of passaging and long-term culture. The results of quantitative reverse transcription PCR and immunostaining showed that the organoids differentiated into major cell types (colonocytes, goblet cells, and enteroendocrine cells) in the intestinal epithelium, enabling the in vitro analysis of these cells in marmosets. The organoids could therefore represent a useful model for the investigation of gut physiology in relation to gastrointestinal diseases and host-microbiome interactions, further expanding medical, biological, and veterinary research in the future.</description>
	<pubDate>2025-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 3: Establishment of Intestinal Organoids from Common Marmosets</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/1/3">doi: 10.3390/organoids4010003</a></p>
	<p>Authors:
		Arisa Ishimura
		Ken Iwatsuki
		Hiroo Imai
		</p>
	<p>Intestinal organoids are useful for the in vitro investigation of the properties of intestinal epithelial cells and their interaction with the gut microbiome. In this study, we cultured cecal and colonic organoids from common marmosets, which are highlighted as model nonhuman primates but are susceptible to gastrointestinal diseases. The organoids established were capable of passaging and long-term culture. The results of quantitative reverse transcription PCR and immunostaining showed that the organoids differentiated into major cell types (colonocytes, goblet cells, and enteroendocrine cells) in the intestinal epithelium, enabling the in vitro analysis of these cells in marmosets. The organoids could therefore represent a useful model for the investigation of gut physiology in relation to gastrointestinal diseases and host-microbiome interactions, further expanding medical, biological, and veterinary research in the future.</p>
	]]></content:encoded>

	<dc:title>Establishment of Intestinal Organoids from Common Marmosets</dc:title>
			<dc:creator>Arisa Ishimura</dc:creator>
			<dc:creator>Ken Iwatsuki</dc:creator>
			<dc:creator>Hiroo Imai</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4010003</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-02-12</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-02-12</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/organoids4010003</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/1/2">

	<title>Organoids, Vol. 4, Pages 2: Precision Medicine for Peritoneal Carcinomatosis&amp;mdash;Current Advances in Organoid Drug Testing and Clinical Applicability</title>
	<link>https://www.mdpi.com/2674-1172/4/1/2</link>
	<description>Peritoneal carcinomatosis from gastrointestinal tumours is considered a poor prognostic factor, with a median overall survival of six to nine months in the absence of intervention. The advent of patient-derived organoid cultures (PDOs) has provided a breakthrough in personalised medicine, allowing researchers and clinicians to model the complexity and heterogeneity of individual tumours in vitro. PDOs hold great promise in this field, as variations in the management of peritoneal carcinomatosis due to differences in the method of delivery of chemotherapeutics, drug selection, exposure duration, and tumour pathology make it impractical to use a single, standardised treatment regimen. We aim to summarise the methodologies and limitations of studies encapsulating organoids derived from peritoneal metastases to encourage design considerations that may improve future clinical relevance, standardise protocols, and address translational challenges in personalising treatment strategies.</description>
	<pubDate>2025-01-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 2: Precision Medicine for Peritoneal Carcinomatosis&amp;mdash;Current Advances in Organoid Drug Testing and Clinical Applicability</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/1/2">doi: 10.3390/organoids4010002</a></p>
	<p>Authors:
		Harleen Kaur
		Josephine A. Wright
		Daniel L. Worthley
		Elizabeth Murphy
		Susan L. Woods
		</p>
	<p>Peritoneal carcinomatosis from gastrointestinal tumours is considered a poor prognostic factor, with a median overall survival of six to nine months in the absence of intervention. The advent of patient-derived organoid cultures (PDOs) has provided a breakthrough in personalised medicine, allowing researchers and clinicians to model the complexity and heterogeneity of individual tumours in vitro. PDOs hold great promise in this field, as variations in the management of peritoneal carcinomatosis due to differences in the method of delivery of chemotherapeutics, drug selection, exposure duration, and tumour pathology make it impractical to use a single, standardised treatment regimen. We aim to summarise the methodologies and limitations of studies encapsulating organoids derived from peritoneal metastases to encourage design considerations that may improve future clinical relevance, standardise protocols, and address translational challenges in personalising treatment strategies.</p>
	]]></content:encoded>

	<dc:title>Precision Medicine for Peritoneal Carcinomatosis&amp;amp;mdash;Current Advances in Organoid Drug Testing and Clinical Applicability</dc:title>
			<dc:creator>Harleen Kaur</dc:creator>
			<dc:creator>Josephine A. Wright</dc:creator>
			<dc:creator>Daniel L. Worthley</dc:creator>
			<dc:creator>Elizabeth Murphy</dc:creator>
			<dc:creator>Susan L. Woods</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4010002</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-01-24</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-01-24</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/organoids4010002</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/4/1/1">

	<title>Organoids, Vol. 4, Pages 1: Three-Dimensional Morphological Characterisation of Human Cortical Organoids Using a Customised Image Analysis Workflow</title>
	<link>https://www.mdpi.com/2674-1172/4/1/1</link>
	<description>Summary Statement: A tailored image analysis workflow was applied to quantify cortical organoid health, development, morphology and cellular composition over time. The assessment of cellular composition and viability of stem cell-derived organoid models is a complex but essential approach to understanding the mechanisms of human development and disease. Aim: Our study was motivated by the need for an image-analysis workflow, including high-cell content, high-throughput methods, to measure the architectural features of developing organoids. We assessed stem cell-derived cortical organoids at 4 and 6 months post-induction using immunohistochemistry-labelled sections as the analysis testbed. The workflow leveraged fluorescence imaging tailored to classify cells as viable and dying or non-viable and assign neuronal and astrocytic perinuclear markers to count cells. Results/Outcomes: Image acquisition was accelerated by capturing the organoid slice in 3D using widefield-fluorescence microscopy. This method used computational clearing to resolve nuclear and perinuclear markers and retain their spatial information within the organoid&amp;amp;rsquo;s heterogeneous structure. The customised workflow analysed over 1.5 million cells using DAPI-stained nuclei, filtering and quantifying viable and non-viable cells and the necrotic-core regions. Temporal analyses of neuronal cell number derived from perinuclear labelling were consistent with organoid maturation from 4 to 6 months of in vitro differentiation. Overall: We have provided a comprehensive and enhanced image analysis workflow for organoid structural evaluation, creating the ability to gather cellular-level statistics in control and disease models.</description>
	<pubDate>2025-01-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 4, Pages 1: Three-Dimensional Morphological Characterisation of Human Cortical Organoids Using a Customised Image Analysis Workflow</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/4/1/1">doi: 10.3390/organoids4010001</a></p>
	<p>Authors:
		Sarah Handcock
		Kay Richards
		Timothy J. Karle
		Pamela Kairath
		Alita Soch
		Carolina A. Chavez
		Steven Petrou
		Snezana Maljevic
		</p>
	<p>Summary Statement: A tailored image analysis workflow was applied to quantify cortical organoid health, development, morphology and cellular composition over time. The assessment of cellular composition and viability of stem cell-derived organoid models is a complex but essential approach to understanding the mechanisms of human development and disease. Aim: Our study was motivated by the need for an image-analysis workflow, including high-cell content, high-throughput methods, to measure the architectural features of developing organoids. We assessed stem cell-derived cortical organoids at 4 and 6 months post-induction using immunohistochemistry-labelled sections as the analysis testbed. The workflow leveraged fluorescence imaging tailored to classify cells as viable and dying or non-viable and assign neuronal and astrocytic perinuclear markers to count cells. Results/Outcomes: Image acquisition was accelerated by capturing the organoid slice in 3D using widefield-fluorescence microscopy. This method used computational clearing to resolve nuclear and perinuclear markers and retain their spatial information within the organoid&amp;amp;rsquo;s heterogeneous structure. The customised workflow analysed over 1.5 million cells using DAPI-stained nuclei, filtering and quantifying viable and non-viable cells and the necrotic-core regions. Temporal analyses of neuronal cell number derived from perinuclear labelling were consistent with organoid maturation from 4 to 6 months of in vitro differentiation. Overall: We have provided a comprehensive and enhanced image analysis workflow for organoid structural evaluation, creating the ability to gather cellular-level statistics in control and disease models.</p>
	]]></content:encoded>

	<dc:title>Three-Dimensional Morphological Characterisation of Human Cortical Organoids Using a Customised Image Analysis Workflow</dc:title>
			<dc:creator>Sarah Handcock</dc:creator>
			<dc:creator>Kay Richards</dc:creator>
			<dc:creator>Timothy J. Karle</dc:creator>
			<dc:creator>Pamela Kairath</dc:creator>
			<dc:creator>Alita Soch</dc:creator>
			<dc:creator>Carolina A. Chavez</dc:creator>
			<dc:creator>Steven Petrou</dc:creator>
			<dc:creator>Snezana Maljevic</dc:creator>
		<dc:identifier>doi: 10.3390/organoids4010001</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2025-01-17</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2025-01-17</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/organoids4010001</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/4/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/4/18">

	<title>Organoids, Vol. 3, Pages 295-308: Pre-Adipocytes in 3D Co-Culture Underwent Self-Differentiation: New Perspectives for an Old Model</title>
	<link>https://www.mdpi.com/2674-1172/3/4/18</link>
	<description>Adipogenesis is a complex process influenced by various cellular interactions within adipose tissue, which plays a critical role in metabolic homeostasis. This study aimed to develop a novel in vitro three-dimensional (3D) co-culture model using murine 3T3-L1 pre-adipocytes, J774 macrophages, and NIH-3T3 fibroblasts to investigate adipogenic differentiation and inflammatory pathways. We first validated an adipogenic differentiation protocol in a two-dimensional (2D) model, where 3T3-L1 pre-adipocytes were subjected to a hormonal medium containing 3-isobutyl-1-methylxanthine, dexamethasone and insulin. After 7 days, differentiated cells were analyzed using Oil Red O and Nile Red staining, confirming lipid accumulation. Subsequently, spheroids were formed in 3D cultures, with monospheroids and heterospheroids maintained in either control medium or MDI for 11 days. Size measurements indicated significant growth in heterospheroids, particularly in the 3T3-L1:J774 combination, underscoring the importance of cellular interactions. Confocal microscopy and flow cytometry analyses demonstrated that even in the absence of hormonal stimuli, control spheroids exhibited adipogenic differentiation, evidenced by a notable proportion of Nile Red-positive cells (75.7 &amp;amp;plusmn; 1.7%). Inflammatory profiling revealed that the heterospheroid 3:J produced the highest levels of nitric oxide (NO), with no significant differences observed between control and MDI conditions. This study highlights the potential of 3D co-culture systems for elucidating the intricate interactions among adipocytes, macrophages, and fibroblasts. The findings may provide valuable insights into novel therapeutic targets for metabolic disorders.</description>
	<pubDate>2024-12-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 295-308: Pre-Adipocytes in 3D Co-Culture Underwent Self-Differentiation: New Perspectives for an Old Model</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/4/18">doi: 10.3390/organoids3040018</a></p>
	<p>Authors:
		Tamara Dal-Mora
		Najla Adel Saleh
		Veridiana Pacheco Goulart Martinazzo
		Maria Luiza Carneiro Buchele
		Michele Patrícia Rode
		Adny Henrique Silva
		Laura Sartori Assunção
		Tânia Beatriz Creczynski-Pasa
		Fabiola Branco Filippin-Monteiro
		</p>
	<p>Adipogenesis is a complex process influenced by various cellular interactions within adipose tissue, which plays a critical role in metabolic homeostasis. This study aimed to develop a novel in vitro three-dimensional (3D) co-culture model using murine 3T3-L1 pre-adipocytes, J774 macrophages, and NIH-3T3 fibroblasts to investigate adipogenic differentiation and inflammatory pathways. We first validated an adipogenic differentiation protocol in a two-dimensional (2D) model, where 3T3-L1 pre-adipocytes were subjected to a hormonal medium containing 3-isobutyl-1-methylxanthine, dexamethasone and insulin. After 7 days, differentiated cells were analyzed using Oil Red O and Nile Red staining, confirming lipid accumulation. Subsequently, spheroids were formed in 3D cultures, with monospheroids and heterospheroids maintained in either control medium or MDI for 11 days. Size measurements indicated significant growth in heterospheroids, particularly in the 3T3-L1:J774 combination, underscoring the importance of cellular interactions. Confocal microscopy and flow cytometry analyses demonstrated that even in the absence of hormonal stimuli, control spheroids exhibited adipogenic differentiation, evidenced by a notable proportion of Nile Red-positive cells (75.7 &amp;amp;plusmn; 1.7%). Inflammatory profiling revealed that the heterospheroid 3:J produced the highest levels of nitric oxide (NO), with no significant differences observed between control and MDI conditions. This study highlights the potential of 3D co-culture systems for elucidating the intricate interactions among adipocytes, macrophages, and fibroblasts. The findings may provide valuable insights into novel therapeutic targets for metabolic disorders.</p>
	]]></content:encoded>

	<dc:title>Pre-Adipocytes in 3D Co-Culture Underwent Self-Differentiation: New Perspectives for an Old Model</dc:title>
			<dc:creator>Tamara Dal-Mora</dc:creator>
			<dc:creator>Najla Adel Saleh</dc:creator>
			<dc:creator>Veridiana Pacheco Goulart Martinazzo</dc:creator>
			<dc:creator>Maria Luiza Carneiro Buchele</dc:creator>
			<dc:creator>Michele Patrícia Rode</dc:creator>
			<dc:creator>Adny Henrique Silva</dc:creator>
			<dc:creator>Laura Sartori Assunção</dc:creator>
			<dc:creator>Tânia Beatriz Creczynski-Pasa</dc:creator>
			<dc:creator>Fabiola Branco Filippin-Monteiro</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3040018</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-12-18</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-12-18</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>295</prism:startingPage>
		<prism:doi>10.3390/organoids3040018</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/4/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/4/17">

	<title>Organoids, Vol. 3, Pages 281-294: Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models</title>
	<link>https://www.mdpi.com/2674-1172/3/4/17</link>
	<description>Background: Recent advances in the personalized treatment of non-small cell lung cancer (NSCLC) require representative in vitro model systems that reflect tumor heterogeneity and maintain the characteristic genetic aberrations. We therefore aimed to establish patient-derived NSCLC organoids that offer a reliable platform for further investigations. Methods: NSCLC organoids were cultured between May 2020 and February 2022 from surgically resected NSCLC tissue specimens. After histological and immunohistochemical validation, genetic validation was performed by targeted next-generation sequencing of tissue and organoid specimens using the Oncomine Focus Assay (ThermoFisher Scientific). Results: From 37 resected NSCLC samples, 18 primary organoid cultures were successfully established and expanded during early passages. Upon histomorphological validation, organoids showed complementary characteristics when compared to the resected parental tumor, including adenocarcinoma, squamous cell carcinoma, mucoepidermoid carcinoma, and lung carcinoid differentiation. Among nine parental tumors, traceable genetic alterations were detected, and three corresponding organoids lines retained this mutational profile, including a KRAS p.Gly12Val mutation, KRAS p.Gly12Cys mutation, and RET-fusion. Conclusions: The establishment of primary NSCLC organoids from surgically resected tissue is feasible. Histological, immunohistochemical, and genetic validation is essential to identify representative NSCLC organoids that maintain the characteristics of the parental tumor. Overall, low establishment rates remain a challenge for broad clinical applications.</description>
	<pubDate>2024-11-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 281-294: Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/4/17">doi: 10.3390/organoids3040017</a></p>
	<p>Authors:
		Raphael S. Werner
		Jae-Hwi Jang
		Markus Rechsteiner
		Michaela B. Kirschner
		Isabelle Opitz
		</p>
	<p>Background: Recent advances in the personalized treatment of non-small cell lung cancer (NSCLC) require representative in vitro model systems that reflect tumor heterogeneity and maintain the characteristic genetic aberrations. We therefore aimed to establish patient-derived NSCLC organoids that offer a reliable platform for further investigations. Methods: NSCLC organoids were cultured between May 2020 and February 2022 from surgically resected NSCLC tissue specimens. After histological and immunohistochemical validation, genetic validation was performed by targeted next-generation sequencing of tissue and organoid specimens using the Oncomine Focus Assay (ThermoFisher Scientific). Results: From 37 resected NSCLC samples, 18 primary organoid cultures were successfully established and expanded during early passages. Upon histomorphological validation, organoids showed complementary characteristics when compared to the resected parental tumor, including adenocarcinoma, squamous cell carcinoma, mucoepidermoid carcinoma, and lung carcinoid differentiation. Among nine parental tumors, traceable genetic alterations were detected, and three corresponding organoids lines retained this mutational profile, including a KRAS p.Gly12Val mutation, KRAS p.Gly12Cys mutation, and RET-fusion. Conclusions: The establishment of primary NSCLC organoids from surgically resected tissue is feasible. Histological, immunohistochemical, and genetic validation is essential to identify representative NSCLC organoids that maintain the characteristics of the parental tumor. Overall, low establishment rates remain a challenge for broad clinical applications.</p>
	]]></content:encoded>

	<dc:title>Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models</dc:title>
			<dc:creator>Raphael S. Werner</dc:creator>
			<dc:creator>Jae-Hwi Jang</dc:creator>
			<dc:creator>Markus Rechsteiner</dc:creator>
			<dc:creator>Michaela B. Kirschner</dc:creator>
			<dc:creator>Isabelle Opitz</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3040017</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-11-09</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-11-09</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>281</prism:startingPage>
		<prism:doi>10.3390/organoids3040017</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/4/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/4/16">

	<title>Organoids, Vol. 3, Pages 266-280: Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing</title>
	<link>https://www.mdpi.com/2674-1172/3/4/16</link>
	<description>Gastric cancer (GC) presents a significant health challenge and ranks as the fifth most common cancer in the world. Unfortunately, most patients with GC exhaust standard care treatment options due to late diagnosis and tumour heterogeneity that leads to drug resistance, resulting in poor survival outcomes. Potentially, this situation can be improved by personalising treatment choice. Organoids are an emerging cell model system that recapitulates tumour heterogeneity and drug responses. Coupled with genomic analysis, organoid culture can be used to guide personalised medicine. The GC organoid field, however, lacks standardised methodologies for assessing organoid drug sensitivities. Comparing results across different GC organoid studies and correlating organoid drug responses with patient outcomes is challenging. Hence, we aim to summarise the methodologies used in GC organoid drug testing and correlation with clinical outcomes and discuss design considerations and limitations to enhance the robustness of such studies in the future.</description>
	<pubDate>2024-10-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 266-280: Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/4/16">doi: 10.3390/organoids3040016</a></p>
	<p>Authors:
		Tharindie N. Silva
		Josephine A. Wright
		Daniel L. Worthley
		Susan L. Woods
		</p>
	<p>Gastric cancer (GC) presents a significant health challenge and ranks as the fifth most common cancer in the world. Unfortunately, most patients with GC exhaust standard care treatment options due to late diagnosis and tumour heterogeneity that leads to drug resistance, resulting in poor survival outcomes. Potentially, this situation can be improved by personalising treatment choice. Organoids are an emerging cell model system that recapitulates tumour heterogeneity and drug responses. Coupled with genomic analysis, organoid culture can be used to guide personalised medicine. The GC organoid field, however, lacks standardised methodologies for assessing organoid drug sensitivities. Comparing results across different GC organoid studies and correlating organoid drug responses with patient outcomes is challenging. Hence, we aim to summarise the methodologies used in GC organoid drug testing and correlation with clinical outcomes and discuss design considerations and limitations to enhance the robustness of such studies in the future.</p>
	]]></content:encoded>

	<dc:title>Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing</dc:title>
			<dc:creator>Tharindie N. Silva</dc:creator>
			<dc:creator>Josephine A. Wright</dc:creator>
			<dc:creator>Daniel L. Worthley</dc:creator>
			<dc:creator>Susan L. Woods</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3040016</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-10-31</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-10-31</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>266</prism:startingPage>
		<prism:doi>10.3390/organoids3040016</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/4/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/4/15">

	<title>Organoids, Vol. 3, Pages 247-265: Bioengineering Tooth and Periodontal Organoids from Stem and Progenitor Cells</title>
	<link>https://www.mdpi.com/2674-1172/3/4/15</link>
	<description>Tooth and periodontal organoids from stem and progenitor cells represent a significant advancement in regenerative dentistry, offering solutions for tooth loss and periodontal diseases. These organoids, which mimic the architecture and function of real organs, provide a cutting-edge platform for studying dental biology and developing therapies. Recent methodologies have been developed to optimize conditions for organoid production, advancing dental regenerative medicine, disease modeling, and developmental studies. The integration of bioengineering strategies with culture techniques enhances both our understanding and the therapeutic potential of these organoids. Additionally, factors such as the extracellular matrix, growth factors, and culture systems profoundly influence organoid formation and maturation. This review explores various bioengineering approaches for generating organoids, emphasizing the pivotal role of stem and progenitor cells.</description>
	<pubDate>2024-10-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 247-265: Bioengineering Tooth and Periodontal Organoids from Stem and Progenitor Cells</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/4/15">doi: 10.3390/organoids3040015</a></p>
	<p>Authors:
		Fuad Gandhi Torizal
		Syarifah Tiara Noorintan
		Zakiya Gania
		</p>
	<p>Tooth and periodontal organoids from stem and progenitor cells represent a significant advancement in regenerative dentistry, offering solutions for tooth loss and periodontal diseases. These organoids, which mimic the architecture and function of real organs, provide a cutting-edge platform for studying dental biology and developing therapies. Recent methodologies have been developed to optimize conditions for organoid production, advancing dental regenerative medicine, disease modeling, and developmental studies. The integration of bioengineering strategies with culture techniques enhances both our understanding and the therapeutic potential of these organoids. Additionally, factors such as the extracellular matrix, growth factors, and culture systems profoundly influence organoid formation and maturation. This review explores various bioengineering approaches for generating organoids, emphasizing the pivotal role of stem and progenitor cells.</p>
	]]></content:encoded>

	<dc:title>Bioengineering Tooth and Periodontal Organoids from Stem and Progenitor Cells</dc:title>
			<dc:creator>Fuad Gandhi Torizal</dc:creator>
			<dc:creator>Syarifah Tiara Noorintan</dc:creator>
			<dc:creator>Zakiya Gania</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3040015</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-10-03</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-10-03</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>247</prism:startingPage>
		<prism:doi>10.3390/organoids3040015</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/4/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/3/14">

	<title>Organoids, Vol. 3, Pages 203-246: Recent Advances and Future Perspectives in Vascular Organoids and Vessel-on-Chip</title>
	<link>https://www.mdpi.com/2674-1172/3/3/14</link>
	<description>Recent advancements in vascular organoid (VO) and vessel-on-chip (VoC) technologies have revolutionized our approach to studying human diseases, offering unprecedented insights through more physiologically relevant models. VOs generated from human pluripotent stem cells exhibit remarkable self-organization capabilities, forming complex three-dimensional structures that closely mimic human blood vessel architecture and function, while VoCs are engineered with microfluidic systems that meticulously recreate the physical and functional attributes of blood vessels. These innovative constructs serve as powerful tools for investigating vascular development, disease progression, and therapeutic efficacy. By enabling the creation of patient-specific VOs and VoCs, they pave the way for personalized medicine approaches, allowing researchers to delve into genetic variations, intricate cellular interactions, and dynamic processes with exceptional resolution. The synergy between VOs and VoCs with newly developed cutting-edge technologies has further amplified their potential, unveiling novel mechanisms underlying human pathologies and identifying promising therapeutic targets. Herein, we summarize different types of VOs and VoCs and present an extensive overview on the generation and applications of VOs and VoCs. We will also highlight clinical and translational challenges and future perspectives around VOs and VoCs.</description>
	<pubDate>2024-09-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 203-246: Recent Advances and Future Perspectives in Vascular Organoids and Vessel-on-Chip</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/3/14">doi: 10.3390/organoids3030014</a></p>
	<p>Authors:
		Gowtham Reddy Cheruku
		Chloe Veronica Wilson
		Suriya Raviendran
		Qingzhong Xiao
		</p>
	<p>Recent advancements in vascular organoid (VO) and vessel-on-chip (VoC) technologies have revolutionized our approach to studying human diseases, offering unprecedented insights through more physiologically relevant models. VOs generated from human pluripotent stem cells exhibit remarkable self-organization capabilities, forming complex three-dimensional structures that closely mimic human blood vessel architecture and function, while VoCs are engineered with microfluidic systems that meticulously recreate the physical and functional attributes of blood vessels. These innovative constructs serve as powerful tools for investigating vascular development, disease progression, and therapeutic efficacy. By enabling the creation of patient-specific VOs and VoCs, they pave the way for personalized medicine approaches, allowing researchers to delve into genetic variations, intricate cellular interactions, and dynamic processes with exceptional resolution. The synergy between VOs and VoCs with newly developed cutting-edge technologies has further amplified their potential, unveiling novel mechanisms underlying human pathologies and identifying promising therapeutic targets. Herein, we summarize different types of VOs and VoCs and present an extensive overview on the generation and applications of VOs and VoCs. We will also highlight clinical and translational challenges and future perspectives around VOs and VoCs.</p>
	]]></content:encoded>

	<dc:title>Recent Advances and Future Perspectives in Vascular Organoids and Vessel-on-Chip</dc:title>
			<dc:creator>Gowtham Reddy Cheruku</dc:creator>
			<dc:creator>Chloe Veronica Wilson</dc:creator>
			<dc:creator>Suriya Raviendran</dc:creator>
			<dc:creator>Qingzhong Xiao</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3030014</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-09-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-09-04</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>203</prism:startingPage>
		<prism:doi>10.3390/organoids3030014</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/3/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/3/13">

	<title>Organoids, Vol. 3, Pages 194-202: A Method to Study Migration and Invasion of Mouse Intestinal Organoids</title>
	<link>https://www.mdpi.com/2674-1172/3/3/13</link>
	<description>Colorectal cancer (CRC) is the third most common cancer worldwide and it is the second leading cause of cancer death. In CRC, as in most cancers, the formation of metastasis through the migration and invasion of cancer cells to distant organs is associated with a dismal prognosis. The study of the mechanisms associated with cancer, and, in particular, CRC, changed in the last decade due to the introduction of organoids. These represent a step forward in terms of complexity from cell lines and allowed the use of mouse models in cancer research to be limited. Although organoids faithfully model the cellular complexity of CRC, current protocols do not allow for the use of organoids in some crucial processes of metastasis, such as migration and invasion. In this study, a method to study migration and invasion using mouse intestinal organoids in vitro is presented. This protocol provides researchers with the opportunity to investigate the migratory behavior of organoid lines and study the impact of distinct mutations on the migratory and invasive capacity of cancer cells.</description>
	<pubDate>2024-08-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 194-202: A Method to Study Migration and Invasion of Mouse Intestinal Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/3/13">doi: 10.3390/organoids3030013</a></p>
	<p>Authors:
		Valérie M. Wouters
		Ciro Longobardi
		Jan Paul Medema
		</p>
	<p>Colorectal cancer (CRC) is the third most common cancer worldwide and it is the second leading cause of cancer death. In CRC, as in most cancers, the formation of metastasis through the migration and invasion of cancer cells to distant organs is associated with a dismal prognosis. The study of the mechanisms associated with cancer, and, in particular, CRC, changed in the last decade due to the introduction of organoids. These represent a step forward in terms of complexity from cell lines and allowed the use of mouse models in cancer research to be limited. Although organoids faithfully model the cellular complexity of CRC, current protocols do not allow for the use of organoids in some crucial processes of metastasis, such as migration and invasion. In this study, a method to study migration and invasion using mouse intestinal organoids in vitro is presented. This protocol provides researchers with the opportunity to investigate the migratory behavior of organoid lines and study the impact of distinct mutations on the migratory and invasive capacity of cancer cells.</p>
	]]></content:encoded>

	<dc:title>A Method to Study Migration and Invasion of Mouse Intestinal Organoids</dc:title>
			<dc:creator>Valérie M. Wouters</dc:creator>
			<dc:creator>Ciro Longobardi</dc:creator>
			<dc:creator>Jan Paul Medema</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3030013</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-08-21</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-08-21</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Study Protocol</prism:section>
	<prism:startingPage>194</prism:startingPage>
		<prism:doi>10.3390/organoids3030013</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/3/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/3/12">

	<title>Organoids, Vol. 3, Pages 174-193: Trophoblast Organoids: Capturing the Complexity of Early Placental Development In Vitro</title>
	<link>https://www.mdpi.com/2674-1172/3/3/12</link>
	<description>First trimester placental development comprises some of the most critical yet understudied events that impact fetal development. Improper placentation leads to a host of health issues that not only impact the fetal period but also influence offspring throughout their lives. Thus, a paradigm to study early placental development is necessary, and this has spurred on the pursuit of new in vitro model systems that recapitulate specific aspects of placentation. One of the most complex and translationally valid models to arise are organoids, three-dimensional structures comprising multiple differentiated cell types that originate from a common progenitor population. Trophoblasts are the progenitor cells of the placenta, serving as the proliferative base for placental development. Recent advances have enabled the derivation of organoids from primary tissue, yet access to first trimester human samples is ethically constrained; derivation from established trophoblast stem cell lines is an alternative source. Organoids have already proven useful in generating insights into molecular events that underlie trophoblast differentiation, with the identification of new cell subtypes that are primed to differentiate down different paths. In this review, (1) we recap early pregnancy development events, (2) provide an overview of the cellular complexity of the placenta, (3) discuss the generation of organoids from tissue versus cellular sources, (4) highlight the value of translational animal models, and (5) focus on the complexities of the molecular regulation of trophoblast organoid development, differentiation, and function.</description>
	<pubDate>2024-08-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 174-193: Trophoblast Organoids: Capturing the Complexity of Early Placental Development In Vitro</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/3/12">doi: 10.3390/organoids3030012</a></p>
	<p>Authors:
		Brady M. Wessel
		Jenna N. Castro
		Victoria H. J. Roberts
		</p>
	<p>First trimester placental development comprises some of the most critical yet understudied events that impact fetal development. Improper placentation leads to a host of health issues that not only impact the fetal period but also influence offspring throughout their lives. Thus, a paradigm to study early placental development is necessary, and this has spurred on the pursuit of new in vitro model systems that recapitulate specific aspects of placentation. One of the most complex and translationally valid models to arise are organoids, three-dimensional structures comprising multiple differentiated cell types that originate from a common progenitor population. Trophoblasts are the progenitor cells of the placenta, serving as the proliferative base for placental development. Recent advances have enabled the derivation of organoids from primary tissue, yet access to first trimester human samples is ethically constrained; derivation from established trophoblast stem cell lines is an alternative source. Organoids have already proven useful in generating insights into molecular events that underlie trophoblast differentiation, with the identification of new cell subtypes that are primed to differentiate down different paths. In this review, (1) we recap early pregnancy development events, (2) provide an overview of the cellular complexity of the placenta, (3) discuss the generation of organoids from tissue versus cellular sources, (4) highlight the value of translational animal models, and (5) focus on the complexities of the molecular regulation of trophoblast organoid development, differentiation, and function.</p>
	]]></content:encoded>

	<dc:title>Trophoblast Organoids: Capturing the Complexity of Early Placental Development In Vitro</dc:title>
			<dc:creator>Brady M. Wessel</dc:creator>
			<dc:creator>Jenna N. Castro</dc:creator>
			<dc:creator>Victoria H. J. Roberts</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3030012</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-08-02</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-08-02</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>174</prism:startingPage>
		<prism:doi>10.3390/organoids3030012</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/3/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/3/11">

	<title>Organoids, Vol. 3, Pages 165-173: Organoids and 3D In Vitro Models as a Platform for Precision Medicine (PM): An Update</title>
	<link>https://www.mdpi.com/2674-1172/3/3/11</link>
	<description>Globally, a number of diseases impact us and while treatment options exist, it is often found that similar treatments have variable effects on different patients with the same disease. Particularly in the case of conditions that are closely associated with genetics (like cancer), the intensity and results of a treatment vary between patients. Even for diseases like arthritis it is not uncommon for only a fraction of patients to achieve remission with the same therapeutic approach. With millions suffering from diseases like cancer and arthritis, precision medicine (PM) has been at the forefront of biomedical and pharmaceutical research since 2015. PM focusses on understanding the genetic and environmental factors affecting the patients and has several platforms. One of the platforms is the use of three-dimensional (3D) in vitro models, especially those derived from the patient themselves. These models, like organ-on-chip (OOC), organoid and spheroid models, 3D biomaterial scaffolds and others, have several advantages over traditional two-dimensional (2D) cell culture approaches. In this opinion paper, the author briefly discusses the different platforms used for PM. Then, the advantages that 3D in vitro models have over traditional 2D models and in vivo models are considered and an overview of their applications is provided. Finally, the author outlines the challenges and future directions and shares their opinion about using 3D in vitro models as a tool for PM towards enhanced patient outcomes.</description>
	<pubDate>2024-08-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 165-173: Organoids and 3D In Vitro Models as a Platform for Precision Medicine (PM): An Update</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/3/11">doi: 10.3390/organoids3030011</a></p>
	<p>Authors:
		Payal Ganguly
		</p>
	<p>Globally, a number of diseases impact us and while treatment options exist, it is often found that similar treatments have variable effects on different patients with the same disease. Particularly in the case of conditions that are closely associated with genetics (like cancer), the intensity and results of a treatment vary between patients. Even for diseases like arthritis it is not uncommon for only a fraction of patients to achieve remission with the same therapeutic approach. With millions suffering from diseases like cancer and arthritis, precision medicine (PM) has been at the forefront of biomedical and pharmaceutical research since 2015. PM focusses on understanding the genetic and environmental factors affecting the patients and has several platforms. One of the platforms is the use of three-dimensional (3D) in vitro models, especially those derived from the patient themselves. These models, like organ-on-chip (OOC), organoid and spheroid models, 3D biomaterial scaffolds and others, have several advantages over traditional two-dimensional (2D) cell culture approaches. In this opinion paper, the author briefly discusses the different platforms used for PM. Then, the advantages that 3D in vitro models have over traditional 2D models and in vivo models are considered and an overview of their applications is provided. Finally, the author outlines the challenges and future directions and shares their opinion about using 3D in vitro models as a tool for PM towards enhanced patient outcomes.</p>
	]]></content:encoded>

	<dc:title>Organoids and 3D In Vitro Models as a Platform for Precision Medicine (PM): An Update</dc:title>
			<dc:creator>Payal Ganguly</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3030011</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-08-01</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-08-01</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>165</prism:startingPage>
		<prism:doi>10.3390/organoids3030011</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/3/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/3/10">

	<title>Organoids, Vol. 3, Pages 148-164: Heparin-Binding Epidermal-like Growth Factor (HB-EGF) Reduces Cell Death in an Organoid Model of Retinal Damage</title>
	<link>https://www.mdpi.com/2674-1172/3/3/10</link>
	<description>In zebrafish and various mammalian species, HB-EGF has been shown to promote M&amp;amp;uuml;ller glia proliferation and activation of repair mechanisms that have not been fully investigated in human retina. In the current study, 70- to 90-day-old human retinal organoids were treated with 20 &amp;amp;mu;M 4-hydroxytamoxifen (4-OHT), and CRX, REC, NRL, PAX6, VIM, GFAP, and VSX2 gene and protein expression were assessed at various times points after treatment. Organoids with or without 4-OHT-induced damage were then cultured with HB-EGF for 7 days. We showed that 20 &amp;amp;mu;M 4-OHT caused a reduction in the number of recoverin-positive cells; an increase in the number of TUNEL-positive cells; and downregulation of the photoreceptor gene markers CRX, NRL, and REC. Culture of organoids with HB-EGF for 7 days after 4-OHT-induced damage caused a marked reduction in the number of TUNEL-positive cells and small increases in the number of Ki67-positive cells and PAX6 and NOTCH1 gene expression. The current results suggest that treatment of human ESC-derived retinal organoids with 4-OHT may be used as a model of retinal degeneration in vitro. Furthermore, HB-EGF treatment of human retinal organoids increases proliferating M&amp;amp;uuml;ller cells, but only after 4-OHT induced damage, and may be an indication of Muller reactivity in response to photoreceptor damage. Further studies will aim to identify factors that may induce M&amp;amp;uuml;ller cell-mediated regeneration of the human retina, aiding in the development of therapies for retinal degeneration.</description>
	<pubDate>2024-07-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 148-164: Heparin-Binding Epidermal-like Growth Factor (HB-EGF) Reduces Cell Death in an Organoid Model of Retinal Damage</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/3/10">doi: 10.3390/organoids3030010</a></p>
	<p>Authors:
		Michelle N. H. Tang
		Mariya Moosajee
		Najam A. Sharif
		G. Astrid Limb
		Karen Eastlake
		</p>
	<p>In zebrafish and various mammalian species, HB-EGF has been shown to promote M&amp;amp;uuml;ller glia proliferation and activation of repair mechanisms that have not been fully investigated in human retina. In the current study, 70- to 90-day-old human retinal organoids were treated with 20 &amp;amp;mu;M 4-hydroxytamoxifen (4-OHT), and CRX, REC, NRL, PAX6, VIM, GFAP, and VSX2 gene and protein expression were assessed at various times points after treatment. Organoids with or without 4-OHT-induced damage were then cultured with HB-EGF for 7 days. We showed that 20 &amp;amp;mu;M 4-OHT caused a reduction in the number of recoverin-positive cells; an increase in the number of TUNEL-positive cells; and downregulation of the photoreceptor gene markers CRX, NRL, and REC. Culture of organoids with HB-EGF for 7 days after 4-OHT-induced damage caused a marked reduction in the number of TUNEL-positive cells and small increases in the number of Ki67-positive cells and PAX6 and NOTCH1 gene expression. The current results suggest that treatment of human ESC-derived retinal organoids with 4-OHT may be used as a model of retinal degeneration in vitro. Furthermore, HB-EGF treatment of human retinal organoids increases proliferating M&amp;amp;uuml;ller cells, but only after 4-OHT induced damage, and may be an indication of Muller reactivity in response to photoreceptor damage. Further studies will aim to identify factors that may induce M&amp;amp;uuml;ller cell-mediated regeneration of the human retina, aiding in the development of therapies for retinal degeneration.</p>
	]]></content:encoded>

	<dc:title>Heparin-Binding Epidermal-like Growth Factor (HB-EGF) Reduces Cell Death in an Organoid Model of Retinal Damage</dc:title>
			<dc:creator>Michelle N. H. Tang</dc:creator>
			<dc:creator>Mariya Moosajee</dc:creator>
			<dc:creator>Najam A. Sharif</dc:creator>
			<dc:creator>G. Astrid Limb</dc:creator>
			<dc:creator>Karen Eastlake</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3030010</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-07-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-07-05</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>148</prism:startingPage>
		<prism:doi>10.3390/organoids3030010</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/3/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/2/9">

	<title>Organoids, Vol. 3, Pages 126-147: Single-Cell Assessment of Human Stem Cell-Derived Mesolimbic Models and Their Responses to Substances of Abuse</title>
	<link>https://www.mdpi.com/2674-1172/3/2/9</link>
	<description>The mesolimbic pathway connects ventral tegmental area dopaminergic neurons and striatal medium spiny neurons, playing a critical role in reward and stress behaviors. Exposure to substances of abuse during development and adulthood has been linked to adverse outcomes and molecular changes. The rise of human cell repositories and whole-genome sequences enables human functional genomics &amp;amp;lsquo;in a dish&amp;amp;rsquo;, offering insights into human-specific responses to substances of abuse. Continued development of new models is needed, and the characterization of in vitro models is also necessary to ensure appropriate experimental designs and the accurate interpretation of results. This study introduces new culture conditions for generating medium spiny neurons and dopaminergic neurons with an early common media, allowing for coculture and assembloid generation. It then provides a comprehensive characterization of these and prior models and their responses to substances of abuse. Single-cell analysis reveals cell-type-specific transcriptomic responses to dopamine, cocaine, and morphine, including compound and cell-type-specific transcriptomic signatures related to neuroinflammation and alterations in signaling pathways. These findings offer a resource for future genomics studies leveraging human stem cell-derived models.</description>
	<pubDate>2024-06-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 126-147: Single-Cell Assessment of Human Stem Cell-Derived Mesolimbic Models and Their Responses to Substances of Abuse</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/2/9">doi: 10.3390/organoids3020009</a></p>
	<p>Authors:
		Thomas P. Rudibaugh
		Ryan W. Tam
		R. Chris Estridge
		Samantha R. Stuppy
		Albert J. Keung
		</p>
	<p>The mesolimbic pathway connects ventral tegmental area dopaminergic neurons and striatal medium spiny neurons, playing a critical role in reward and stress behaviors. Exposure to substances of abuse during development and adulthood has been linked to adverse outcomes and molecular changes. The rise of human cell repositories and whole-genome sequences enables human functional genomics &amp;amp;lsquo;in a dish&amp;amp;rsquo;, offering insights into human-specific responses to substances of abuse. Continued development of new models is needed, and the characterization of in vitro models is also necessary to ensure appropriate experimental designs and the accurate interpretation of results. This study introduces new culture conditions for generating medium spiny neurons and dopaminergic neurons with an early common media, allowing for coculture and assembloid generation. It then provides a comprehensive characterization of these and prior models and their responses to substances of abuse. Single-cell analysis reveals cell-type-specific transcriptomic responses to dopamine, cocaine, and morphine, including compound and cell-type-specific transcriptomic signatures related to neuroinflammation and alterations in signaling pathways. These findings offer a resource for future genomics studies leveraging human stem cell-derived models.</p>
	]]></content:encoded>

	<dc:title>Single-Cell Assessment of Human Stem Cell-Derived Mesolimbic Models and Their Responses to Substances of Abuse</dc:title>
			<dc:creator>Thomas P. Rudibaugh</dc:creator>
			<dc:creator>Ryan W. Tam</dc:creator>
			<dc:creator>R. Chris Estridge</dc:creator>
			<dc:creator>Samantha R. Stuppy</dc:creator>
			<dc:creator>Albert J. Keung</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3020009</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-06-20</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-06-20</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>126</prism:startingPage>
		<prism:doi>10.3390/organoids3020009</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/2/8">

	<title>Organoids, Vol. 3, Pages 113-125: Development and Optimization of a Lactate Dehydrogenase Assay Adapted to 3D Cell Cultures</title>
	<link>https://www.mdpi.com/2674-1172/3/2/8</link>
	<description>In recent years, 3D cell culture systems have emerged as sophisticated in vitro models, providing valuable insights into human physiology and diseases. The transition from traditional 2D to advanced 3D cultures has introduced novel obstacles, complicating the characterization and analysis of these models. While the lactate dehydrogenase (LDH) activity assay has long been a standard readout for viability and cytotoxicity assessments in 2D cultures, its applicability in long-term 3D cultures is hindered by inappropriate normalization and low LDH stability over time. In response to these challenges, we propose an optimization of LDH assays, including a crucial normalization step based on total protein quantification and a storage method using an LDH preservation buffer. We applied it to compare unexposed cerebral organoids with organoids exposed to a toxic dose of valproic acid, and showed efficient normalization of cellular viability as well as enhanced LDH stability within the buffer. Importantly, normalized LDH activity results obtained were independent of organoid dimension and cell density. This refined LDH assay, tailored to address 3D culture constraints, allows for the transposition of this routine test from 2D to 3D cultures.</description>
	<pubDate>2024-06-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 113-125: Development and Optimization of a Lactate Dehydrogenase Assay Adapted to 3D Cell Cultures</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/2/8">doi: 10.3390/organoids3020008</a></p>
	<p>Authors:
		Héloïse Castiglione
		Lucie Madrange
		Thomas Lemonnier
		Jean-Philippe Deslys
		Frank Yates
		Pierre-Antoine Vigneron
		</p>
	<p>In recent years, 3D cell culture systems have emerged as sophisticated in vitro models, providing valuable insights into human physiology and diseases. The transition from traditional 2D to advanced 3D cultures has introduced novel obstacles, complicating the characterization and analysis of these models. While the lactate dehydrogenase (LDH) activity assay has long been a standard readout for viability and cytotoxicity assessments in 2D cultures, its applicability in long-term 3D cultures is hindered by inappropriate normalization and low LDH stability over time. In response to these challenges, we propose an optimization of LDH assays, including a crucial normalization step based on total protein quantification and a storage method using an LDH preservation buffer. We applied it to compare unexposed cerebral organoids with organoids exposed to a toxic dose of valproic acid, and showed efficient normalization of cellular viability as well as enhanced LDH stability within the buffer. Importantly, normalized LDH activity results obtained were independent of organoid dimension and cell density. This refined LDH assay, tailored to address 3D culture constraints, allows for the transposition of this routine test from 2D to 3D cultures.</p>
	]]></content:encoded>

	<dc:title>Development and Optimization of a Lactate Dehydrogenase Assay Adapted to 3D Cell Cultures</dc:title>
			<dc:creator>Héloïse Castiglione</dc:creator>
			<dc:creator>Lucie Madrange</dc:creator>
			<dc:creator>Thomas Lemonnier</dc:creator>
			<dc:creator>Jean-Philippe Deslys</dc:creator>
			<dc:creator>Frank Yates</dc:creator>
			<dc:creator>Pierre-Antoine Vigneron</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3020008</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-06-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-06-05</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Protocol</prism:section>
	<prism:startingPage>113</prism:startingPage>
		<prism:doi>10.3390/organoids3020008</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/2/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/2/7">

	<title>Organoids, Vol. 3, Pages 83-112: Organoids, Biocybersecurity, and Cyberbiosecurity&amp;mdash;A Light Exploration</title>
	<link>https://www.mdpi.com/2674-1172/3/2/7</link>
	<description>Organoids present immense promise for studying organ systems and their functionality. Recently, they have become the subject of exploration outside of purely biomedical uses in multiple directions. We will explore the rapidly evolving landscape of organoid research over the 21st century, discussing significant advancements in organoid research and highlighting breakthroughs, methodologies, and their transformative impact on our understanding of physiology and modeling. In addition, we will explore their potential use for biocomputing and harnessing organoid intelligence, investigate how these miniaturized organ-like structures promise to create novel computational models and processing platforms allowing for innovative approaches in drug discovery, personalized medicine, and disease prediction. Lastly, we will address the ethical dilemmas surrounding organoid research by dissecting the intricate ethical considerations related to the creation, use, and potential implications of these in vitro models. Through this work, the goal of this paper is to provide introductory perspectives and bridges that will connect organoids to cybersecurity applications and the imperative ethical discourse accompanying its advancements with commentary on future uses.</description>
	<pubDate>2024-05-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 83-112: Organoids, Biocybersecurity, and Cyberbiosecurity&amp;mdash;A Light Exploration</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/2/7">doi: 10.3390/organoids3020007</a></p>
	<p>Authors:
		Xavier Palmer
		Cyril Akafia
		Eleasa Woodson
		Amanda Woodson
		Lucas Potter
		</p>
	<p>Organoids present immense promise for studying organ systems and their functionality. Recently, they have become the subject of exploration outside of purely biomedical uses in multiple directions. We will explore the rapidly evolving landscape of organoid research over the 21st century, discussing significant advancements in organoid research and highlighting breakthroughs, methodologies, and their transformative impact on our understanding of physiology and modeling. In addition, we will explore their potential use for biocomputing and harnessing organoid intelligence, investigate how these miniaturized organ-like structures promise to create novel computational models and processing platforms allowing for innovative approaches in drug discovery, personalized medicine, and disease prediction. Lastly, we will address the ethical dilemmas surrounding organoid research by dissecting the intricate ethical considerations related to the creation, use, and potential implications of these in vitro models. Through this work, the goal of this paper is to provide introductory perspectives and bridges that will connect organoids to cybersecurity applications and the imperative ethical discourse accompanying its advancements with commentary on future uses.</p>
	]]></content:encoded>

	<dc:title>Organoids, Biocybersecurity, and Cyberbiosecurity&amp;amp;mdash;A Light Exploration</dc:title>
			<dc:creator>Xavier Palmer</dc:creator>
			<dc:creator>Cyril Akafia</dc:creator>
			<dc:creator>Eleasa Woodson</dc:creator>
			<dc:creator>Amanda Woodson</dc:creator>
			<dc:creator>Lucas Potter</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3020007</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-05-13</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-05-13</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>83</prism:startingPage>
		<prism:doi>10.3390/organoids3020007</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/2/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/2/6">

	<title>Organoids, Vol. 3, Pages 67-82: Treatment of Canine Type 1 Diabetes Mellitus: The Long Road from Twice Daily Insulin Injection towards Long-Lasting Cell-Based Therapy</title>
	<link>https://www.mdpi.com/2674-1172/3/2/6</link>
	<description>For over 150 years, researchers have studied the (patho)physiology of the endocrine pancreas and devised treatment options for diabetes mellitus (DM). However, no cure has been developed so far. In dogs, diabetes mellitus type 1 (T1DM) is the most common presentation. Treatment consists of twice daily insulin injections, monitored by spatial blood glucose measurements. Even though dogs were instrumental in the discovery of insulin and islet transplantations, the treatment in diabetic dogs has remained unchanged for decades. Providing twice daily insulin injections is demanding for both owners and dogs and may result in hypoglycaemic events, creating the need for new treatment strategies. Novel regenerative medicine-based tools, such as improved &amp;amp;beta;-cell culture protocols and artificial devices, have sparked hope for a cure. In human medicine, emerging technologies such as the transplantation of insulin-producing &amp;amp;beta;-cells, generated by stem cell differentiation, with or without an encapsulation device, are currently tested in phase I/II clinical trials. As the pathogenesis of T1DM is remarkably similar between humans and dogs, novel treatment methods could be implemented in canine medicine. This review briefly summarises the physiology of the canine endocrine pancreas and the pathophysiology of canine DM before exploring current and possible future treatment options for canine DM.</description>
	<pubDate>2024-04-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 67-82: Treatment of Canine Type 1 Diabetes Mellitus: The Long Road from Twice Daily Insulin Injection towards Long-Lasting Cell-Based Therapy</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/2/6">doi: 10.3390/organoids3020006</a></p>
	<p>Authors:
		Flavia C. M. Oliveira
		Annemarie W. Y. Voorbij
		Elisa C. Pereira
		Leonor M. M. Alves e Almeida
		Geanne R. Moraes
		Joana T. De Oliveira
		Boyd H. T. Gouw
		Sabrina A. M. Legatti
		Hans S. Kooistra
		Bart Spee
		Andre M. C. Meneses
		Louis C. Penning
		</p>
	<p>For over 150 years, researchers have studied the (patho)physiology of the endocrine pancreas and devised treatment options for diabetes mellitus (DM). However, no cure has been developed so far. In dogs, diabetes mellitus type 1 (T1DM) is the most common presentation. Treatment consists of twice daily insulin injections, monitored by spatial blood glucose measurements. Even though dogs were instrumental in the discovery of insulin and islet transplantations, the treatment in diabetic dogs has remained unchanged for decades. Providing twice daily insulin injections is demanding for both owners and dogs and may result in hypoglycaemic events, creating the need for new treatment strategies. Novel regenerative medicine-based tools, such as improved &amp;amp;beta;-cell culture protocols and artificial devices, have sparked hope for a cure. In human medicine, emerging technologies such as the transplantation of insulin-producing &amp;amp;beta;-cells, generated by stem cell differentiation, with or without an encapsulation device, are currently tested in phase I/II clinical trials. As the pathogenesis of T1DM is remarkably similar between humans and dogs, novel treatment methods could be implemented in canine medicine. This review briefly summarises the physiology of the canine endocrine pancreas and the pathophysiology of canine DM before exploring current and possible future treatment options for canine DM.</p>
	]]></content:encoded>

	<dc:title>Treatment of Canine Type 1 Diabetes Mellitus: The Long Road from Twice Daily Insulin Injection towards Long-Lasting Cell-Based Therapy</dc:title>
			<dc:creator>Flavia C. M. Oliveira</dc:creator>
			<dc:creator>Annemarie W. Y. Voorbij</dc:creator>
			<dc:creator>Elisa C. Pereira</dc:creator>
			<dc:creator>Leonor M. M. Alves e Almeida</dc:creator>
			<dc:creator>Geanne R. Moraes</dc:creator>
			<dc:creator>Joana T. De Oliveira</dc:creator>
			<dc:creator>Boyd H. T. Gouw</dc:creator>
			<dc:creator>Sabrina A. M. Legatti</dc:creator>
			<dc:creator>Hans S. Kooistra</dc:creator>
			<dc:creator>Bart Spee</dc:creator>
			<dc:creator>Andre M. C. Meneses</dc:creator>
			<dc:creator>Louis C. Penning</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3020006</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-04-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-04-04</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>67</prism:startingPage>
		<prism:doi>10.3390/organoids3020006</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/2/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/1/5">

	<title>Organoids, Vol. 3, Pages 54-66: Generation of Trophoblast Organoids from Chorionic Villus Sampling</title>
	<link>https://www.mdpi.com/2674-1172/3/1/5</link>
	<description>Studying human placental development and function presents significant challenges due to the inherent difficulties in obtaining and maintaining placental tissue throughout the course of an ongoing pregnancy. Here, we provide a detailed protocol for generating trophoblast organoids from chorionic villi obtained during ongoing pregnancy. Our method results in efficient generation of trophoblast organoids from chorionic villus sampling, does not require preselection of chorionic villi, and controls contamination of decidual gland organoids. The resulting trophoblast organoids spontaneously form syncytiotrophoblasts that start secreting hCG hormone amongst other placenta-specific factors. Our approach facilitates the generation of trophoblast organoids from a variety of genetic backgrounds, including trisomies and gene mutations, and can be aligned with prenatal diagnostic routines. The protocol requires up to 14 days and can be carried out by users with expertise in cell culture.</description>
	<pubDate>2024-03-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 54-66: Generation of Trophoblast Organoids from Chorionic Villus Sampling</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/1/5">doi: 10.3390/organoids3010005</a></p>
	<p>Authors:
		Bas van Rijn
		Diane Van Opstal
		Nicole van Koetsveld
		Maarten Knapen
		Joost Gribnau
		Olivier Schäffers
		</p>
	<p>Studying human placental development and function presents significant challenges due to the inherent difficulties in obtaining and maintaining placental tissue throughout the course of an ongoing pregnancy. Here, we provide a detailed protocol for generating trophoblast organoids from chorionic villi obtained during ongoing pregnancy. Our method results in efficient generation of trophoblast organoids from chorionic villus sampling, does not require preselection of chorionic villi, and controls contamination of decidual gland organoids. The resulting trophoblast organoids spontaneously form syncytiotrophoblasts that start secreting hCG hormone amongst other placenta-specific factors. Our approach facilitates the generation of trophoblast organoids from a variety of genetic backgrounds, including trisomies and gene mutations, and can be aligned with prenatal diagnostic routines. The protocol requires up to 14 days and can be carried out by users with expertise in cell culture.</p>
	]]></content:encoded>

	<dc:title>Generation of Trophoblast Organoids from Chorionic Villus Sampling</dc:title>
			<dc:creator>Bas van Rijn</dc:creator>
			<dc:creator>Diane Van Opstal</dc:creator>
			<dc:creator>Nicole van Koetsveld</dc:creator>
			<dc:creator>Maarten Knapen</dc:creator>
			<dc:creator>Joost Gribnau</dc:creator>
			<dc:creator>Olivier Schäffers</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3010005</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-03-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-03-05</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Protocol</prism:section>
	<prism:startingPage>54</prism:startingPage>
		<prism:doi>10.3390/organoids3010005</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/1/4">

	<title>Organoids, Vol. 3, Pages 35-53: Analysis of Osteosarcoma Cell Lines and Patient Tissue Using a 3D In Vivo Tumor Model&amp;mdash;Possible Effects of Punicalagin</title>
	<link>https://www.mdpi.com/2674-1172/3/1/4</link>
	<description>Osteosarcomas are the most common primary malignant bone tumors and mostly affect children, adolescents, and young adults. Despite current treatment options such as surgery and polychemotherapy, the survival of patients with metastatic disease remains poor. In recent studies, punicalagin has reduced the cell viability, angiogenesis, and invasion in cell culture trials. The aim of this study was to examine the effects of punicalagin on osteosarcomas in a 3D in vivo tumor model. Human osteosarcoma biopsies and SaOs-2 and MG-63 cells, were grown in a 3D in vivo chorioallantoic membrane (CAM) model. After a cultivation period of up to 72 h, the tumors received daily treatment with punicalagin for 4 days. Weight measurements of the CAM tumors were performed, and laser speckle contrast imaging (LSCI) and a deep learning-based image analysis software (CAM Assay Application v.3.1.0) were used to measure angiogenesis. HE, Ki-67, and Caspase-3 staining was performed after explantation. The osteosarcoma cell lines SaOs-2 and MG-63 and osteosarcoma patient tissue displayed satisfactory growth patterns on the CAM. Treatment with punicalagin decreased tumor weight, proliferation, and tumor-induced angiogenesis, and the tumor tissue showed pro-apoptotic characteristics. These results provide a robust foundation for the implementation of further studies and show that punicalagin offers a promising supplementary treatment option for osteosarcoma patients. The 3D in vivo tumor model represents a beneficial model for the testing of anti-cancer therapies.</description>
	<pubDate>2024-03-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 35-53: Analysis of Osteosarcoma Cell Lines and Patient Tissue Using a 3D In Vivo Tumor Model&amp;mdash;Possible Effects of Punicalagin</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/1/4">doi: 10.3390/organoids3010004</a></p>
	<p>Authors:
		Anna Rebecca Dorn
		Sara Neff
		Sophia Hupp
		Melissa Engelhardt
		Eric Pion
		Ulrich Lenze
		Carolin Knebel
		Anna Duprée
		Simone Schewe
		Markus Weber
		Christian Wulbrand
		Axel Hillmann
		Florian Weber
		Phillip Clarke
		Philipp Kainz
		Thiha Aung
		Silke Haerteis
		</p>
	<p>Osteosarcomas are the most common primary malignant bone tumors and mostly affect children, adolescents, and young adults. Despite current treatment options such as surgery and polychemotherapy, the survival of patients with metastatic disease remains poor. In recent studies, punicalagin has reduced the cell viability, angiogenesis, and invasion in cell culture trials. The aim of this study was to examine the effects of punicalagin on osteosarcomas in a 3D in vivo tumor model. Human osteosarcoma biopsies and SaOs-2 and MG-63 cells, were grown in a 3D in vivo chorioallantoic membrane (CAM) model. After a cultivation period of up to 72 h, the tumors received daily treatment with punicalagin for 4 days. Weight measurements of the CAM tumors were performed, and laser speckle contrast imaging (LSCI) and a deep learning-based image analysis software (CAM Assay Application v.3.1.0) were used to measure angiogenesis. HE, Ki-67, and Caspase-3 staining was performed after explantation. The osteosarcoma cell lines SaOs-2 and MG-63 and osteosarcoma patient tissue displayed satisfactory growth patterns on the CAM. Treatment with punicalagin decreased tumor weight, proliferation, and tumor-induced angiogenesis, and the tumor tissue showed pro-apoptotic characteristics. These results provide a robust foundation for the implementation of further studies and show that punicalagin offers a promising supplementary treatment option for osteosarcoma patients. The 3D in vivo tumor model represents a beneficial model for the testing of anti-cancer therapies.</p>
	]]></content:encoded>

	<dc:title>Analysis of Osteosarcoma Cell Lines and Patient Tissue Using a 3D In Vivo Tumor Model&amp;amp;mdash;Possible Effects of Punicalagin</dc:title>
			<dc:creator>Anna Rebecca Dorn</dc:creator>
			<dc:creator>Sara Neff</dc:creator>
			<dc:creator>Sophia Hupp</dc:creator>
			<dc:creator>Melissa Engelhardt</dc:creator>
			<dc:creator>Eric Pion</dc:creator>
			<dc:creator>Ulrich Lenze</dc:creator>
			<dc:creator>Carolin Knebel</dc:creator>
			<dc:creator>Anna Duprée</dc:creator>
			<dc:creator>Simone Schewe</dc:creator>
			<dc:creator>Markus Weber</dc:creator>
			<dc:creator>Christian Wulbrand</dc:creator>
			<dc:creator>Axel Hillmann</dc:creator>
			<dc:creator>Florian Weber</dc:creator>
			<dc:creator>Phillip Clarke</dc:creator>
			<dc:creator>Philipp Kainz</dc:creator>
			<dc:creator>Thiha Aung</dc:creator>
			<dc:creator>Silke Haerteis</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3010004</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-03-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-03-04</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>35</prism:startingPage>
		<prism:doi>10.3390/organoids3010004</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/1/3">

	<title>Organoids, Vol. 3, Pages 32-34: The Next Generation of Organoids Will Be More Complex and Even Closer to Resembling Real Organs: An Interview with Prof. Dr. Hans Clevers</title>
	<link>https://www.mdpi.com/2674-1172/3/1/3</link>
	<description>In this issue, we are pleased and honored to have an interview with Professor Hans Clevers, who is the Advisory Board Member of Organoids [...]</description>
	<pubDate>2024-02-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 32-34: The Next Generation of Organoids Will Be More Complex and Even Closer to Resembling Real Organs: An Interview with Prof. Dr. Hans Clevers</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/1/3">doi: 10.3390/organoids3010003</a></p>
	<p>Authors:
		Süleyman Ergün
		Organoids Editorial Office Organoids Editorial Office
		</p>
	<p>In this issue, we are pleased and honored to have an interview with Professor Hans Clevers, who is the Advisory Board Member of Organoids [...]</p>
	]]></content:encoded>

	<dc:title>The Next Generation of Organoids Will Be More Complex and Even Closer to Resembling Real Organs: An Interview with Prof. Dr. Hans Clevers</dc:title>
			<dc:creator>Süleyman Ergün</dc:creator>
			<dc:creator>Organoids Editorial Office Organoids Editorial Office</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3010003</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-02-20</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-02-20</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>32</prism:startingPage>
		<prism:doi>10.3390/organoids3010003</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/1/2">

	<title>Organoids, Vol. 3, Pages 18-31: Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine</title>
	<link>https://www.mdpi.com/2674-1172/3/1/2</link>
	<description>Existing mRNA COVID-19 vaccines have shown efficacy in reducing severe cases and fatalities. However, their effectiveness against infection caused by emerging SARS-CoV-2 variants has waned considerably, necessitating the development of variant vaccines. Ideally, next-generation vaccines will be capable of eliciting broader and more sustained immune responses to effectively counteract new variants. Additionally, in vitro assays that more closely represent virus neutralization in humans would greatly assist in the analysis of protective vaccine-induced antibody responses. Here, we present findings from a SARS-CoV-2 VLP vaccine encompassing three key structural proteins: Spike (S), Envelope (E), and Membrane (M). The VLP vaccine effectively produced neutralizing antibodies as determined by surrogate virus neutralization test, and induced virus-specific T-cell responses: predominantly CD4+, although CD8+ T cell responses were detected. T cell responses were more prominent with vaccine delivered with AddaVax compared to vaccine alone. The adjuvanted vaccine was completely protective against live virus challenge in mice. Furthermore, we utilized air&amp;amp;ndash;liquid-interface (ALI)-differentiated human nasal epithelium (HNE) as an in vitro system, which authentically models human SARS-CoV-2 infection and neutralization. We show that immune sera from VLP-vaccinated mice completely neutralized SARS-CoV-2 virus infection, demonstrating the potential of ALI-HNE to assess vaccine induced Nab.</description>
	<pubDate>2024-02-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 18-31: Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/1/2">doi: 10.3390/organoids3010002</a></p>
	<p>Authors:
		Julio Carrera Montoya
		Simon Collett
		Daniel Fernandez Ruiz
		Linda Earnest
		Melissa A. Edeling
		Ashley Huey Yiing Yap
		Chinn Yi Wong
		James P. Cooney
		Kathryn C. Davidson
		Jason Roberts
		Steven Rockman
		Bang M. Tran
		Julie L. McAuley
		Georgia Deliyannis
		Samantha L. Grimley
		Damian F. J. Purcell
		Shafagh A. Waters
		Dale I. Godfrey
		Dhiraj Hans
		Marc Pellegrini
		Jason M. Mackenzie
		Elizabeth Vincan
		William R. Heath
		Joseph Torresi
		</p>
	<p>Existing mRNA COVID-19 vaccines have shown efficacy in reducing severe cases and fatalities. However, their effectiveness against infection caused by emerging SARS-CoV-2 variants has waned considerably, necessitating the development of variant vaccines. Ideally, next-generation vaccines will be capable of eliciting broader and more sustained immune responses to effectively counteract new variants. Additionally, in vitro assays that more closely represent virus neutralization in humans would greatly assist in the analysis of protective vaccine-induced antibody responses. Here, we present findings from a SARS-CoV-2 VLP vaccine encompassing three key structural proteins: Spike (S), Envelope (E), and Membrane (M). The VLP vaccine effectively produced neutralizing antibodies as determined by surrogate virus neutralization test, and induced virus-specific T-cell responses: predominantly CD4+, although CD8+ T cell responses were detected. T cell responses were more prominent with vaccine delivered with AddaVax compared to vaccine alone. The adjuvanted vaccine was completely protective against live virus challenge in mice. Furthermore, we utilized air&amp;amp;ndash;liquid-interface (ALI)-differentiated human nasal epithelium (HNE) as an in vitro system, which authentically models human SARS-CoV-2 infection and neutralization. We show that immune sera from VLP-vaccinated mice completely neutralized SARS-CoV-2 virus infection, demonstrating the potential of ALI-HNE to assess vaccine induced Nab.</p>
	]]></content:encoded>

	<dc:title>Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine</dc:title>
			<dc:creator>Julio Carrera Montoya</dc:creator>
			<dc:creator>Simon Collett</dc:creator>
			<dc:creator>Daniel Fernandez Ruiz</dc:creator>
			<dc:creator>Linda Earnest</dc:creator>
			<dc:creator>Melissa A. Edeling</dc:creator>
			<dc:creator>Ashley Huey Yiing Yap</dc:creator>
			<dc:creator>Chinn Yi Wong</dc:creator>
			<dc:creator>James P. Cooney</dc:creator>
			<dc:creator>Kathryn C. Davidson</dc:creator>
			<dc:creator>Jason Roberts</dc:creator>
			<dc:creator>Steven Rockman</dc:creator>
			<dc:creator>Bang M. Tran</dc:creator>
			<dc:creator>Julie L. McAuley</dc:creator>
			<dc:creator>Georgia Deliyannis</dc:creator>
			<dc:creator>Samantha L. Grimley</dc:creator>
			<dc:creator>Damian F. J. Purcell</dc:creator>
			<dc:creator>Shafagh A. Waters</dc:creator>
			<dc:creator>Dale I. Godfrey</dc:creator>
			<dc:creator>Dhiraj Hans</dc:creator>
			<dc:creator>Marc Pellegrini</dc:creator>
			<dc:creator>Jason M. Mackenzie</dc:creator>
			<dc:creator>Elizabeth Vincan</dc:creator>
			<dc:creator>William R. Heath</dc:creator>
			<dc:creator>Joseph Torresi</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3010002</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-02-01</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-02-01</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:doi>10.3390/organoids3010002</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/3/1/1">

	<title>Organoids, Vol. 3, Pages 1-17: Visualization of Vascular Perfusion of Human Pancreatic Cancer Tissue in the CAM Model and Its Impact on Future Personalized Drug Testing</title>
	<link>https://www.mdpi.com/2674-1172/3/1/1</link>
	<description>Although significant improvements have been made in the treatment of pancreatic cancer, its prognosis remains poor with an overall 5-year survival rate of less than 10%. New experimental approaches are necessary to develop novel therapeutics. In this study, the investigation of pancreatic cancer tissue growth in the chorioallantoic membrane (CAM) model and the subsequent use of indocyanine green (ICG) injections for the verification of intratumoral perfusion was conducted. ICG was injected into the CAM vasculature to visualize the perfusion of the tumor tissue. The presence of metastasis was investigated through PCR for the human-specific ALU element in the liver of the chicken embryo. Additionally, the usage of cryopreserved pancreatic tumors was established. Intratumoral perfusion of tumor tissue on the CAM was observed in recently obtained and cryopreserved tumors. ALU-PCR detected metastasis in the chick embryos&amp;amp;rsquo; livers. After cryopreservation, the tissue was still vital, and the xenografts generated from these tumors resembled the histological features of the primary tumor. This methodology represents the proof of principle for intravenous drug testing of pancreatic cancer in the CAM model. The cryopreserved tumors can be used for testing novel therapeutics and can be integrated into the molecular tumor board, facilitating personalized tumor treatment.</description>
	<pubDate>2024-01-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 3, Pages 1-17: Visualization of Vascular Perfusion of Human Pancreatic Cancer Tissue in the CAM Model and Its Impact on Future Personalized Drug Testing</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/3/1/1">doi: 10.3390/organoids3010001</a></p>
	<p>Authors:
		Andreas Ettner-Sitter
		Agata Montagner
		Jonas Kuenzel
		Kathrin Brackmann
		Maximilian Schäfer
		Robert Schober
		Florian Weber
		Thiha Aung
		Christina Hackl
		Silke Haerteis
		</p>
	<p>Although significant improvements have been made in the treatment of pancreatic cancer, its prognosis remains poor with an overall 5-year survival rate of less than 10%. New experimental approaches are necessary to develop novel therapeutics. In this study, the investigation of pancreatic cancer tissue growth in the chorioallantoic membrane (CAM) model and the subsequent use of indocyanine green (ICG) injections for the verification of intratumoral perfusion was conducted. ICG was injected into the CAM vasculature to visualize the perfusion of the tumor tissue. The presence of metastasis was investigated through PCR for the human-specific ALU element in the liver of the chicken embryo. Additionally, the usage of cryopreserved pancreatic tumors was established. Intratumoral perfusion of tumor tissue on the CAM was observed in recently obtained and cryopreserved tumors. ALU-PCR detected metastasis in the chick embryos&amp;amp;rsquo; livers. After cryopreservation, the tissue was still vital, and the xenografts generated from these tumors resembled the histological features of the primary tumor. This methodology represents the proof of principle for intravenous drug testing of pancreatic cancer in the CAM model. The cryopreserved tumors can be used for testing novel therapeutics and can be integrated into the molecular tumor board, facilitating personalized tumor treatment.</p>
	]]></content:encoded>

	<dc:title>Visualization of Vascular Perfusion of Human Pancreatic Cancer Tissue in the CAM Model and Its Impact on Future Personalized Drug Testing</dc:title>
			<dc:creator>Andreas Ettner-Sitter</dc:creator>
			<dc:creator>Agata Montagner</dc:creator>
			<dc:creator>Jonas Kuenzel</dc:creator>
			<dc:creator>Kathrin Brackmann</dc:creator>
			<dc:creator>Maximilian Schäfer</dc:creator>
			<dc:creator>Robert Schober</dc:creator>
			<dc:creator>Florian Weber</dc:creator>
			<dc:creator>Thiha Aung</dc:creator>
			<dc:creator>Christina Hackl</dc:creator>
			<dc:creator>Silke Haerteis</dc:creator>
		<dc:identifier>doi: 10.3390/organoids3010001</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2024-01-08</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2024-01-08</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/organoids3010001</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/3/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/19">

	<title>Organoids, Vol. 2, Pages 239-255: Vascularizing Organoids to Promote Long-Term Organogenesis on a Chip</title>
	<link>https://www.mdpi.com/2674-1172/2/4/19</link>
	<description>Organoids have emerged as a powerful tool for studying organ development, disease modeling, and drug discovery due to their ability to mimic the in vivo structure and function of organs in a three-dimensional in vitro model. During in vivo organ maturation, the process of vascularization is crucial for the provision of nutrients and oxygen to cells and the removal of waste products as the organ increases in size. Similarly, organoids can grow to sizes greater than the millimeter scale, yet transport of oxygen and nutrients to the center becomes increasingly difficult, often resulting in the formation of a necrotic core. Herein, we provide a concise summary of the recent development of methods to initiate and maintain vascularization of organoids. Broadly, vascularization of organoids has been achieved primarily by two means: generating organoids that contain endothelial cells or employing the secretion of vascular growth factors to promote vascularization. Growth factors play a fundamental role in regulating blood vessel formation through chemical signals that cause changes in the cell–cell adhesions and ultimately the migration of endothelial cells. Furthermore, models with perfusable systems demonstrate that through the application of growth factors and cells, the vascular network in vascularization-based organoids can administer biological substances to the interior of the organoid, opening up new possibilities for long-term organoid culture in vitro. This goal is being realized through the development of bioengineering tools, such as vascularized organoids on a chip, which are currently tested for various organ systems, including the lung, brain, kidney, and tumors, with applications in cancer angiogenesis and metastasis research. Taken together, our review underlines the vast potential of vascularized organoids to improve the understanding of organ development, while also proposing exciting avenues of organoid-on-a-chip and disease modeling.</description>
	<pubDate>2023-12-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 239-255: Vascularizing Organoids to Promote Long-Term Organogenesis on a Chip</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/19">doi: 10.3390/organoids2040019</a></p>
	<p>Authors:
		Xinhui Wang
		Brent Bijonowski
		Nicholas Kurniawan
		</p>
	<p>Organoids have emerged as a powerful tool for studying organ development, disease modeling, and drug discovery due to their ability to mimic the in vivo structure and function of organs in a three-dimensional in vitro model. During in vivo organ maturation, the process of vascularization is crucial for the provision of nutrients and oxygen to cells and the removal of waste products as the organ increases in size. Similarly, organoids can grow to sizes greater than the millimeter scale, yet transport of oxygen and nutrients to the center becomes increasingly difficult, often resulting in the formation of a necrotic core. Herein, we provide a concise summary of the recent development of methods to initiate and maintain vascularization of organoids. Broadly, vascularization of organoids has been achieved primarily by two means: generating organoids that contain endothelial cells or employing the secretion of vascular growth factors to promote vascularization. Growth factors play a fundamental role in regulating blood vessel formation through chemical signals that cause changes in the cell–cell adhesions and ultimately the migration of endothelial cells. Furthermore, models with perfusable systems demonstrate that through the application of growth factors and cells, the vascular network in vascularization-based organoids can administer biological substances to the interior of the organoid, opening up new possibilities for long-term organoid culture in vitro. This goal is being realized through the development of bioengineering tools, such as vascularized organoids on a chip, which are currently tested for various organ systems, including the lung, brain, kidney, and tumors, with applications in cancer angiogenesis and metastasis research. Taken together, our review underlines the vast potential of vascularized organoids to improve the understanding of organ development, while also proposing exciting avenues of organoid-on-a-chip and disease modeling.</p>
	]]></content:encoded>

	<dc:title>Vascularizing Organoids to Promote Long-Term Organogenesis on a Chip</dc:title>
			<dc:creator>Xinhui Wang</dc:creator>
			<dc:creator>Brent Bijonowski</dc:creator>
			<dc:creator>Nicholas Kurniawan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040019</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-12-07</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-12-07</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>239</prism:startingPage>
		<prism:doi>10.3390/organoids2040019</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/18">

	<title>Organoids, Vol. 2, Pages 231-238: Stem Cell-Derived Organoids, Embryoids, and Embryos: Advances in Organismic Development In Vitro Force Us to Re-Focus on Ethical and Legal Aspects of Model Choice</title>
	<link>https://www.mdpi.com/2674-1172/2/4/18</link>
	<description>While research on stem cell-derived tissues and organoids is rapidly expanding, the technically related creation of complex embryoids has recently excited a vivid discussion since it raises ethical questions about individuation and the possible gain of viability. The present study focuses on the onset of organismic development and the proposed biological and legal definitions for the terms embryo, embryoid, and organoid. It is concluded that such considerations have become important for investigators&amp;amp;rsquo; choices of the appropriate in vitro model systems, allowing the formation of organoids vs. complex embryoids.</description>
	<pubDate>2023-12-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 231-238: Stem Cell-Derived Organoids, Embryoids, and Embryos: Advances in Organismic Development In Vitro Force Us to Re-Focus on Ethical and Legal Aspects of Model Choice</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/18">doi: 10.3390/organoids2040018</a></p>
	<p>Authors:
		Hans-Werner Denker
		</p>
	<p>While research on stem cell-derived tissues and organoids is rapidly expanding, the technically related creation of complex embryoids has recently excited a vivid discussion since it raises ethical questions about individuation and the possible gain of viability. The present study focuses on the onset of organismic development and the proposed biological and legal definitions for the terms embryo, embryoid, and organoid. It is concluded that such considerations have become important for investigators&amp;amp;rsquo; choices of the appropriate in vitro model systems, allowing the formation of organoids vs. complex embryoids.</p>
	]]></content:encoded>

	<dc:title>Stem Cell-Derived Organoids, Embryoids, and Embryos: Advances in Organismic Development In Vitro Force Us to Re-Focus on Ethical and Legal Aspects of Model Choice</dc:title>
			<dc:creator>Hans-Werner Denker</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040018</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-12-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-12-05</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Commentary</prism:section>
	<prism:startingPage>231</prism:startingPage>
		<prism:doi>10.3390/organoids2040018</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/17">

	<title>Organoids, Vol. 2, Pages 218-230: Modelling Meningioma Using Organoids: A Review of Methodologies and Applications</title>
	<link>https://www.mdpi.com/2674-1172/2/4/17</link>
	<description>Meningiomas are the most common tumours of the central nervous system. According to the World Health Organization (WHO), this disease is classified into three different grades: 80% of meningioma patients present with benign grade I tumours, while less than 2% present with malignant grade III meningiomas. Despite affecting thousands of people worldwide, much remains unknown about this disease, and the development of systemic treatments is still far behind in comparison to other types of tumours. Therefore, forming 3D structures (spheroids and organoids) could facilitate research on the mechanisms of formation, proliferation, migration, and invasion of these, for the most part, benign tumours, while also helping in the process of drug development. To date, there are three published methods for the formation of meningioma organoids primarily derived from patient tissue samples. Organoids offer many advantages in the development of treatments because they recapitulate the cellular complexity within tumours. These new methodological advances could open a substantial number of possibilities for the further characterisation and treatment of meningiomas. This review includes an overview of the disease and a description and comparison of established protocols for meningioma organoid formation.</description>
	<pubDate>2023-12-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 218-230: Modelling Meningioma Using Organoids: A Review of Methodologies and Applications</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/17">doi: 10.3390/organoids2040017</a></p>
	<p>Authors:
		Clara Elena López Vásquez
		Clint Gray
		Claire Henry
		Matthew J. Munro
		</p>
	<p>Meningiomas are the most common tumours of the central nervous system. According to the World Health Organization (WHO), this disease is classified into three different grades: 80% of meningioma patients present with benign grade I tumours, while less than 2% present with malignant grade III meningiomas. Despite affecting thousands of people worldwide, much remains unknown about this disease, and the development of systemic treatments is still far behind in comparison to other types of tumours. Therefore, forming 3D structures (spheroids and organoids) could facilitate research on the mechanisms of formation, proliferation, migration, and invasion of these, for the most part, benign tumours, while also helping in the process of drug development. To date, there are three published methods for the formation of meningioma organoids primarily derived from patient tissue samples. Organoids offer many advantages in the development of treatments because they recapitulate the cellular complexity within tumours. These new methodological advances could open a substantial number of possibilities for the further characterisation and treatment of meningiomas. This review includes an overview of the disease and a description and comparison of established protocols for meningioma organoid formation.</p>
	]]></content:encoded>

	<dc:title>Modelling Meningioma Using Organoids: A Review of Methodologies and Applications</dc:title>
			<dc:creator>Clara Elena López Vásquez</dc:creator>
			<dc:creator>Clint Gray</dc:creator>
			<dc:creator>Claire Henry</dc:creator>
			<dc:creator>Matthew J. Munro</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040017</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-12-04</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-12-04</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>218</prism:startingPage>
		<prism:doi>10.3390/organoids2040017</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/16">

	<title>Organoids, Vol. 2, Pages 204-217: The Rapid Generation of Cell-Laden, FACS-Compatible Collagen Gels</title>
	<link>https://www.mdpi.com/2674-1172/2/4/16</link>
	<description>A three-dimensional cell culture in hydrogel beads can support cell growth and differentiation into multi-cellular structures, and these gel beads could be used as building blocks for more complex three-dimensional assemblies. This requires hydrogel beads that are robust enough to sort via FACS yet can be degraded by cell-secreted enzymes. Collagen polymers form hydrogels that are excellent cell growth substrates; however, collagen-containing hydrogel beads typically include additional polymers that limit their degradation. Here, we introduce a simple microfluidic method to generate robust, sortable, cell-laden collagen hydrogel beads. We use on-device pH control to trigger collagen gelation without exposing cells to low pH, ensuring high cell viability. We fabricate microfluidic devices to generate droplets with a wide size range, as demonstrated by production of both small (~55 &amp;amp;micro;m diameter) and large (~300 &amp;amp;micro;m diameter) collagen gels. All hydrogels are sufficiently robust to allow for sorting using FACS. Moreover, high cell viability is maintained throughout the process.</description>
	<pubDate>2023-11-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 204-217: The Rapid Generation of Cell-Laden, FACS-Compatible Collagen Gels</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/16">doi: 10.3390/organoids2040016</a></p>
	<p>Authors:
		Yi Xiao
		Qiaoling Huang
		Jesse W. Collins
		Julie Brouchon
		Jeffery A. Nelson
		Zachary Niziolek
		Alison O’Neil
		Fangfu Ye
		David A. Weitz
		John A. Heyman
		</p>
	<p>A three-dimensional cell culture in hydrogel beads can support cell growth and differentiation into multi-cellular structures, and these gel beads could be used as building blocks for more complex three-dimensional assemblies. This requires hydrogel beads that are robust enough to sort via FACS yet can be degraded by cell-secreted enzymes. Collagen polymers form hydrogels that are excellent cell growth substrates; however, collagen-containing hydrogel beads typically include additional polymers that limit their degradation. Here, we introduce a simple microfluidic method to generate robust, sortable, cell-laden collagen hydrogel beads. We use on-device pH control to trigger collagen gelation without exposing cells to low pH, ensuring high cell viability. We fabricate microfluidic devices to generate droplets with a wide size range, as demonstrated by production of both small (~55 &amp;amp;micro;m diameter) and large (~300 &amp;amp;micro;m diameter) collagen gels. All hydrogels are sufficiently robust to allow for sorting using FACS. Moreover, high cell viability is maintained throughout the process.</p>
	]]></content:encoded>

	<dc:title>The Rapid Generation of Cell-Laden, FACS-Compatible Collagen Gels</dc:title>
			<dc:creator>Yi Xiao</dc:creator>
			<dc:creator>Qiaoling Huang</dc:creator>
			<dc:creator>Jesse W. Collins</dc:creator>
			<dc:creator>Julie Brouchon</dc:creator>
			<dc:creator>Jeffery A. Nelson</dc:creator>
			<dc:creator>Zachary Niziolek</dc:creator>
			<dc:creator>Alison O’Neil</dc:creator>
			<dc:creator>Fangfu Ye</dc:creator>
			<dc:creator>David A. Weitz</dc:creator>
			<dc:creator>John A. Heyman</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040016</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-11-17</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-11-17</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>204</prism:startingPage>
		<prism:doi>10.3390/organoids2040016</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/15">

	<title>Organoids, Vol. 2, Pages 192-203: SMAD1 Is Dispensable for CDX2 Induction but Required for the Repression of Ectopic Small-Intestinal Gene Expression in Human-Pluripotent-Stem-Cell-Derived Colonic Organoids</title>
	<link>https://www.mdpi.com/2674-1172/2/4/15</link>
	<description>The generation of gastrointestinal tissues from human pluripotent stem cells has provided unprecedented insight into the molecular mechanisms that drive the patterning of the primitive gut tube. Previous work has identified bone-morphogenetic-protein (BMP) signaling as an important mediator of mid/hindgut versus foregut and hindgut versus midgut cell fate choice. Inhibition of BMP signaling during gut tube morphogenesis inhibits the expression of the pan-intestinal transcription factor CDX2. Treatment of CDX2+ mid/hindgut cultures with BMP patterns them into hindgut, which gives rise to colonic organoids (HCOs). While the role for BMP signaling is clear, the molecular mechanisms through which BMP signaling patterns the mid/hindgut and colon remain unclear. BMPs bind to BMP receptors, activating a signaling cascade that results in the activation of SMADs, which function as transcription factors. We hypothesized that one of these factors, SMAD1, would be necessary for establishing the CDX2 domain and the colon domain. Unexpectedly, endoderm derived from SMAD1-deficient induced pluripotent stem cells was capable of inducing CDX2 in response to WNT and FGF signaling. In addition, CDX2+ gut tube cultures could activate posterior HOX genes in response to BMP. However, examination of HCOs following cytodifferentiation revealed that SMAD1-deficient HCOs ectopically expressed small-intestinal markers despite expressing posterior HOX genes. These results indicate that there is redundancy of SMADs during early hindgut patterning but that SMAD1 is required for the inhibition of small-intestinal gene expression in HCOs.</description>
	<pubDate>2023-11-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 192-203: SMAD1 Is Dispensable for CDX2 Induction but Required for the Repression of Ectopic Small-Intestinal Gene Expression in Human-Pluripotent-Stem-Cell-Derived Colonic Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/15">doi: 10.3390/organoids2040015</a></p>
	<p>Authors:
		Na Qu
		Abdelkader Daoud
		Braxton Jeffcoat
		Jorge O. Múnera
		</p>
	<p>The generation of gastrointestinal tissues from human pluripotent stem cells has provided unprecedented insight into the molecular mechanisms that drive the patterning of the primitive gut tube. Previous work has identified bone-morphogenetic-protein (BMP) signaling as an important mediator of mid/hindgut versus foregut and hindgut versus midgut cell fate choice. Inhibition of BMP signaling during gut tube morphogenesis inhibits the expression of the pan-intestinal transcription factor CDX2. Treatment of CDX2+ mid/hindgut cultures with BMP patterns them into hindgut, which gives rise to colonic organoids (HCOs). While the role for BMP signaling is clear, the molecular mechanisms through which BMP signaling patterns the mid/hindgut and colon remain unclear. BMPs bind to BMP receptors, activating a signaling cascade that results in the activation of SMADs, which function as transcription factors. We hypothesized that one of these factors, SMAD1, would be necessary for establishing the CDX2 domain and the colon domain. Unexpectedly, endoderm derived from SMAD1-deficient induced pluripotent stem cells was capable of inducing CDX2 in response to WNT and FGF signaling. In addition, CDX2+ gut tube cultures could activate posterior HOX genes in response to BMP. However, examination of HCOs following cytodifferentiation revealed that SMAD1-deficient HCOs ectopically expressed small-intestinal markers despite expressing posterior HOX genes. These results indicate that there is redundancy of SMADs during early hindgut patterning but that SMAD1 is required for the inhibition of small-intestinal gene expression in HCOs.</p>
	]]></content:encoded>

	<dc:title>SMAD1 Is Dispensable for CDX2 Induction but Required for the Repression of Ectopic Small-Intestinal Gene Expression in Human-Pluripotent-Stem-Cell-Derived Colonic Organoids</dc:title>
			<dc:creator>Na Qu</dc:creator>
			<dc:creator>Abdelkader Daoud</dc:creator>
			<dc:creator>Braxton Jeffcoat</dc:creator>
			<dc:creator>Jorge O. Múnera</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040015</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-11-14</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-11-14</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>192</prism:startingPage>
		<prism:doi>10.3390/organoids2040015</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/14">

	<title>Organoids, Vol. 2, Pages 177-191: Contraindicated Drug Responses in Dravet Syndrome Brain Organoids Utilizing Micro Electrode Array Assessment Methods</title>
	<link>https://www.mdpi.com/2674-1172/2/4/14</link>
	<description>Ensuring drug safety for patients with specific neurological disorders is of paramount importance. For instance, certain antiepileptic drugs (AEDs) are contraindicated in Dravet Syndrome (DS), which is characterized by a deficiency in Na+ channel function. Constructing in vitro assessment methods capable of detecting contraindicated drug responses and medication effects on neurons derived from DS patients is highly anticipated for drug safety assessment and therapeutic innovation. This study used micro electrode array (MEA) measurements with low-frequency analysis on human iPSC-derived DS organoids to investigate AED responses. When exposed to the contraindicated drugs carbamazepine and phenytoin, the number of network oscillations increased in DS organoids while maintaining oscillation intensity. Furthermore, carbamazepine administration appeared to enhance activities beyond oscillations which is partially consistent with findings in the DS mouse model. Conversely, treatment with the therapeutic drug sodium valproate resulted in a similar decrease in activity both in healthy and DS organoids. The frequency characteristics of spontaneous firings and AEDs responsiveness in DS organoids demonstrated partial correlation with typical electroencephalography patterns observed in vivo. In conclusion, this study, employing MEA measurements with low-frequency analysis, revealed contraindicated drug responses and disease-specific functional characteristics in DS organoids, effective for DS patient safety assessment, precision medicine, and antiepileptic drug screening.</description>
	<pubDate>2023-10-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 177-191: Contraindicated Drug Responses in Dravet Syndrome Brain Organoids Utilizing Micro Electrode Array Assessment Methods</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/14">doi: 10.3390/organoids2040014</a></p>
	<p>Authors:
		Remi Yokoi
		Nami Nagafuku
		Yuto Ishibashi
		Naoki Matsuda
		Ikuro Suzuki
		</p>
	<p>Ensuring drug safety for patients with specific neurological disorders is of paramount importance. For instance, certain antiepileptic drugs (AEDs) are contraindicated in Dravet Syndrome (DS), which is characterized by a deficiency in Na+ channel function. Constructing in vitro assessment methods capable of detecting contraindicated drug responses and medication effects on neurons derived from DS patients is highly anticipated for drug safety assessment and therapeutic innovation. This study used micro electrode array (MEA) measurements with low-frequency analysis on human iPSC-derived DS organoids to investigate AED responses. When exposed to the contraindicated drugs carbamazepine and phenytoin, the number of network oscillations increased in DS organoids while maintaining oscillation intensity. Furthermore, carbamazepine administration appeared to enhance activities beyond oscillations which is partially consistent with findings in the DS mouse model. Conversely, treatment with the therapeutic drug sodium valproate resulted in a similar decrease in activity both in healthy and DS organoids. The frequency characteristics of spontaneous firings and AEDs responsiveness in DS organoids demonstrated partial correlation with typical electroencephalography patterns observed in vivo. In conclusion, this study, employing MEA measurements with low-frequency analysis, revealed contraindicated drug responses and disease-specific functional characteristics in DS organoids, effective for DS patient safety assessment, precision medicine, and antiepileptic drug screening.</p>
	]]></content:encoded>

	<dc:title>Contraindicated Drug Responses in Dravet Syndrome Brain Organoids Utilizing Micro Electrode Array Assessment Methods</dc:title>
			<dc:creator>Remi Yokoi</dc:creator>
			<dc:creator>Nami Nagafuku</dc:creator>
			<dc:creator>Yuto Ishibashi</dc:creator>
			<dc:creator>Naoki Matsuda</dc:creator>
			<dc:creator>Ikuro Suzuki</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040014</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-10-26</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-10-26</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>177</prism:startingPage>
		<prism:doi>10.3390/organoids2040014</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/4/13">

	<title>Organoids, Vol. 2, Pages 165-176: Matrigel Tunes H9 Stem Cell-Derived Human Cerebral Organoid Development</title>
	<link>https://www.mdpi.com/2674-1172/2/4/13</link>
	<description>Human cerebral organoids are readily generated from human embryonic stem cells and human induced pluripotent stem cells and are useful in studying human neurodevelopment. Recent work with human cerebral organoids have explored the creation of different brain regions and the impacts of soluble and mechanical cues. Matrigel is a gelatinous, heterogenous mixture of extracellular matrix proteins, morphogens, and growth factors secreted by Engelbreth-Holm-Swarm mouse sarcoma cells. It is a core component of almost all cerebral organoid protocols, generally supporting neuroepithelial budding and tissue polarization; yet, its roles and effects beyond its general requirement in organoid protocols are not well understood, and its mode of delivery is variable, including the embedding of organoids within it or its delivery in soluble form. Given its widespread usage, we asked how H9 stem cell-derived hCO development and composition are affected by Matrigel dosage and delivery method. We found Matrigel exposure influences organoid size, morphology, and cell type composition. We also showed that greater amounts of Matrigel promote an increase in the number of choroid plexus (ChP) cells, and this increase is regulated by the BMP4 pathway. These results illuminate the effects of Matrigel on human cerebral organoid development and the importance of delivery mode and amount on organoid phenotype and composition.</description>
	<pubDate>2023-10-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 165-176: Matrigel Tunes H9 Stem Cell-Derived Human Cerebral Organoid Development</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/4/13">doi: 10.3390/organoids2040013</a></p>
	<p>Authors:
		R. Chris Estridge
		Jennifer E. O’Neill
		Albert J. Keung
		</p>
	<p>Human cerebral organoids are readily generated from human embryonic stem cells and human induced pluripotent stem cells and are useful in studying human neurodevelopment. Recent work with human cerebral organoids have explored the creation of different brain regions and the impacts of soluble and mechanical cues. Matrigel is a gelatinous, heterogenous mixture of extracellular matrix proteins, morphogens, and growth factors secreted by Engelbreth-Holm-Swarm mouse sarcoma cells. It is a core component of almost all cerebral organoid protocols, generally supporting neuroepithelial budding and tissue polarization; yet, its roles and effects beyond its general requirement in organoid protocols are not well understood, and its mode of delivery is variable, including the embedding of organoids within it or its delivery in soluble form. Given its widespread usage, we asked how H9 stem cell-derived hCO development and composition are affected by Matrigel dosage and delivery method. We found Matrigel exposure influences organoid size, morphology, and cell type composition. We also showed that greater amounts of Matrigel promote an increase in the number of choroid plexus (ChP) cells, and this increase is regulated by the BMP4 pathway. These results illuminate the effects of Matrigel on human cerebral organoid development and the importance of delivery mode and amount on organoid phenotype and composition.</p>
	]]></content:encoded>

	<dc:title>Matrigel Tunes H9 Stem Cell-Derived Human Cerebral Organoid Development</dc:title>
			<dc:creator>R. Chris Estridge</dc:creator>
			<dc:creator>Jennifer E. O’Neill</dc:creator>
			<dc:creator>Albert J. Keung</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2040013</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-10-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-10-05</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>165</prism:startingPage>
		<prism:doi>10.3390/organoids2040013</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/4/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/3/12">

	<title>Organoids, Vol. 2, Pages 156-164: The Intricacies of Inflammatory Bowel Disease: A Preliminary Study of Redox Biology in Intestinal Organoids</title>
	<link>https://www.mdpi.com/2674-1172/2/3/12</link>
	<description>We evaluated the redox status, precisely glutathione levels, which have a major impact in cellular detoxification and antioxidant defence in IBD-derived and healthy intestinal organoids. Therefore, we wanted to explore the differences in terms of their redox balance and mitochondrial fitness. To this end, we introduced a Grx1-roGFP2 construct into the organoids by lentiviral transduction before performing a stress assay by treating the organoids with hydrogen peroxide and examined the GSH/GSSG ratio using confocal imaging. Using ratio imaging, we could detect statistically significant differences between healthy and IBD-derived samples. To gain more insight, we also performed a GSH/GSSG assay, which directly measured glutathione levels. This analysis revealed that both organoid lines had higher levels of oxidized glutathione due to the stress treatment demonstrated by a lower GSH/GSSG ratio compared to the untreated control. Nevertheless, the results showed no significant difference between healthy and IBD-derived organoids. We further challenged organoids with hydrogen peroxide after incubation with MitoTracker&amp;amp;reg; to see if mitochondrial fitness might be different in IBD-derived organoids. However, these results were also very comparable. In summary, our preliminary findings indicate that both organoid lines demonstrate a well-functioning system in terms of analysis but show no clear difference between healthy and IBD-derived samples.</description>
	<pubDate>2023-09-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 156-164: The Intricacies of Inflammatory Bowel Disease: A Preliminary Study of Redox Biology in Intestinal Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/3/12">doi: 10.3390/organoids2030012</a></p>
	<p>Authors:
		Georg Csukovich
		Janina Huainig
		Selina Troester
		Barbara Pratscher
		Iwan Anton Burgener
		</p>
	<p>We evaluated the redox status, precisely glutathione levels, which have a major impact in cellular detoxification and antioxidant defence in IBD-derived and healthy intestinal organoids. Therefore, we wanted to explore the differences in terms of their redox balance and mitochondrial fitness. To this end, we introduced a Grx1-roGFP2 construct into the organoids by lentiviral transduction before performing a stress assay by treating the organoids with hydrogen peroxide and examined the GSH/GSSG ratio using confocal imaging. Using ratio imaging, we could detect statistically significant differences between healthy and IBD-derived samples. To gain more insight, we also performed a GSH/GSSG assay, which directly measured glutathione levels. This analysis revealed that both organoid lines had higher levels of oxidized glutathione due to the stress treatment demonstrated by a lower GSH/GSSG ratio compared to the untreated control. Nevertheless, the results showed no significant difference between healthy and IBD-derived organoids. We further challenged organoids with hydrogen peroxide after incubation with MitoTracker&amp;amp;reg; to see if mitochondrial fitness might be different in IBD-derived organoids. However, these results were also very comparable. In summary, our preliminary findings indicate that both organoid lines demonstrate a well-functioning system in terms of analysis but show no clear difference between healthy and IBD-derived samples.</p>
	]]></content:encoded>

	<dc:title>The Intricacies of Inflammatory Bowel Disease: A Preliminary Study of Redox Biology in Intestinal Organoids</dc:title>
			<dc:creator>Georg Csukovich</dc:creator>
			<dc:creator>Janina Huainig</dc:creator>
			<dc:creator>Selina Troester</dc:creator>
			<dc:creator>Barbara Pratscher</dc:creator>
			<dc:creator>Iwan Anton Burgener</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2030012</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-09-03</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-09-03</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>156</prism:startingPage>
		<prism:doi>10.3390/organoids2030012</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/3/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/3/11">

	<title>Organoids, Vol. 2, Pages 140-155: Incorporating Immune Cells into Organoid Models: Essential for Studying Human Disease</title>
	<link>https://www.mdpi.com/2674-1172/2/3/11</link>
	<description>Organoid-based research has made significant discoveries and contributions to our understanding of human organ function in both health and disease. To continue making progress, it is crucial to acknowledge the crucial role of the immune system in all organs. Various immune cells, such as macrophages, T cells, and neutrophils, are resident in almost all human tissues and play essential roles in organ homeostasis, function, and disease. Using diverse methods, researchers have begun integrating immune cells into organoid models, leading to more physiologically relevant models that better represent various aspects of human disease. These methods range from immune cell injection to co-culture and tissue expansion with existing immune cells. Immune cells can be sourced from mature patients or generated from stem cells as immature immune cells. The successful incorporation of immune cells into organoids will enhance our understanding of organ function and provide a more accurate approximation of human disease.</description>
	<pubDate>2023-08-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 140-155: Incorporating Immune Cells into Organoid Models: Essential for Studying Human Disease</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/3/11">doi: 10.3390/organoids2030011</a></p>
	<p>Authors:
		Ania Bogoslowski
		Meilin An
		Josef M. Penninger
		</p>
	<p>Organoid-based research has made significant discoveries and contributions to our understanding of human organ function in both health and disease. To continue making progress, it is crucial to acknowledge the crucial role of the immune system in all organs. Various immune cells, such as macrophages, T cells, and neutrophils, are resident in almost all human tissues and play essential roles in organ homeostasis, function, and disease. Using diverse methods, researchers have begun integrating immune cells into organoid models, leading to more physiologically relevant models that better represent various aspects of human disease. These methods range from immune cell injection to co-culture and tissue expansion with existing immune cells. Immune cells can be sourced from mature patients or generated from stem cells as immature immune cells. The successful incorporation of immune cells into organoids will enhance our understanding of organ function and provide a more accurate approximation of human disease.</p>
	]]></content:encoded>

	<dc:title>Incorporating Immune Cells into Organoid Models: Essential for Studying Human Disease</dc:title>
			<dc:creator>Ania Bogoslowski</dc:creator>
			<dc:creator>Meilin An</dc:creator>
			<dc:creator>Josef M. Penninger</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2030011</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-08-12</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-08-12</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>140</prism:startingPage>
		<prism:doi>10.3390/organoids2030011</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/3/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/3/10">

	<title>Organoids, Vol. 2, Pages 123-139: Organoid Models and Next-Generation Sequencing for Bone Marrow and Related Disorders</title>
	<link>https://www.mdpi.com/2674-1172/2/3/10</link>
	<description>Challenges to the musculoskeletal system negatively impact the quality of life of people suffering from them, leading to pain, a decline in mobility, genetic alterations, and potential disorders. The bone marrow (BM) forms an integral part of the musculoskeletal system responsible for erythropoiesis and optimal survival of the various immune and stem cells within the BM. However, due to its dynamic and complex three-dimensional (3D) structure, replicating the BM physiologically in traditional two-dimensional (2D) cell culture settings is often challenging, giving rise to the need for 3D in vitro models to better dissect the BM and its regeneration. Several researchers globally have been investigating various approaches to define an appropriate 3D model for their research. Organoids are novel preclinical models that provide a 3D platform for several tissues and have been analysed using next-generation sequencing (NGS) to identify new molecular pathways at the genetic level. The 3D in vitro models and organoids are increasingly considered important platforms for precision medicine. This review outlines the current knowledge of organoid and 3D in vitro models for the BM. We also discuss different types of 3D models which may be more adaptable for the BM. Finally, we critically review the NGS techniques used for such models and the future combination of these techniques.</description>
	<pubDate>2023-07-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 123-139: Organoid Models and Next-Generation Sequencing for Bone Marrow and Related Disorders</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/3/10">doi: 10.3390/organoids2030010</a></p>
	<p>Authors:
		Magdalena Rausch
		Neelam Iqbal
		Shelly Pathak
		Heather E. Owston
		Payal Ganguly
		</p>
	<p>Challenges to the musculoskeletal system negatively impact the quality of life of people suffering from them, leading to pain, a decline in mobility, genetic alterations, and potential disorders. The bone marrow (BM) forms an integral part of the musculoskeletal system responsible for erythropoiesis and optimal survival of the various immune and stem cells within the BM. However, due to its dynamic and complex three-dimensional (3D) structure, replicating the BM physiologically in traditional two-dimensional (2D) cell culture settings is often challenging, giving rise to the need for 3D in vitro models to better dissect the BM and its regeneration. Several researchers globally have been investigating various approaches to define an appropriate 3D model for their research. Organoids are novel preclinical models that provide a 3D platform for several tissues and have been analysed using next-generation sequencing (NGS) to identify new molecular pathways at the genetic level. The 3D in vitro models and organoids are increasingly considered important platforms for precision medicine. This review outlines the current knowledge of organoid and 3D in vitro models for the BM. We also discuss different types of 3D models which may be more adaptable for the BM. Finally, we critically review the NGS techniques used for such models and the future combination of these techniques.</p>
	]]></content:encoded>

	<dc:title>Organoid Models and Next-Generation Sequencing for Bone Marrow and Related Disorders</dc:title>
			<dc:creator>Magdalena Rausch</dc:creator>
			<dc:creator>Neelam Iqbal</dc:creator>
			<dc:creator>Shelly Pathak</dc:creator>
			<dc:creator>Heather E. Owston</dc:creator>
			<dc:creator>Payal Ganguly</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2030010</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-07-01</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-07-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>123</prism:startingPage>
		<prism:doi>10.3390/organoids2030010</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/3/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/2/9">

	<title>Organoids, Vol. 2, Pages 120-122: Organoids Are Us</title>
	<link>https://www.mdpi.com/2674-1172/2/2/9</link>
	<description>&amp;amp;ldquo;Organoids Are Us&amp;amp;rdquo; is an annual one-day symposium organised to highlight the advances in science and medicine that are the direct result of organoid technology [...]</description>
	<pubDate>2023-06-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 120-122: Organoids Are Us</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/2/9">doi: 10.3390/organoids2020009</a></p>
	<p>Authors:
		Elizabeth Vincan
		</p>
	<p>&amp;amp;ldquo;Organoids Are Us&amp;amp;rdquo; is an annual one-day symposium organised to highlight the advances in science and medicine that are the direct result of organoid technology [...]</p>
	]]></content:encoded>

	<dc:title>Organoids Are Us</dc:title>
			<dc:creator>Elizabeth Vincan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2020009</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-06-16</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-06-16</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>120</prism:startingPage>
		<prism:doi>10.3390/organoids2020009</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/2/8">

	<title>Organoids, Vol. 2, Pages 102-119: A Microwell Device for the Efficient Generation of Arrays of Microtissues and Humanized Bone Marrow Micro-Ossicles</title>
	<link>https://www.mdpi.com/2674-1172/2/2/8</link>
	<description>(1) Background: There are no high-throughput microtissue platforms for generating bone marrow micro-ossicles. Herein, we describe a method for the assembly of arrays of microtissues from bone marrow stromal cells (BMSC) in vitro and their maturation into bone marrow micro-ossicles in vivo. (2) Methods: Discs with arrays of 50 microwells were used to assemble microtissues from 3 &amp;amp;times; 105 BMSCs each on a nylon mesh carrier. Microtissues were cultured in chondrogenic induction medium followed by hypertrophic medium in an attempt to drive endochondral ossification, and then they were implanted in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, where they were remodeled into bone marrow micro-ossicles. Mice were transplanted with 105 human umbilical cord blood CD34+ cells. (3) Results: Micro-ossicles contained more human CD45+ cells, but fewer human CD34+ progenitor cells than mouse marrow. Human hematopoietic progenitor cells cycle rapidly at non-physiological rates in mouse marrow, and reduced CD34+ cell content in micro-ossicles is consistent with the notion that the humanized niche better controls progenitor cell cycling. (4) Conclusions: Assembling microtissues in microwells, linked by a nylon membrane carrier, provides an elegant method to manufacture and handle arrays of microtissues with bone organ-like properties. More generally, this approach and platform could aid bridging the gap between in vitro microtissue manipulation and in vivo microtissue implantation.</description>
	<pubDate>2023-06-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 102-119: A Microwell Device for the Efficient Generation of Arrays of Microtissues and Humanized Bone Marrow Micro-Ossicles</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/2/8">doi: 10.3390/organoids2020008</a></p>
	<p>Authors:
		Kathryn Futrega
		Md. Shafiullah Shajib
		Pamela G. Robey
		Michael R. Doran
		</p>
	<p>(1) Background: There are no high-throughput microtissue platforms for generating bone marrow micro-ossicles. Herein, we describe a method for the assembly of arrays of microtissues from bone marrow stromal cells (BMSC) in vitro and their maturation into bone marrow micro-ossicles in vivo. (2) Methods: Discs with arrays of 50 microwells were used to assemble microtissues from 3 &amp;amp;times; 105 BMSCs each on a nylon mesh carrier. Microtissues were cultured in chondrogenic induction medium followed by hypertrophic medium in an attempt to drive endochondral ossification, and then they were implanted in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, where they were remodeled into bone marrow micro-ossicles. Mice were transplanted with 105 human umbilical cord blood CD34+ cells. (3) Results: Micro-ossicles contained more human CD45+ cells, but fewer human CD34+ progenitor cells than mouse marrow. Human hematopoietic progenitor cells cycle rapidly at non-physiological rates in mouse marrow, and reduced CD34+ cell content in micro-ossicles is consistent with the notion that the humanized niche better controls progenitor cell cycling. (4) Conclusions: Assembling microtissues in microwells, linked by a nylon membrane carrier, provides an elegant method to manufacture and handle arrays of microtissues with bone organ-like properties. More generally, this approach and platform could aid bridging the gap between in vitro microtissue manipulation and in vivo microtissue implantation.</p>
	]]></content:encoded>

	<dc:title>A Microwell Device for the Efficient Generation of Arrays of Microtissues and Humanized Bone Marrow Micro-Ossicles</dc:title>
			<dc:creator>Kathryn Futrega</dc:creator>
			<dc:creator>Md. Shafiullah Shajib</dc:creator>
			<dc:creator>Pamela G. Robey</dc:creator>
			<dc:creator>Michael R. Doran</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2020008</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-06-01</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-06-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>102</prism:startingPage>
		<prism:doi>10.3390/organoids2020008</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/2/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/2/7">

	<title>Organoids, Vol. 2, Pages 82-101: Development of Matrix-Embedded Bovine Tracheal Organoids to Study the Innate Immune Response against Bovine Respiratory Disease</title>
	<link>https://www.mdpi.com/2674-1172/2/2/7</link>
	<description>Bovine respiratory disease (BRD) is the leading cause of morbidity and mortality in feedlot cattle. Bovine herpesvirus-1 (BHV-1) is one of the main culprits of BRD; however, research on BHV-1 is hampered by the lack of suitable models for infection and drug testing. In this study, we established a novel bovine tracheal organoid culture grown in a basement membrane extract type 2 (BME2) matrix and compared it with the air&amp;amp;ndash;liquid interface (ALI) culture system. After differentiation, the matrix-embedded organoids developed beating cilia and demonstrated a transcriptomic profile similar to the ALI culture system. The matrix-embedded organoids were also highly susceptible to BHV-1 infection and immune stimulation by Pam2Cys, an immunomodulator, which resulted in robust cytokine production and tracheal antimicrobial peptide mRNA upregulation. However, treatment of bovine tracheal organoid cultures with Pam2Cys was not sufficient to inhibit viral infection or replication, suggesting a role of the non-epithelial cellular microenvironment in vivo.</description>
	<pubDate>2023-05-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 82-101: Development of Matrix-Embedded Bovine Tracheal Organoids to Study the Innate Immune Response against Bovine Respiratory Disease</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/2/7">doi: 10.3390/organoids2020007</a></p>
	<p>Authors:
		Pin Shie Quah
		Bang M. Tran
		Vincent D.A. Corbin
		Jessie J.-Y. Chang
		Chinn Yi Wong
		Andrés Diaz-Méndez
		Carol A. Hartley
		Weiguang Zeng
		Eric Hanssen
		Zlatan Trifunovic
		Patrick C. Reading
		David C. Jackson
		Elizabeth Vincan
		Lachlan J.M. Coin
		Georgia Deliyannis
		</p>
	<p>Bovine respiratory disease (BRD) is the leading cause of morbidity and mortality in feedlot cattle. Bovine herpesvirus-1 (BHV-1) is one of the main culprits of BRD; however, research on BHV-1 is hampered by the lack of suitable models for infection and drug testing. In this study, we established a novel bovine tracheal organoid culture grown in a basement membrane extract type 2 (BME2) matrix and compared it with the air&amp;amp;ndash;liquid interface (ALI) culture system. After differentiation, the matrix-embedded organoids developed beating cilia and demonstrated a transcriptomic profile similar to the ALI culture system. The matrix-embedded organoids were also highly susceptible to BHV-1 infection and immune stimulation by Pam2Cys, an immunomodulator, which resulted in robust cytokine production and tracheal antimicrobial peptide mRNA upregulation. However, treatment of bovine tracheal organoid cultures with Pam2Cys was not sufficient to inhibit viral infection or replication, suggesting a role of the non-epithelial cellular microenvironment in vivo.</p>
	]]></content:encoded>

	<dc:title>Development of Matrix-Embedded Bovine Tracheal Organoids to Study the Innate Immune Response against Bovine Respiratory Disease</dc:title>
			<dc:creator>Pin Shie Quah</dc:creator>
			<dc:creator>Bang M. Tran</dc:creator>
			<dc:creator>Vincent D.A. Corbin</dc:creator>
			<dc:creator>Jessie J.-Y. Chang</dc:creator>
			<dc:creator>Chinn Yi Wong</dc:creator>
			<dc:creator>Andrés Diaz-Méndez</dc:creator>
			<dc:creator>Carol A. Hartley</dc:creator>
			<dc:creator>Weiguang Zeng</dc:creator>
			<dc:creator>Eric Hanssen</dc:creator>
			<dc:creator>Zlatan Trifunovic</dc:creator>
			<dc:creator>Patrick C. Reading</dc:creator>
			<dc:creator>David C. Jackson</dc:creator>
			<dc:creator>Elizabeth Vincan</dc:creator>
			<dc:creator>Lachlan J.M. Coin</dc:creator>
			<dc:creator>Georgia Deliyannis</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2020007</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-05-11</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-05-11</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>82</prism:startingPage>
		<prism:doi>10.3390/organoids2020007</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/2/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/2/6">

	<title>Organoids, Vol. 2, Pages 79-81: &amp;ldquo;Organoids&amp;rdquo;: Insights from the First Issues</title>
	<link>https://www.mdpi.com/2674-1172/2/2/6</link>
	<description>Organoids are taking the scientific world by storm, revolutionizing the ways in which we study complex biological systems [...]</description>
	<pubDate>2023-04-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 79-81: &amp;ldquo;Organoids&amp;rdquo;: Insights from the First Issues</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/2/6">doi: 10.3390/organoids2020006</a></p>
	<p>Authors:
		Philipp Wörsdörfer
		Süleyman Ergün
		</p>
	<p>Organoids are taking the scientific world by storm, revolutionizing the ways in which we study complex biological systems [...]</p>
	]]></content:encoded>

	<dc:title>&amp;amp;ldquo;Organoids&amp;amp;rdquo;: Insights from the First Issues</dc:title>
			<dc:creator>Philipp Wörsdörfer</dc:creator>
			<dc:creator>Süleyman Ergün</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2020006</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-04-07</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-04-07</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>79</prism:startingPage>
		<prism:doi>10.3390/organoids2020006</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/2/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/1/5">

	<title>Organoids, Vol. 2, Pages 66-78: Decellularization of Mouse Kidneys to Generate an Extracellular Matrix Gel for Human Induced Pluripotent Stem Cell Derived Renal Organoids</title>
	<link>https://www.mdpi.com/2674-1172/2/1/5</link>
	<description>Chronic Kidney Disease (CKD) is a major cause of morbidity and mortality characterized by progressive renal fibrosis, and in extreme cases, renal failure. Human CKD models that replicate the biological complexity of the kidney and CKD are lacking and will be invaluable in identifying drugs to revert and/or prevent fibrosis. To address this unmet need, we developed 3D renal organoids where human induced pluripotent stem cells (hiPSCs) were differentiated to renal progenitors within a renal extracellular matrix (rECM) gel, based on the premise that an rECM could recreate the renal niche to facilitate hiPSC-derived renal progenitor generation. We used mouse kidneys as a source of rECM and identified that superior detergent-mediated decellularization of mouse kidneys was achieved with a combination of 0.5% w/v Sodium Dodecyl Sulphate and 1% v/v Triton-X and mechanical agitation for 60 h. HiPSCs that underwent specification to become metanephric mesenchyme (MM) were subsequently cultured within the rECM gel and, notably, mesenchymal to epithelial transition (MET) was observed, as judged by expression of nephron markers K-cadherin, Nephrin and WT1. These data demonstrate a role for rECM gel in developing human renal organoids from hiPSCs, which will aid the further development of a human disease model for renal fibrosis.</description>
	<pubDate>2023-03-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 66-78: Decellularization of Mouse Kidneys to Generate an Extracellular Matrix Gel for Human Induced Pluripotent Stem Cell Derived Renal Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/1/5">doi: 10.3390/organoids2010005</a></p>
	<p>Authors:
		Sparshita Nag
		Ashleigh S. Boyd
		</p>
	<p>Chronic Kidney Disease (CKD) is a major cause of morbidity and mortality characterized by progressive renal fibrosis, and in extreme cases, renal failure. Human CKD models that replicate the biological complexity of the kidney and CKD are lacking and will be invaluable in identifying drugs to revert and/or prevent fibrosis. To address this unmet need, we developed 3D renal organoids where human induced pluripotent stem cells (hiPSCs) were differentiated to renal progenitors within a renal extracellular matrix (rECM) gel, based on the premise that an rECM could recreate the renal niche to facilitate hiPSC-derived renal progenitor generation. We used mouse kidneys as a source of rECM and identified that superior detergent-mediated decellularization of mouse kidneys was achieved with a combination of 0.5% w/v Sodium Dodecyl Sulphate and 1% v/v Triton-X and mechanical agitation for 60 h. HiPSCs that underwent specification to become metanephric mesenchyme (MM) were subsequently cultured within the rECM gel and, notably, mesenchymal to epithelial transition (MET) was observed, as judged by expression of nephron markers K-cadherin, Nephrin and WT1. These data demonstrate a role for rECM gel in developing human renal organoids from hiPSCs, which will aid the further development of a human disease model for renal fibrosis.</p>
	]]></content:encoded>

	<dc:title>Decellularization of Mouse Kidneys to Generate an Extracellular Matrix Gel for Human Induced Pluripotent Stem Cell Derived Renal Organoids</dc:title>
			<dc:creator>Sparshita Nag</dc:creator>
			<dc:creator>Ashleigh S. Boyd</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2010005</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-03-22</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-03-22</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>66</prism:startingPage>
		<prism:doi>10.3390/organoids2010005</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/1/4">

	<title>Organoids, Vol. 2, Pages 50-65: Human Brain Organoids and Consciousness: Moral Claims and Epistemic Uncertainty</title>
	<link>https://www.mdpi.com/2674-1172/2/1/4</link>
	<description>Human brain organoids provide a remarkable opportunity to model prenatal human brain biology in vitro by recapitulating features of in utero molecular, cellular and systems biology. An ethical concern peculiar to human brain organoids is whether they are or could become capable of supporting sentience through the experience of pain or pleasure and/or consciousness, including higher cognitive abilities such as self-awareness. Identifying the presence of these traits is complicated by several factors, beginning with consciousness&amp;amp;mdash;which is a highly contested concept among neuroscientists, cognitive scientists, and philosophers and so there is no agreed definition. Secondly, given human brain organoids are disembodied, there is no practical way to identify evidence of consciousness as we might in humans or animals. What would count as evidence of organoid consciousness is an emerging area of research. To address concerns about consciousness and human brain organoids, in this paper we clarify the morally relevant aspects of human consciousness, phenomenal experience and embodied development and explore the empirical basis of consciousness to develop a defensible framework for informed decision-making on the moral significance and utility of brain organoids, which can also guide regulation and future research of these novel biological systems.</description>
	<pubDate>2023-02-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 50-65: Human Brain Organoids and Consciousness: Moral Claims and Epistemic Uncertainty</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/1/4">doi: 10.3390/organoids2010004</a></p>
	<p>Authors:
		Eliza Goddard
		Eva Tomaskovic-Crook
		Jeremy Micah Crook
		Susan Dodds
		</p>
	<p>Human brain organoids provide a remarkable opportunity to model prenatal human brain biology in vitro by recapitulating features of in utero molecular, cellular and systems biology. An ethical concern peculiar to human brain organoids is whether they are or could become capable of supporting sentience through the experience of pain or pleasure and/or consciousness, including higher cognitive abilities such as self-awareness. Identifying the presence of these traits is complicated by several factors, beginning with consciousness&amp;amp;mdash;which is a highly contested concept among neuroscientists, cognitive scientists, and philosophers and so there is no agreed definition. Secondly, given human brain organoids are disembodied, there is no practical way to identify evidence of consciousness as we might in humans or animals. What would count as evidence of organoid consciousness is an emerging area of research. To address concerns about consciousness and human brain organoids, in this paper we clarify the morally relevant aspects of human consciousness, phenomenal experience and embodied development and explore the empirical basis of consciousness to develop a defensible framework for informed decision-making on the moral significance and utility of brain organoids, which can also guide regulation and future research of these novel biological systems.</p>
	]]></content:encoded>

	<dc:title>Human Brain Organoids and Consciousness: Moral Claims and Epistemic Uncertainty</dc:title>
			<dc:creator>Eliza Goddard</dc:creator>
			<dc:creator>Eva Tomaskovic-Crook</dc:creator>
			<dc:creator>Jeremy Micah Crook</dc:creator>
			<dc:creator>Susan Dodds</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2010004</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-02-07</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-02-07</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Perspective</prism:section>
	<prism:startingPage>50</prism:startingPage>
		<prism:doi>10.3390/organoids2010004</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/1/3">

	<title>Organoids, Vol. 2, Pages 37-49: Applications for Colon Organoid Models in Cancer Research</title>
	<link>https://www.mdpi.com/2674-1172/2/1/3</link>
	<description>Organoids are 3D organ-like structures grown from stem cells in vitro that mimic the organ or disease from which they are derived. Due to their stem cell origin, organoids contain a heterogeneous population of cells reflecting the diversity of cell types seen in vivo. Similarly, tumour organoids reflect intratumoural heterogeneity in a way that traditional 2D cell culture and cell lines do not, and, therefore, they show greater promise as a more relevant model for effective disease modelling and drug testing. Tumour organoids arise from cancer stem cells, which contribute to many of the greatest challenges to cancer treatment, including therapy resistance, tumour recurrence, and metastasis. In this review, we outline methods for generating colon organoids from patient-derived normal and tumour tissues. Furthermore, we discuss organoid biobanking, applications of organoids in disease modelling, and a range of platforms applicable to high-throughput drug testing, including apical-out/reverse-polarity colon organoids.</description>
	<pubDate>2023-01-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 37-49: Applications for Colon Organoid Models in Cancer Research</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/1/3">doi: 10.3390/organoids2010003</a></p>
	<p>Authors:
		Matthew J. Munro
		Swee T. Tan
		Clint Gray
		</p>
	<p>Organoids are 3D organ-like structures grown from stem cells in vitro that mimic the organ or disease from which they are derived. Due to their stem cell origin, organoids contain a heterogeneous population of cells reflecting the diversity of cell types seen in vivo. Similarly, tumour organoids reflect intratumoural heterogeneity in a way that traditional 2D cell culture and cell lines do not, and, therefore, they show greater promise as a more relevant model for effective disease modelling and drug testing. Tumour organoids arise from cancer stem cells, which contribute to many of the greatest challenges to cancer treatment, including therapy resistance, tumour recurrence, and metastasis. In this review, we outline methods for generating colon organoids from patient-derived normal and tumour tissues. Furthermore, we discuss organoid biobanking, applications of organoids in disease modelling, and a range of platforms applicable to high-throughput drug testing, including apical-out/reverse-polarity colon organoids.</p>
	]]></content:encoded>

	<dc:title>Applications for Colon Organoid Models in Cancer Research</dc:title>
			<dc:creator>Matthew J. Munro</dc:creator>
			<dc:creator>Swee T. Tan</dc:creator>
			<dc:creator>Clint Gray</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2010003</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-01-12</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-01-12</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>37</prism:startingPage>
		<prism:doi>10.3390/organoids2010003</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/1/2">

	<title>Organoids, Vol. 2, Pages 20-36: Defined, Simplified, Scalable, and Clinically Compatible Hydrogel-Based Production of Human Brain Organoids</title>
	<link>https://www.mdpi.com/2674-1172/2/1/2</link>
	<description>Human brain organoids present a new paradigm for modeling human brain organogenesis, providing unprecedented insight to the molecular and cellular processes of brain development and maturation. Other potential applications include in vitro models of disease and tissue trauma, as well as three-dimensional (3D) clinically relevant tissues for pharmaceuticals development and cell or tissue replacement. A key requirement for this emerging technology in both research and medicine is the simple, scalable, and reproducible generation of organoids using reliable, economical, and high-throughput culture platforms. Here we describe such a platform using a defined, clinically compliant, and readily available hydrogel generated from gelatin methacrylate (GelMA). We demonstrate the efficient production of organoids on GelMA from human induced pluripotent stem cells (iPSCs), with scalable production attained using 3D printed GelMA-based multiwell arrays. The differentiation of iPSCs was systematic, rapid, and direct to enable iPSCs to form organoids in their original position following seeding on GelMA, thereby avoiding further cell and organoid disruption. Early neural precursors formed by day 5, neural rosettes and early-stage neurons by day 14, and organoids with cellular and regional heterogeneity, including mature and electrophysiologically active neurons, by day 28. The optimised method provides a simplified and well-defined platform for both research and translation of iPSCs and derivative brain organoids, enabling reliable 3D in vitro modelling and experimentation, as well as the provision of clinically relevant cells and tissues for future therapeutics.</description>
	<pubDate>2023-01-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 20-36: Defined, Simplified, Scalable, and Clinically Compatible Hydrogel-Based Production of Human Brain Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/1/2">doi: 10.3390/organoids2010002</a></p>
	<p>Authors:
		Eva Tomaskovic-Crook
		Sarah Liza Higginbottom
		Binbin Zhang
		Justin Bourke
		Gordon George Wallace
		Jeremy Micah Crook
		</p>
	<p>Human brain organoids present a new paradigm for modeling human brain organogenesis, providing unprecedented insight to the molecular and cellular processes of brain development and maturation. Other potential applications include in vitro models of disease and tissue trauma, as well as three-dimensional (3D) clinically relevant tissues for pharmaceuticals development and cell or tissue replacement. A key requirement for this emerging technology in both research and medicine is the simple, scalable, and reproducible generation of organoids using reliable, economical, and high-throughput culture platforms. Here we describe such a platform using a defined, clinically compliant, and readily available hydrogel generated from gelatin methacrylate (GelMA). We demonstrate the efficient production of organoids on GelMA from human induced pluripotent stem cells (iPSCs), with scalable production attained using 3D printed GelMA-based multiwell arrays. The differentiation of iPSCs was systematic, rapid, and direct to enable iPSCs to form organoids in their original position following seeding on GelMA, thereby avoiding further cell and organoid disruption. Early neural precursors formed by day 5, neural rosettes and early-stage neurons by day 14, and organoids with cellular and regional heterogeneity, including mature and electrophysiologically active neurons, by day 28. The optimised method provides a simplified and well-defined platform for both research and translation of iPSCs and derivative brain organoids, enabling reliable 3D in vitro modelling and experimentation, as well as the provision of clinically relevant cells and tissues for future therapeutics.</p>
	]]></content:encoded>

	<dc:title>Defined, Simplified, Scalable, and Clinically Compatible Hydrogel-Based Production of Human Brain Organoids</dc:title>
			<dc:creator>Eva Tomaskovic-Crook</dc:creator>
			<dc:creator>Sarah Liza Higginbottom</dc:creator>
			<dc:creator>Binbin Zhang</dc:creator>
			<dc:creator>Justin Bourke</dc:creator>
			<dc:creator>Gordon George Wallace</dc:creator>
			<dc:creator>Jeremy Micah Crook</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2010002</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2023-01-11</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2023-01-11</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>20</prism:startingPage>
		<prism:doi>10.3390/organoids2010002</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/2/1/1">

	<title>Organoids, Vol. 2, Pages 1-19: High-Throughput Live and Fixed Cell Imaging Method to Screen Matrigel-Embedded Organoids</title>
	<link>https://www.mdpi.com/2674-1172/2/1/1</link>
	<description>Technical advances in microscopy and automation have enabled image-based phenotypic screening of spheroids and organoids to become increasingly high throughput and high content at the same time. In particular, matrix-embedded 3D structures can recapitulate many aspects of parent (e.g., patient) tissues. Live-cell imaging of growing structures allows tremendous insight into population heterogeneity during drug treatment. However, screening for targeted markers and more detailed morphological analyses typically require fixation of 3D structures, and standard formaldehyde (FA) incubation conditions can dissolve collagen-based extracellular matrices such as Matrigel. The dislocation and clumping of the spheroids make image-based segmentation very difficult and the tracking of structures from the live cell stage to their fixed cell location virtually impossible. In this method, we present a fixation and staining protocol that is gentle enough to maintain 3D structures exactly in their live-cell location and does not alter their morphology. This opens up analytical strategies that connect the spheroid&amp;amp;rsquo;s growth kinetics and heterogeneity of treatment responses with the more targeted fixed cell stains. Furthermore, we optimized the automated seeding and imaging of spheroids so that screening and phenotypic characterization can be performed in high-throughput at either low or high magnification and yield the same result, independent of the microscope used.</description>
	<pubDate>2022-12-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 2, Pages 1-19: High-Throughput Live and Fixed Cell Imaging Method to Screen Matrigel-Embedded Organoids</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/2/1/1">doi: 10.3390/organoids2010001</a></p>
	<p>Authors:
		Susanne Ramm
		Robert Vary
		Twishi Gulati
		Jennii Luu
		Karla J. Cowley
		Michael S. Janes
		Nicholas Radio
		Kaylene J. Simpson
		</p>
	<p>Technical advances in microscopy and automation have enabled image-based phenotypic screening of spheroids and organoids to become increasingly high throughput and high content at the same time. In particular, matrix-embedded 3D structures can recapitulate many aspects of parent (e.g., patient) tissues. Live-cell imaging of growing structures allows tremendous insight into population heterogeneity during drug treatment. However, screening for targeted markers and more detailed morphological analyses typically require fixation of 3D structures, and standard formaldehyde (FA) incubation conditions can dissolve collagen-based extracellular matrices such as Matrigel. The dislocation and clumping of the spheroids make image-based segmentation very difficult and the tracking of structures from the live cell stage to their fixed cell location virtually impossible. In this method, we present a fixation and staining protocol that is gentle enough to maintain 3D structures exactly in their live-cell location and does not alter their morphology. This opens up analytical strategies that connect the spheroid&amp;amp;rsquo;s growth kinetics and heterogeneity of treatment responses with the more targeted fixed cell stains. Furthermore, we optimized the automated seeding and imaging of spheroids so that screening and phenotypic characterization can be performed in high-throughput at either low or high magnification and yield the same result, independent of the microscope used.</p>
	]]></content:encoded>

	<dc:title>High-Throughput Live and Fixed Cell Imaging Method to Screen Matrigel-Embedded Organoids</dc:title>
			<dc:creator>Susanne Ramm</dc:creator>
			<dc:creator>Robert Vary</dc:creator>
			<dc:creator>Twishi Gulati</dc:creator>
			<dc:creator>Jennii Luu</dc:creator>
			<dc:creator>Karla J. Cowley</dc:creator>
			<dc:creator>Michael S. Janes</dc:creator>
			<dc:creator>Nicholas Radio</dc:creator>
			<dc:creator>Kaylene J. Simpson</dc:creator>
		<dc:identifier>doi: 10.3390/organoids2010001</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-12-24</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-12-24</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/organoids2010001</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/2/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/2/13">

	<title>Organoids, Vol. 1, Pages 168-183: Pancreatic Cancer 3D Cell Line Organoids (CLOs) Maintain the Phenotypic Characteristics of Organoids and Accurately Reflect the Cellular Architecture and Heterogeneity In Vivo</title>
	<link>https://www.mdpi.com/2674-1172/1/2/13</link>
	<description>Pancreatic cancer is a highly lethal disease. Therapeutic resistance to chemotherapy is a major cause of treatment failure and recurrence in pancreatic cancer. Organoids derived from cancer stem cells (CSC) are promising models for the advancement of personalised therapeutic responses to inform clinical decisions. However, scaling-up of 3D organoids for high-throughput screening is time-consuming and costly. Here, we successfully developed organoid-derived cell lines (2.5D) from 3D organoids; the cells were then expanded and recapitulated back into organoids known as cell line organoids (CLOs). The 2.5D lines were cultured long term into 2D established cell lines for downstream comparison analysis. Experimental characterisation of the models revealed that the proliferation of CLOs was slightly faster than that of parental organoids. The therapeutic response to chemotherapeutic agents in 3D CLOs and organoids showed a similar responsive profile. Compared to 3D CLOs and organoids, 2D cell lines tended to be less responsive to all the drugs tested. Stem cell marker expression was higher in either 3D CLOs or organoids compared to 2D cell lines. An in vivo tumorigenicity study found CLOs form tumours at a similar rate to organoids and retain enhanced CSC marker expression, indicating the plasticity of CSCs within the in vivo microenvironment.</description>
	<pubDate>2022-12-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 168-183: Pancreatic Cancer 3D Cell Line Organoids (CLOs) Maintain the Phenotypic Characteristics of Organoids and Accurately Reflect the Cellular Architecture and Heterogeneity In Vivo</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/2/13">doi: 10.3390/organoids1020013</a></p>
	<p>Authors:
		Sara Noorani
		Shannon R. Nelson
		Neil T. Conlon
		Justine Meiller
		Ekaterina Shcheglova
		Alice Usai
		Jojanneke Stoof
		Letizia Palanga
		Fiona O’Neill
		Sandra Roche
		Maura B. Cotter
		Niall Swan
		Naomi Walsh
		</p>
	<p>Pancreatic cancer is a highly lethal disease. Therapeutic resistance to chemotherapy is a major cause of treatment failure and recurrence in pancreatic cancer. Organoids derived from cancer stem cells (CSC) are promising models for the advancement of personalised therapeutic responses to inform clinical decisions. However, scaling-up of 3D organoids for high-throughput screening is time-consuming and costly. Here, we successfully developed organoid-derived cell lines (2.5D) from 3D organoids; the cells were then expanded and recapitulated back into organoids known as cell line organoids (CLOs). The 2.5D lines were cultured long term into 2D established cell lines for downstream comparison analysis. Experimental characterisation of the models revealed that the proliferation of CLOs was slightly faster than that of parental organoids. The therapeutic response to chemotherapeutic agents in 3D CLOs and organoids showed a similar responsive profile. Compared to 3D CLOs and organoids, 2D cell lines tended to be less responsive to all the drugs tested. Stem cell marker expression was higher in either 3D CLOs or organoids compared to 2D cell lines. An in vivo tumorigenicity study found CLOs form tumours at a similar rate to organoids and retain enhanced CSC marker expression, indicating the plasticity of CSCs within the in vivo microenvironment.</p>
	]]></content:encoded>

	<dc:title>Pancreatic Cancer 3D Cell Line Organoids (CLOs) Maintain the Phenotypic Characteristics of Organoids and Accurately Reflect the Cellular Architecture and Heterogeneity In Vivo</dc:title>
			<dc:creator>Sara Noorani</dc:creator>
			<dc:creator>Shannon R. Nelson</dc:creator>
			<dc:creator>Neil T. Conlon</dc:creator>
			<dc:creator>Justine Meiller</dc:creator>
			<dc:creator>Ekaterina Shcheglova</dc:creator>
			<dc:creator>Alice Usai</dc:creator>
			<dc:creator>Jojanneke Stoof</dc:creator>
			<dc:creator>Letizia Palanga</dc:creator>
			<dc:creator>Fiona O’Neill</dc:creator>
			<dc:creator>Sandra Roche</dc:creator>
			<dc:creator>Maura B. Cotter</dc:creator>
			<dc:creator>Niall Swan</dc:creator>
			<dc:creator>Naomi Walsh</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1020013</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-12-12</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-12-12</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>168</prism:startingPage>
		<prism:doi>10.3390/organoids1020013</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/2/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/2/12">

	<title>Organoids, Vol. 1, Pages 149-167: 3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy</title>
	<link>https://www.mdpi.com/2674-1172/1/2/12</link>
	<description>The intricate microenvironment in which malignant cells reside is essential for the progression of tumor growth. Both the physical and biochemical features of the tumor microenvironment (TME) play a critical role in promoting the differentiation, proliferation, invasion, and metastasis of cancer cells. It is therefore essential to understand how malignant cells interact and communicate with an assortment of supportive tumor-associated cells including macrophages, fibroblasts, endothelial cells, and other immune cells. To study the complex mechanisms behind cancer progression, 3D spheroid and organoid models are widely in favor because they replicate the stromal environment and multicellular structure present within an in vivo tumor. It provides more precise data about the cell&amp;amp;ndash;cell interactions, tumor characteristics, drug discovery, and metabolic profile of cancer cells compared to oversimplified 2D systems and unrepresentative animal models. This review provides a description of the key elements of the tumor microenvironment as well as early research using cell-line derived, 3D spheroid tumor models that paved the way for the adoption of patient-derived spheroid and organoid models. In particular, 3D spheroid and organoid models provide a method for drug screening with a particular emphasis on influence of the TME in cancer immunotherapy.</description>
	<pubDate>2022-12-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 149-167: 3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/2/12">doi: 10.3390/organoids1020012</a></p>
	<p>Authors:
		Yichen Zhu
		Elliot Kang
		Matthew Wilson
		Taylor Basso
		Evelynn Chen
		Yanqi Yu
		Yan-Ruide Li
		</p>
	<p>The intricate microenvironment in which malignant cells reside is essential for the progression of tumor growth. Both the physical and biochemical features of the tumor microenvironment (TME) play a critical role in promoting the differentiation, proliferation, invasion, and metastasis of cancer cells. It is therefore essential to understand how malignant cells interact and communicate with an assortment of supportive tumor-associated cells including macrophages, fibroblasts, endothelial cells, and other immune cells. To study the complex mechanisms behind cancer progression, 3D spheroid and organoid models are widely in favor because they replicate the stromal environment and multicellular structure present within an in vivo tumor. It provides more precise data about the cell&amp;amp;ndash;cell interactions, tumor characteristics, drug discovery, and metabolic profile of cancer cells compared to oversimplified 2D systems and unrepresentative animal models. This review provides a description of the key elements of the tumor microenvironment as well as early research using cell-line derived, 3D spheroid tumor models that paved the way for the adoption of patient-derived spheroid and organoid models. In particular, 3D spheroid and organoid models provide a method for drug screening with a particular emphasis on influence of the TME in cancer immunotherapy.</p>
	]]></content:encoded>

	<dc:title>3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy</dc:title>
			<dc:creator>Yichen Zhu</dc:creator>
			<dc:creator>Elliot Kang</dc:creator>
			<dc:creator>Matthew Wilson</dc:creator>
			<dc:creator>Taylor Basso</dc:creator>
			<dc:creator>Evelynn Chen</dc:creator>
			<dc:creator>Yanqi Yu</dc:creator>
			<dc:creator>Yan-Ruide Li</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1020012</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-12-05</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-12-05</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>149</prism:startingPage>
		<prism:doi>10.3390/organoids1020012</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/2/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/2/11">

	<title>Organoids, Vol. 1, Pages 135-148: Articular Tissue-Mimicking Organoids Derived from Mesenchymal Stem Cells and Induced Pluripotent Stem Cells</title>
	<link>https://www.mdpi.com/2674-1172/1/2/11</link>
	<description>Organoids offer a promising strategy for articular tissue regeneration, joint disease modeling, and development of precision medicine. In this study, two types of human stem cells&amp;amp;mdash;primary mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs)&amp;amp;mdash;were employed to engineer organoids that mimicked bone, cartilage and adipose tissue, three key tissue components in articular joints. Prior to organoidogenesis, the iPSCs were first induced into mesenchymal progenitor cells (iMPCs). After characterizing the MSCs and iMPCs, they were used to generate cell-embedded extracellular matrix (ECM) constructs, which then underwent self-aggregation and lineage-specific differentiation in different induction media. Hydroxyapatite nanorods, an osteoinductive bioceramic, were leveraged to generate bone and osteochondral organoids, which effectively enhanced mineralization. The phenotypes of the generated organoids were confirmed on the basis of gene expression profiling and histology. Our findings demonstrate the feasibility and potential of generating articular tissue-recapitulating organoids from MSCs and iPSCs.</description>
	<pubDate>2022-11-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 135-148: Articular Tissue-Mimicking Organoids Derived from Mesenchymal Stem Cells and Induced Pluripotent Stem Cells</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/2/11">doi: 10.3390/organoids1020011</a></p>
	<p>Authors:
		Zhong Alan Li
		Jiangyinzi Shang
		Shiqi Xiang
		Eileen N. Li
		Haruyo Yagi
		Kanyakorn Riewruja
		Hang Lin
		Rocky S. Tuan
		</p>
	<p>Organoids offer a promising strategy for articular tissue regeneration, joint disease modeling, and development of precision medicine. In this study, two types of human stem cells&amp;amp;mdash;primary mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs)&amp;amp;mdash;were employed to engineer organoids that mimicked bone, cartilage and adipose tissue, three key tissue components in articular joints. Prior to organoidogenesis, the iPSCs were first induced into mesenchymal progenitor cells (iMPCs). After characterizing the MSCs and iMPCs, they were used to generate cell-embedded extracellular matrix (ECM) constructs, which then underwent self-aggregation and lineage-specific differentiation in different induction media. Hydroxyapatite nanorods, an osteoinductive bioceramic, were leveraged to generate bone and osteochondral organoids, which effectively enhanced mineralization. The phenotypes of the generated organoids were confirmed on the basis of gene expression profiling and histology. Our findings demonstrate the feasibility and potential of generating articular tissue-recapitulating organoids from MSCs and iPSCs.</p>
	]]></content:encoded>

	<dc:title>Articular Tissue-Mimicking Organoids Derived from Mesenchymal Stem Cells and Induced Pluripotent Stem Cells</dc:title>
			<dc:creator>Zhong Alan Li</dc:creator>
			<dc:creator>Jiangyinzi Shang</dc:creator>
			<dc:creator>Shiqi Xiang</dc:creator>
			<dc:creator>Eileen N. Li</dc:creator>
			<dc:creator>Haruyo Yagi</dc:creator>
			<dc:creator>Kanyakorn Riewruja</dc:creator>
			<dc:creator>Hang Lin</dc:creator>
			<dc:creator>Rocky S. Tuan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1020011</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-11-14</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-11-14</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>135</prism:startingPage>
		<prism:doi>10.3390/organoids1020011</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/2/10">

	<title>Organoids, Vol. 1, Pages 116-134: Meniscus Repair: From In Vitro Research to Patients</title>
	<link>https://www.mdpi.com/2674-1172/1/2/10</link>
	<description>Walking, running, jumping, or even just standing up are habits that we all have to perform in our everyday lives. However, defects in tissues composing the knee joint can drastically alter our ability to complete those simple actions. The knee joint is made up of the interaction between bones (femur, tibia, and patella), tendons, ligaments, and the two menisci (lateral and medial) in order to ensure smooth body movements. The meniscus corresponds to a crescent-shaped fibrocartilaginous tissue, which is found in the knee joint between the femoral condyles and the tibial plateau. It plays a key role in the stability of the knee joint. However, it is quite vulnerable and therefore tears can occur within this tissue and compromise the proper function of the knee. Recently, numerous efforts have been made in order to find solutions to repair and regenerate the meniscus, supported by both bioengineering researchers and orthopedic surgeons. However, due to its poor healing capacity and its complex structure, the reconstruction of the meniscus remains particularly challenging. In this review, the current treatment options will be explained and the possibility of using organoids as building blocks for implant formation or as an in vitro three-dimensional model will be highlighted.</description>
	<pubDate>2022-11-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 116-134: Meniscus Repair: From In Vitro Research to Patients</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/2/10">doi: 10.3390/organoids1020010</a></p>
	<p>Authors:
		Hélène Vignes
		Guillaume Conzatti
		Guoqiang Hua
		Nadia Benkirane-Jessel
		</p>
	<p>Walking, running, jumping, or even just standing up are habits that we all have to perform in our everyday lives. However, defects in tissues composing the knee joint can drastically alter our ability to complete those simple actions. The knee joint is made up of the interaction between bones (femur, tibia, and patella), tendons, ligaments, and the two menisci (lateral and medial) in order to ensure smooth body movements. The meniscus corresponds to a crescent-shaped fibrocartilaginous tissue, which is found in the knee joint between the femoral condyles and the tibial plateau. It plays a key role in the stability of the knee joint. However, it is quite vulnerable and therefore tears can occur within this tissue and compromise the proper function of the knee. Recently, numerous efforts have been made in order to find solutions to repair and regenerate the meniscus, supported by both bioengineering researchers and orthopedic surgeons. However, due to its poor healing capacity and its complex structure, the reconstruction of the meniscus remains particularly challenging. In this review, the current treatment options will be explained and the possibility of using organoids as building blocks for implant formation or as an in vitro three-dimensional model will be highlighted.</p>
	]]></content:encoded>

	<dc:title>Meniscus Repair: From In Vitro Research to Patients</dc:title>
			<dc:creator>Hélène Vignes</dc:creator>
			<dc:creator>Guillaume Conzatti</dc:creator>
			<dc:creator>Guoqiang Hua</dc:creator>
			<dc:creator>Nadia Benkirane-Jessel</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1020010</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-11-02</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-11-02</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>116</prism:startingPage>
		<prism:doi>10.3390/organoids1020010</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/2/9">

	<title>Organoids, Vol. 1, Pages 106-115: Single-Cell Atlas of Patient-Derived Trophoblast Organoids in Ongoing Pregnancies</title>
	<link>https://www.mdpi.com/2674-1172/1/2/9</link>
	<description>Trophoblast organoids (TOs) hold great promise for elucidating human placental development and function. By deriving TOs in ongoing pregnancies using chorionic villus sampling (CVS), we established a platform to study trophoblast differentiation and function in early pregnancy, including pregnancies with different fetal genetic abnormalities. We addressed cellular heterogeneity of CVS-derived TOs by providing a single-cell transcriptomic atlas and showed that CVS-TOs recapitulate key aspects of the human placenta, including syncytial fusion and hormone synthesis. This study demonstrates the utility of trophoblast organoids for investigating genetic defects in the placenta and describes an experimental platform for future personalized placental medicine approaches, including genotype&amp;amp;ndash;phenotype mapping.</description>
	<pubDate>2022-10-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 106-115: Single-Cell Atlas of Patient-Derived Trophoblast Organoids in Ongoing Pregnancies</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/2/9">doi: 10.3390/organoids1020009</a></p>
	<p>Authors:
		Olivier J. M. Schäffers
		Catherine Dupont
		Eric M. Bindels
		Diane Van Opstal
		Dick H. W. Dekkers
		Jeroen A. A. Demmers
		Joost Gribnau
		Bas B. van Rijn
		</p>
	<p>Trophoblast organoids (TOs) hold great promise for elucidating human placental development and function. By deriving TOs in ongoing pregnancies using chorionic villus sampling (CVS), we established a platform to study trophoblast differentiation and function in early pregnancy, including pregnancies with different fetal genetic abnormalities. We addressed cellular heterogeneity of CVS-derived TOs by providing a single-cell transcriptomic atlas and showed that CVS-TOs recapitulate key aspects of the human placenta, including syncytial fusion and hormone synthesis. This study demonstrates the utility of trophoblast organoids for investigating genetic defects in the placenta and describes an experimental platform for future personalized placental medicine approaches, including genotype&amp;amp;ndash;phenotype mapping.</p>
	]]></content:encoded>

	<dc:title>Single-Cell Atlas of Patient-Derived Trophoblast Organoids in Ongoing Pregnancies</dc:title>
			<dc:creator>Olivier J. M. Schäffers</dc:creator>
			<dc:creator>Catherine Dupont</dc:creator>
			<dc:creator>Eric M. Bindels</dc:creator>
			<dc:creator>Diane Van Opstal</dc:creator>
			<dc:creator>Dick H. W. Dekkers</dc:creator>
			<dc:creator>Jeroen A. A. Demmers</dc:creator>
			<dc:creator>Joost Gribnau</dc:creator>
			<dc:creator>Bas B. van Rijn</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1020009</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-10-02</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-10-02</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>106</prism:startingPage>
		<prism:doi>10.3390/organoids1020009</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/8">

	<title>Organoids, Vol. 1, Pages 85-105: Metabolic Studies in Organoids: Current Applications, Opportunities and Challenges</title>
	<link>https://www.mdpi.com/2674-1172/1/1/8</link>
	<description>Organoid technologies represent a major breakthrough in biomedical research since they offer increasingly sophisticated models for studying biological mechanisms supporting human development and disease. Organoids are three-dimensional (3D) physiological in vitro systems that recapitulate the genetic, histological and functional features of the in vivo tissues of origin more accurately than classical cell culture methods. In the last decade, organoids have been derived from various healthy and diseased tissues and used for a wide range of applications in basic and translational research, including (cancer) tissue biology, development, regeneration, disease modeling, precision medicine, gene editing, biobanking and drug screening. Here, we report the current applications of organoid models to study (stem) cell metabolism in several pathophysiological contexts such as cancer and metabolic diseases. More precisely, we discuss the relevance and limitations of these 3D cultures to model and study metabolic (dys)functions associated with hepatic, renal or pancreatic disorders, as well as tumor development and progression. We also describe the use of organoids to understand the dynamic interaction between diet, microbiota and the intestinal epithelium. Finally, this review explores recent methodological improvements in organoid culture that may help to better integrate the influence of microenvironmental conditions in the study of tumor cell metabolic phenotypes.</description>
	<pubDate>2022-06-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 85-105: Metabolic Studies in Organoids: Current Applications, Opportunities and Challenges</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/8">doi: 10.3390/organoids1010008</a></p>
	<p>Authors:
		Elena Richiardone
		Valentin Van den Bossche
		Cyril Corbet
		</p>
	<p>Organoid technologies represent a major breakthrough in biomedical research since they offer increasingly sophisticated models for studying biological mechanisms supporting human development and disease. Organoids are three-dimensional (3D) physiological in vitro systems that recapitulate the genetic, histological and functional features of the in vivo tissues of origin more accurately than classical cell culture methods. In the last decade, organoids have been derived from various healthy and diseased tissues and used for a wide range of applications in basic and translational research, including (cancer) tissue biology, development, regeneration, disease modeling, precision medicine, gene editing, biobanking and drug screening. Here, we report the current applications of organoid models to study (stem) cell metabolism in several pathophysiological contexts such as cancer and metabolic diseases. More precisely, we discuss the relevance and limitations of these 3D cultures to model and study metabolic (dys)functions associated with hepatic, renal or pancreatic disorders, as well as tumor development and progression. We also describe the use of organoids to understand the dynamic interaction between diet, microbiota and the intestinal epithelium. Finally, this review explores recent methodological improvements in organoid culture that may help to better integrate the influence of microenvironmental conditions in the study of tumor cell metabolic phenotypes.</p>
	]]></content:encoded>

	<dc:title>Metabolic Studies in Organoids: Current Applications, Opportunities and Challenges</dc:title>
			<dc:creator>Elena Richiardone</dc:creator>
			<dc:creator>Valentin Van den Bossche</dc:creator>
			<dc:creator>Cyril Corbet</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010008</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-06-13</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-06-13</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>85</prism:startingPage>
		<prism:doi>10.3390/organoids1010008</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/7">

	<title>Organoids, Vol. 1, Pages 69-84: Why Can Organoids Improve Current Organ-on-Chip Platforms?</title>
	<link>https://www.mdpi.com/2674-1172/1/1/7</link>
	<description>Preclinical studies are the first stage of introducing a new potential drug to the pharmaceutical market. Many of the compounds with promising results approved in the preclinical stage show poor prognosis during the first stage of clinical studies, which is connected with inadequate in vitro and in vivo models used in this stage. Both basic in vitro models, and in vivo animal models do not represent the human conditions. Therefore, scientists work on creating an appropriate model that will highly reproduce the characteristics of the human body. The solution could be an organoids model: a laboratory-produced human miniature organ, grown in a specially designed Organ-on-Chip microfluidic tools. This review focuses on characterizing the 3D cell culture types, focusing mainly on organoids, the Organ-on-Chip approach, and presenting the latest reports about the application of their combination in biological research, including toxicological studies.</description>
	<pubDate>2022-05-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 69-84: Why Can Organoids Improve Current Organ-on-Chip Platforms?</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/7">doi: 10.3390/organoids1010007</a></p>
	<p>Authors:
		Patrycja Sokolowska
		Agnieszka Zuchowska
		Zbigniew Brzozka
		</p>
	<p>Preclinical studies are the first stage of introducing a new potential drug to the pharmaceutical market. Many of the compounds with promising results approved in the preclinical stage show poor prognosis during the first stage of clinical studies, which is connected with inadequate in vitro and in vivo models used in this stage. Both basic in vitro models, and in vivo animal models do not represent the human conditions. Therefore, scientists work on creating an appropriate model that will highly reproduce the characteristics of the human body. The solution could be an organoids model: a laboratory-produced human miniature organ, grown in a specially designed Organ-on-Chip microfluidic tools. This review focuses on characterizing the 3D cell culture types, focusing mainly on organoids, the Organ-on-Chip approach, and presenting the latest reports about the application of their combination in biological research, including toxicological studies.</p>
	]]></content:encoded>

	<dc:title>Why Can Organoids Improve Current Organ-on-Chip Platforms?</dc:title>
			<dc:creator>Patrycja Sokolowska</dc:creator>
			<dc:creator>Agnieszka Zuchowska</dc:creator>
			<dc:creator>Zbigniew Brzozka</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010007</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-05-24</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-05-24</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>69</prism:startingPage>
		<prism:doi>10.3390/organoids1010007</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/6">

	<title>Organoids, Vol. 1, Pages 54-68: Adenoma-Derived Organoids for Precision Therapy</title>
	<link>https://www.mdpi.com/2674-1172/1/1/6</link>
	<description>Human colonic organoids derived from adult tissue biopsies are based on the ability of isolated somatic epithelial stem cells to reconstitute the structure and function of the colon, offering new opportunities for studying the biology of the large intestine in both health and disease. These colonoids may also function as efficient platforms for drug screening and discovery. Here, we describe the establishment of human colonic organoids derived from healthy, and adenomatous polyp tissues. We then demonstrate that organoids grown from adenomas of familial adenomatous polyposis (FAP) patients harboring nonsense mutations in the tumor suppressor gene adenomatous polyposis coli (APC), can be used to establish a personalized therapeutic strategy which relies on nonsense mutation readthrough therapy.</description>
	<pubDate>2022-05-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 54-68: Adenoma-Derived Organoids for Precision Therapy</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/6">doi: 10.3390/organoids1010006</a></p>
	<p>Authors:
		Tamar Evron-Levy
		Michal Caspi
		Amnon Wittenstein
		Yamit Shorer-Arbel
		Olga Shomron
		Koret Hirschberg
		Revital Kariv
		Rina Rosin-Arbesfeld
		</p>
	<p>Human colonic organoids derived from adult tissue biopsies are based on the ability of isolated somatic epithelial stem cells to reconstitute the structure and function of the colon, offering new opportunities for studying the biology of the large intestine in both health and disease. These colonoids may also function as efficient platforms for drug screening and discovery. Here, we describe the establishment of human colonic organoids derived from healthy, and adenomatous polyp tissues. We then demonstrate that organoids grown from adenomas of familial adenomatous polyposis (FAP) patients harboring nonsense mutations in the tumor suppressor gene adenomatous polyposis coli (APC), can be used to establish a personalized therapeutic strategy which relies on nonsense mutation readthrough therapy.</p>
	]]></content:encoded>

	<dc:title>Adenoma-Derived Organoids for Precision Therapy</dc:title>
			<dc:creator>Tamar Evron-Levy</dc:creator>
			<dc:creator>Michal Caspi</dc:creator>
			<dc:creator>Amnon Wittenstein</dc:creator>
			<dc:creator>Yamit Shorer-Arbel</dc:creator>
			<dc:creator>Olga Shomron</dc:creator>
			<dc:creator>Koret Hirschberg</dc:creator>
			<dc:creator>Revital Kariv</dc:creator>
			<dc:creator>Rina Rosin-Arbesfeld</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010006</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-05-23</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-05-23</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>54</prism:startingPage>
		<prism:doi>10.3390/organoids1010006</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/5">

	<title>Organoids, Vol. 1, Pages 41-53: A Blood Vessel Organoid Model Recapitulating Aspects of Vasculogenesis, Angiogenesis and Vessel Wall Maturation</title>
	<link>https://www.mdpi.com/2674-1172/1/1/5</link>
	<description>Blood vessel organoids are an important in vitro model to understand the underlying mechanisms of human blood vessel development and for toxicity testing or high throughput drug screening. Here we present a novel, cost-effective, and easy to manufacture vascular organoid model. To engineer the organoids, a defined number of human induced pluripotent stem cells are seeded in non-adhesive agarose coated wells of a 96-well plate and directed towards a lateral plate mesoderm fate by activation of Wnt and BMP4 signaling. We observe the formation of a circular layer of angioblasts around days 5&amp;amp;ndash;6. Induced by VEGF application, CD31+ vascular endothelial cells appear within this vasculogenic zone at approximately day 7 of organoid culture. These cells arrange to form a primitive vascular plexus from which angiogenic sprouting is observed after 10 days of culture. The differentiation outcome is highly reproducible, and the size of organoids is scalable depending on the number of starting cells. We observe that the initial vascular ring forms at the interface between two cell populations. The inner cellular compartment can be distinguished from the outer by the expression of GATA6, a marker of lateral plate mesoderm. Finally, 14-days-old organoids were transplanted on the chorioallantois membrane of chicken embryos resulting in a functional connection of the human vascular network to the chicken circulation. Perfusion of the vessels leads to vessel wall maturation and remodeling as indicated by the formation of a continuous layer of smooth muscle actin expressing cells enwrapping the endothelium. In summary, our organoid model recapitulates human vasculogenesis, angiogenesis as well as vessel wall maturation and therefore represents an easy and cost-effective tool to study all steps of blood vessel development and maturation directly in the human setting without animal experimentation.</description>
	<pubDate>2022-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 41-53: A Blood Vessel Organoid Model Recapitulating Aspects of Vasculogenesis, Angiogenesis and Vessel Wall Maturation</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/5">doi: 10.3390/organoids1010005</a></p>
	<p>Authors:
		Sven Schmidt
		Yvonne Alt
		Nikita Deoghare
		Sarah Krüger
		Anna Kern
		Anna Frederike Rockel
		Nicole Wagner
		Süleyman Ergün
		Philipp Wörsdörfer
		</p>
	<p>Blood vessel organoids are an important in vitro model to understand the underlying mechanisms of human blood vessel development and for toxicity testing or high throughput drug screening. Here we present a novel, cost-effective, and easy to manufacture vascular organoid model. To engineer the organoids, a defined number of human induced pluripotent stem cells are seeded in non-adhesive agarose coated wells of a 96-well plate and directed towards a lateral plate mesoderm fate by activation of Wnt and BMP4 signaling. We observe the formation of a circular layer of angioblasts around days 5&amp;amp;ndash;6. Induced by VEGF application, CD31+ vascular endothelial cells appear within this vasculogenic zone at approximately day 7 of organoid culture. These cells arrange to form a primitive vascular plexus from which angiogenic sprouting is observed after 10 days of culture. The differentiation outcome is highly reproducible, and the size of organoids is scalable depending on the number of starting cells. We observe that the initial vascular ring forms at the interface between two cell populations. The inner cellular compartment can be distinguished from the outer by the expression of GATA6, a marker of lateral plate mesoderm. Finally, 14-days-old organoids were transplanted on the chorioallantois membrane of chicken embryos resulting in a functional connection of the human vascular network to the chicken circulation. Perfusion of the vessels leads to vessel wall maturation and remodeling as indicated by the formation of a continuous layer of smooth muscle actin expressing cells enwrapping the endothelium. In summary, our organoid model recapitulates human vasculogenesis, angiogenesis as well as vessel wall maturation and therefore represents an easy and cost-effective tool to study all steps of blood vessel development and maturation directly in the human setting without animal experimentation.</p>
	]]></content:encoded>

	<dc:title>A Blood Vessel Organoid Model Recapitulating Aspects of Vasculogenesis, Angiogenesis and Vessel Wall Maturation</dc:title>
			<dc:creator>Sven Schmidt</dc:creator>
			<dc:creator>Yvonne Alt</dc:creator>
			<dc:creator>Nikita Deoghare</dc:creator>
			<dc:creator>Sarah Krüger</dc:creator>
			<dc:creator>Anna Kern</dc:creator>
			<dc:creator>Anna Frederike Rockel</dc:creator>
			<dc:creator>Nicole Wagner</dc:creator>
			<dc:creator>Süleyman Ergün</dc:creator>
			<dc:creator>Philipp Wörsdörfer</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010005</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-04-28</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-04-28</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>41</prism:startingPage>
		<prism:doi>10.3390/organoids1010005</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/4">

	<title>Organoids, Vol. 1, Pages 37-40: Organoids, Assembloids and Embryoids: New Avenues for Developmental Biology, Disease Modeling, Drug Testing and Toxicity Assessment without Animal Experimentation</title>
	<link>https://www.mdpi.com/2674-1172/1/1/4</link>
	<description>The organs and tissues of our bodies consist of a specific set of cell types [...]</description>
	<pubDate>2022-04-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 37-40: Organoids, Assembloids and Embryoids: New Avenues for Developmental Biology, Disease Modeling, Drug Testing and Toxicity Assessment without Animal Experimentation</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/4">doi: 10.3390/organoids1010004</a></p>
	<p>Authors:
		Süleyman Ergün
		Philipp Wörsdörfer
		</p>
	<p>The organs and tissues of our bodies consist of a specific set of cell types [...]</p>
	]]></content:encoded>

	<dc:title>Organoids, Assembloids and Embryoids: New Avenues for Developmental Biology, Disease Modeling, Drug Testing and Toxicity Assessment without Animal Experimentation</dc:title>
			<dc:creator>Süleyman Ergün</dc:creator>
			<dc:creator>Philipp Wörsdörfer</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010004</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-04-22</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-04-22</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>37</prism:startingPage>
		<prism:doi>10.3390/organoids1010004</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/3">

	<title>Organoids, Vol. 1, Pages 28-36: Organoids as Miniature Twins&amp;mdash;Challenges for Comparability and Need for Data Standardization and Access</title>
	<link>https://www.mdpi.com/2674-1172/1/1/3</link>
	<description>Organoids derived from human stem cell lines represent genetically mostly identical models of their donors. Their use as personalized in vitro miniature twins of living individuals creates challenges of reproducibility, comparability and standardization. To fully exploit personalization, it is essential to assess individual variabilities in organoid function, morphology or maturity. There is a need to establish platforms to compare individual organoids and to link them to data elements related to the individual donor. Moreover, principal ethical issues arise because of their infinite repetition for an unlimited period of time and global dissemination. This infinite temporal and spatial space applies to the biological material but also to the data associated with it. It increases the possibility of uses that are unpredictable at the time of donation, and thus, beyond the donor&amp;amp;rsquo;s consented choices. We propose an open data platform to address the issue of authenticity and persistent comparability of the biological organoid models, and of preserving the ethical provenance information. The platform would collect standardized donors, organoids and ethical information to create a system suitable for quality control of individual organoids. We discuss whether the human pluripotent stem cell registry (hPSCreg), a well-established resource for stem cell data, provides a suitable model platform.</description>
	<pubDate>2022-04-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 28-36: Organoids as Miniature Twins&amp;mdash;Challenges for Comparability and Need for Data Standardization and Access</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/3">doi: 10.3390/organoids1010003</a></p>
	<p>Authors:
		Antonie Fuhr
		Andreas Kurtz
		Christian Hiepen
		Sabine Müller
		</p>
	<p>Organoids derived from human stem cell lines represent genetically mostly identical models of their donors. Their use as personalized in vitro miniature twins of living individuals creates challenges of reproducibility, comparability and standardization. To fully exploit personalization, it is essential to assess individual variabilities in organoid function, morphology or maturity. There is a need to establish platforms to compare individual organoids and to link them to data elements related to the individual donor. Moreover, principal ethical issues arise because of their infinite repetition for an unlimited period of time and global dissemination. This infinite temporal and spatial space applies to the biological material but also to the data associated with it. It increases the possibility of uses that are unpredictable at the time of donation, and thus, beyond the donor&amp;amp;rsquo;s consented choices. We propose an open data platform to address the issue of authenticity and persistent comparability of the biological organoid models, and of preserving the ethical provenance information. The platform would collect standardized donors, organoids and ethical information to create a system suitable for quality control of individual organoids. We discuss whether the human pluripotent stem cell registry (hPSCreg), a well-established resource for stem cell data, provides a suitable model platform.</p>
	]]></content:encoded>

	<dc:title>Organoids as Miniature Twins&amp;amp;mdash;Challenges for Comparability and Need for Data Standardization and Access</dc:title>
			<dc:creator>Antonie Fuhr</dc:creator>
			<dc:creator>Andreas Kurtz</dc:creator>
			<dc:creator>Christian Hiepen</dc:creator>
			<dc:creator>Sabine Müller</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010003</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-04-09</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-04-09</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>28</prism:startingPage>
		<prism:doi>10.3390/organoids1010003</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/2">

	<title>Organoids, Vol. 1, Pages 2-27: Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?</title>
	<link>https://www.mdpi.com/2674-1172/1/1/2</link>
	<description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which was classified as a pandemic in March 2020. As of 22 January 2022, globally more than 347 million cases of COVID-19 have been diagnosed, with 5.6 million deaths, making it the deadliest pandemic since the influenza pandemic in 1918. The clinical presentation of COVID-19-related illness spans from asymptomatic to mild respiratory symptoms akin to influenza infection to acute symptoms, including pneumonia necessitating hospitalisation and admission to intensive care units. COVID-19 starts in the upper respiratory tract and lungs but in severe cases can also involve the heart, blood vessels, brain, liver, kidneys and intestine. The increasing global health and economic burden of COVID-19 necessitates an urgent and global response. Understanding the functional characteristics and cellular tropism of SARS-CoV-2, and the pathogenesis that leads to multi-organ failure and death, has prompted an unprecedented adoption of organoid models. Successful drug discovery and vaccine development rely on pre-clinical models that faithfully recapitulate the viral life cycle and the host cell response to infection. Human stem cell-derived organoids fulfill these criteria. Here we highlight the role of organoids in the study of SARS-CoV-2 infection and modelling of COVID-19 pathogenesis.</description>
	<pubDate>2022-03-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 2-27: Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/2">doi: 10.3390/organoids1010002</a></p>
	<p>Authors:
		Bang M. Tran
		Georgia Deliyannis
		Abderrahman Hachani
		Linda Earnest
		Joseph Torresi
		Elizabeth Vincan
		</p>
	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which was classified as a pandemic in March 2020. As of 22 January 2022, globally more than 347 million cases of COVID-19 have been diagnosed, with 5.6 million deaths, making it the deadliest pandemic since the influenza pandemic in 1918. The clinical presentation of COVID-19-related illness spans from asymptomatic to mild respiratory symptoms akin to influenza infection to acute symptoms, including pneumonia necessitating hospitalisation and admission to intensive care units. COVID-19 starts in the upper respiratory tract and lungs but in severe cases can also involve the heart, blood vessels, brain, liver, kidneys and intestine. The increasing global health and economic burden of COVID-19 necessitates an urgent and global response. Understanding the functional characteristics and cellular tropism of SARS-CoV-2, and the pathogenesis that leads to multi-organ failure and death, has prompted an unprecedented adoption of organoid models. Successful drug discovery and vaccine development rely on pre-clinical models that faithfully recapitulate the viral life cycle and the host cell response to infection. Human stem cell-derived organoids fulfill these criteria. Here we highlight the role of organoids in the study of SARS-CoV-2 infection and modelling of COVID-19 pathogenesis.</p>
	]]></content:encoded>

	<dc:title>Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?</dc:title>
			<dc:creator>Bang M. Tran</dc:creator>
			<dc:creator>Georgia Deliyannis</dc:creator>
			<dc:creator>Abderrahman Hachani</dc:creator>
			<dc:creator>Linda Earnest</dc:creator>
			<dc:creator>Joseph Torresi</dc:creator>
			<dc:creator>Elizabeth Vincan</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010002</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2022-03-02</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2022-03-02</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/organoids1010002</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2674-1172/1/1/1">

	<title>Organoids, Vol. 1, Pages 1: Publisher’s Note: Organoids—A New Open Access Journal</title>
	<link>https://www.mdpi.com/2674-1172/1/1/1</link>
	<description>Organoids are stem cell-derived 3D multicellular tissue constructs that mimic some of the structures and functions of a corresponding organ [...]</description>
	<pubDate>2021-10-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Organoids, Vol. 1, Pages 1: Publisher’s Note: Organoids—A New Open Access Journal</b></p>
	<p>Organoids <a href="https://www.mdpi.com/2674-1172/1/1/1">doi: 10.3390/organoids1010001</a></p>
	<p>Authors:
		Constanze Schelhorn
		</p>
	<p>Organoids are stem cell-derived 3D multicellular tissue constructs that mimic some of the structures and functions of a corresponding organ [...]</p>
	]]></content:encoded>

	<dc:title>Publisher’s Note: Organoids—A New Open Access Journal</dc:title>
			<dc:creator>Constanze Schelhorn</dc:creator>
		<dc:identifier>doi: 10.3390/organoids1010001</dc:identifier>
	<dc:source>Organoids</dc:source>
	<dc:date>2021-10-22</dc:date>

	<prism:publicationName>Organoids</prism:publicationName>
	<prism:publicationDate>2021-10-22</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/organoids1010001</prism:doi>
	<prism:url>https://www.mdpi.com/2674-1172/1/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
